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Summary 
 
Human papillomaviruses (HPV) infect mucosal and cutaneous tissue. They induce 
several epithelial lesions ranging from benign warts to cancer. HPV infection has been 
demonstrated to play a role in the pathogenesis of cervical, vulvar, penile, anal, skin, head and 
neck cancers. HPV infection is associated with benign and malignant lesions in the hereditary 
skin disease Epidermodysplasia verruciformis (EV), characterized by cutaneous lesions that 
progress to squamous cell carcinoma after UV exposure.  
Head and neck tumor (HNSCC) patients have been classified into two epidemiological 
entities, corresponding to either alcohol/tobacco use or HPV infection. High risk mucosal 
HPV is involved in the pathogenesis of a subset of HNSCC, particularly those that arise from 
the lingual and palatine tonsils within the oropharynx. Although low risk HPV have been 
found in several cancers, their gene products do not induce immortalization per se, and they 
probably need other co-factors to modify cellular genes and contribute to tumorigenesis. 
Cutaneous HPV20 has been found in a number of non melanoma skin cancers as well as in 
esophageal carcinoma and in HNSCC patients. HPV20 infection combined with UV exposure 
promotes malignant progression in skin as demonstrated in HPV20 E6/E7 transgenic mice in 
the presence of chronic UV irradiation. These animals presented papilloma formation that 
lead to transformation. However, involvement of HPV20 in esophageal cancer and HNSCC 
have to date not been elucidated. 
 In this study, the cooperation between HPV20 infection and a chemical carcinogen in 
the pathogenesis of oropharynx and esophageal cancer was investigated. The synthetic 
carcinogen 4-NQO is a UV-mimetic that shares the same mechanistic action with the 
carcinogenic compounds present in tobacco. In order to examine its involvement (comparable 
with the effect of tobacco) in increasing the viral oncogenic potential, 4-NQO was applied 
either to cells or organotypic cultures and combined with HPV20 by following two 
approaches: 
 Promoter activation assays demonstrated that HPV20 E6 and/or E7 up-regulated its 
own viral promoter and this effect was further enhanced by 4-NQO treatment. These changes 
in the viral promoter activity may indicate a positive cooperation between the virus and the 
chemical in the onset of disease. 
Secondly, alterations in proliferation, differentiation, apoptosis and skin barrier 
functionality were studied in organotypic cultures expressing HPV20 E6 and treated with 4-
NQO. Although these cultures were able to stratify and differentiate they failed to form a 
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normal epidermis. Moreover, the normal differentiation markers pattern was disturbed, 
resembling simpler epithelia and this phenotype was enhanced after 4-NQO treatment. 
Cellular protein p53 accumulated whereas p21CIP1 and ∆Np63α modifed their expression 
pattern in the epithelia.  
Organotypic raft cultures expressing HPV20 E6 gene presented foamy-like 
keratinocytes resembling the typical structures found in Epidermodysplasia verruciformis 
patients and pityriasis versicolor -like lesions infected with HPV20. In addition, HPV20 E6 
expression was capable of altering the functionality of the skin barrier function by abrogation 
of tight junction formation in the stratum granulosum and by changes in the lipid metabolism 
of the skin leading to its accumulation and deregulated composition. Disruption of the skin 
barrier has been observed in a number of cutaneous diseases as ichthyosis, atopic dermatitis 
and other eczemas.  
These studies provide insight into the functionality of HPV20 E6 in the epidermis. 
Moreover, the up-regulation in viral promoter activity and alterations in differentiation pattern 
under the context of HPV20 E6 expression and 4-NQO treatment compared with pLXSN and 
HPV16 E6/E7 controls showed the cooperation between HPV20 and chemical carcinogens. 
However, epithelial transformation was not observed and longer 4-NQO treatment would be 
necessary to analyze its influence in malignancy. Taken together, the conclusions obtained in 
the present work will be helpful in future experiments to elucidate the role of HPV20 
infection and chemical carcinogens in the pathogenesis of esophageal and oropharyngeal 
tumors.  
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Zusammenfassung
Humane Papillomaviren (HPV) infizieren das Plattenepithel der Haut und der 
Schleimhäute. Die daraus folgenden Läsionen des Epithels sind Ursache für die Bildung von 
gutartigen Warzen bis hin zu Tumoren. HPV-Infektion spielt nachgewiesenermaßen eine 
Rolle in der Pathogenese von Gebärmutterhals-, Vulva-, Penis-, Anal-, Haut-, Kopf- und 
Halstumoren. HPV-Infektionen stehen im Zusammenhang mit gut - und bösartigen 
Hautveränderungen bei der Erberkrankung der Haut Hauterkrankung Epidermodysplasia 
verruciformis (EV). Diese ist charakterisiert durch Hautläsionen, die sich nach UV – 
Bestrahlung zum Plattenepithelkarzinom weiterentwickeln. 
Patienten mit Kopf- und Hals-Tumoren (HNSCC) wurden in zwei epidemiologische 
Einheiten unterteilt. Die eine bestand aus Patienten mit gesundheitlichen Schäden nach 
Alkohol- bzw. Tabakverbrauch, die andere aus Patienten mit HPV-Infektion. Infektionen mit 
„High-risk“ HPV der Schleimhäute hängen mit der Pathogenese bei einem Teil der HNSCC 
zusammen, insbesondere derjenigen, die aus der Tonsilla lingualis und Tonsilla palatina 
innerhalb des Oropharynx hervorgehen. Obwohl die „low-risk“ HPV Typen in mehrere 
Krebsarten vorhanden sind, verursachen ihre Genprodukte per se keine Immortalization. 
Womöglich benötigen sie weitere Faktoren um zelluläre Gene zu verändern und somit die 
Tumorentstehung zu verursachen. Der Kutaner HPV20 Typ wurde in einer Reihe von Nicht-
melanomatösen Hautkrebs- (NMSC), sowie in Ösophagus-Karzinom- und in HNSCC-
Patienten nachgewiesen. Eine HPV20-Infektion in Kombination mit UV-Bestrahlung führt zu 
malignen Hautveränderungen. Dies wurde in HPV20 E6/E7 transgenen Mäusen, die 
chronischer UV-Bestrahlung ausgesetzt waren, nachgewiesen. Diese Tiere zeigten ein höheres 
Proliferationsverhalten und eine Tendenz zur malignen Entartung durch eine größere Anzahl 
an Papillomen. Die Rolle der HPV20 bei Ösophagus-Karzinom und HNSCC ist bisher nicht 
geklärt. 
In der vorliegenden Studie wurde die Wechselwirkung zwischen einer HPV20-
Infektion und einem chemischen Karzinogen in der Pathogenese des Oropharynx- und 
Ösophagus-Karzinoms untersucht. Das synthetische Karzinogen 4-NQO ist ein UV-
Mimetikum, dass die gleichen Pathomechanismen hat wie die karzinogenen 
Tabakbestandteile. Um den Einfluss auf das virale-onkogene Potenzials zu untersuchen, 
wurde 4-NQO (ähnlich wie der Tabak) an Zellen bzw. organotypische Kulturen zugesetzt und 
mit HPV20 infiziert. Folgende zwei Forschungsansätze lagen zugrunde: 
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Promotor activation assays zeigten, dass HPV20 E6 und / oder E7 seinen eigenen 
Virus-Promotor hochregulierte und dass dieser Effekt durch die 4-NQO-Behandlung noch 
zusätzlich verstärkt wurde. Die genannten Veränderungen in der Aktivität des viralen 
Promotors könnten auf eine positive Wechselwirkung zwischen dem Virus und der 
Chemikalie hindeuten, und dadurch eine Rolle in der Pathogenese von Krankheiten spielen.  
Die Änderungen in der Proliferation, Differenzierung, Apoptose und der 
Hautbarrierefunktion wurden in organotypischen Kulturen untersucht, wobei die HPV20 E6-
Expression betrachtet und mit 4-NQO behandelt wurde. Diese Kulturen konnten 
Zellschichten bilden und eine Differenzierung konnte zwar stattfinden, doch war die Bildung 
einer normalen Epidermis nicht möglich. Der normale Differenzierungsmarker war 
beeinträchtigt und ähnelte einem einfachen Epithel, wobei dieser Phänotyp nach der 4-NQO-
Behandlung verstärkt wurde. Es wurde eine Anhäufung des Zellproteins p53 beobachtet, 
während p21CIP1 und ∆Np63α ihre Epithel-Expressionsmuster veränderten. 
Organotypische Kulturen, die das HPV20 E6 Gen beinhalteten, bildeten schaumig 
aussehende Keratinozyten. Diese stellen die typischen Strukturen dar, die in 
Epidermodysplasia verruciformis Patienten und Pityriasis versicolor-aussehenden, HPV 20 
infizierten, Läsionen gefunden wurden. Darüber hinaus konnte eine Veränderung der 
Hautbarrierefunktion durch die  HPV20 E6 Expression gezeigt werden. Dies geschah durch 
eine Unterbrechung der Tight Junctions Bildung im Stratum granulosum und einen Einfluss 
des Stoffwechsels der Hautlipide, was zu ihrer Anhäufung und unregelmäßigen 
Zusammensetzung führte. Hautbarrierestörungen wurden bei zahlreichen Hauterkrankungen 
beobachtet, darunter Ichthyosis, atopische Dermatitis und anderen Ekzemen. 
Diese Studien zeigen die Wirkung und Funktion des HPV20 E6 auf die Epidermis. 
Ferner zeigten die Aktivierung des viralen Promotors und die Änderungen des 
Differenzierungsmarkers im Rahmen der Expression von HPV20 E6 und der 4-NQO-
Behandlung im Vergleich zu den pLXSN- und HPV16-E6/E7-Kontrollen die 
Wechselwirkungen zwischen HPV20 und den chemischen Karzinogenen. Eine 
Transformation des Epithels wurde jedoch nicht erreicht. Für die Analyse ihrer Wirkung auf 
eine maligne Entartung ist eine längere 4-NQO-Behandlung vonnöten.  
Die oben erläuterten Beobachtungen können als Grundlage für weiterführende 
Untersuchungen und Experimente über die Rolle der HPV20-Infektion und der chemischen 
Karzinogene in der Pathogenese der Ösophagus- und Oropharynx-Tumore dienen. 
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1 Introduction 
1.1 Papillomaviruses 
1.1.1 General aspects 
Papillomaviruses (PV) belong to the viral family Papillomaviridae. They comprise a 
heterogeneous group with high specificity in host and cell type (Lancaster and Olson, 1982). 
They infect skin and mucosal epithelia and give rise to different epithelial lesions, ranging 
from benign hyperplasia (e.g. warts or papillomas) to cancer.  
To date, 113 human papillomaviruses (HPV) types have been characterized and more 
than 300 putative new PV have been identified by PCR amplification (de Villiers et al., 
2004). PV infect different hosts: humans, primates, ungulates, rodents, birds, cetaceans and 
reptiles. They are species specific and therefore, named depending on the species they infect. 
PV are classified based on their L1 open reading frame (ORF) sequence homology (Fig. 1). 
PV species share between 50-60% nucleotide identity of the ORF L1 within a genus. A PV is 
defined as new a type if its L1 ORF sequence differs more than 10% to the closest known PV. 
Subspecies share 2-10% of L1 ORF homology and variants, 2% (de Villiers et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Phylogenetic tree of the Papillomaviridae family (de Villiers et al., 2004). 
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1.1.2 HPV types 
HPV play a role in the pathogenesis of several cancers such as cervical, vulvar, penile, 
anal, skin, esophageal and oropharyngeal cancers. HPV infection is also associated with skin 
warts (common plantar and flat warts) as well as genital warts. Moreover, infection with 
HPV6 and 11 is related with recurrent laryngeal papillomatosis. HPV are historically 
classified in cutaneous and genital/mucosal types depending on the epithelia they infect. 
 
1.1.2.1 Mucosal types 
Genital/mucosal PV, mainly grouped within the genus Alpha papillomaviruses, infect 
the anogenital area, the upper respiratory tract and the head and neck regions. They are 
classified as high risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 73, and 82) or low risk (6, 
11, 40, 42, 43, 44, 54, 61, 70, and 72) types, based on their association with malignant, pre-
malignant or benign lesions (Munoz et al., 2003; zur Hausen, 1990). 
High risk HPV types are associated with 90% of the cervical cancers, HPV16 and 18 
being the most common HPV types found in 70% of the cases. They are also implicated in 
anal, penile, and head and neck pre-malignant and malignant tumors. HPV16 is the most 
common HPV type associated with a malignant phenotype regardless of organ origin 
(Sanclemente and Gill, 2002). 
Low risk HPV types are associated with over 90% of HPV-related benign lesions. 
Laryngeal papillomatosis is a rare disease occurring both in infants and adults caused by low 
risk HPV6 and 11 (Aaltonen et al., 2002), which also cause genital warts. A few types 
classified in the genus Alpha papillomaviruses are most commonly associated with cutaneous 
warts (reviewed in zur Hausen, 1996). HPV2, 27 and 57 have however been described 
causing benign anogenital lesions in children (de Villiers, 1995; Handley et al., 1997) 
(reviewed in Cason and Mant, 2005).  
 
1.1.2.2 Cutaneous types 
Cutaneous papillomaviruses infect skin epithelia, causing warts with varying clinical 
entities depending on the HPV type (de Villiers, 1998). HPV have been implicated in the 
pathogenesis of non-melanoma skin cancer (NMSC), although recent epidemiological data 
failed to provide convincing evidence. A number of HPV types classified in the genus Beta 
papillomaviruses are being associated mainly with squamous cell carcinomas (SCC) of the 
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skin, but it has not been possible to attribute any individual HPV type to its pathogenesis 
(Asgari et al., 2008; Forslund et al., 2007). 
Epidermodysplasia verruciformis (EV) is a rare recessive autosomal hereditary disease 
that manifests early in childhood. EV is characterized by generalized wart development, with 
multiple papillomatous lesions, disseminated wart-like and pytiriasis versicolor-like lesions, 
with infection of a broad spectrum of genus Beta papillomaviruses (reviewed in de Villiers et 
al., 2004 and in Jablonska and Majewski, 1994). EV patients carry mutations in two genes in 
chromosomes 2 and 17 that cause defects in cellular innate immunity (Ramoz et al., 2002). 
 
1.1.3 HPV20 
HPV20 belongs to the cutaneous genus Beta papillomavirus and is associated with 
benign and malignant lesions in the skin disease EV (reviewed in Jablonska and Majewski, 
1994; Watzig and Jablonska, 1987). It has been detected in a number of NMSC either by 
DNA detection in biopsies (Astori et al., 1998; de Villiers, 1998) or seroreactivity to HPV20 
L1 (Feltkamp et al., 2003) as well as in esophageal carcinoma patients (de Villiers et al. 
1999) and in patients with head and neck cancer (Lavergne and de Villiers, 1999). 
Previous studies in our group demonstrated that chronic exposure of HPV20- and 
HPV27 E6/E7 transgenic mice to ultraviolet (UV) irradiation resulted in the formation of 
papillomas and malignant lesions of the skin (Michel et al., 2006). Moreover, using in vitro 
conditions with ectopically expressed proteins, the wtp53-mediated degradation of HPV20 E6 
by caspase 3 was described, in contrast to the protective effect exerted by UV-induced mutant 
p53R248W and ∆Np63α (Fei and de Villiers, 2008).  
 
1.1.4 HPV genomic organization 
Viral genome consists of a small, double-stranded circular DNA molecule. It varies in 
size among HPV types but typically contains around 8000 bp and codes for eight open 
reading frames (ORF). The genome is organized in three different regions (Fig. 2): the long 
control region (LCR) (also commonly named the upstream regulatory region, URR) and the 
early (E) and late (L) coding regions.  Proteins are expressed from polycistronic mRNAs 
transcribed from a single DNA strand (Fig. 3). E6 and E7 are oncogenes able to induce 
immortalization in high risk HPV types (Munger et al., 1992). E1 and E2 are regulatory 
proteins involved in viral transcription and replication (Chiang et al., 1992). E4 regulates viral 
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replication and induces viral DNA synthesis in suprabasal epithelial layers (Nakahara et al., 
2005).  E5 is only present in genital HPV types, where enhances E6 and E7 oncogenic effect 
during early stages of infection (DiMaio and Mattoon, 2001). Late proteins L1 and L2 form 
the viral capsid (Munger and Howley, 2002).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Circular genome representation of HPV16 (adapted from Narisawa-Saito and Kiyono, 2007). 
 
In high risk HPV, transcripts are initiated at two major viral promoters which position 
varies for each type. The early promoter is located upstream of the E6 ORF. It controls the 
expression of early viral proteins, and is activated in parabasal epidermal layers prior to 
replication. In HPV16 and 31 this promoter is referred to as p97 (Smotkin and Wettstein, 
1986), while in HPV 18 is named p105 (Butz and Hoppe-Seyler, 1993). The late promoter 
located within the E7 ORF is activated when the productive replication starts and regulates 
late protein expression, and is referred to as p670 in HPV16 (Grassmann et al., 1996) and 
p742 in HPV18 and 31 (Frattini et al., 1997). The location of viral promoters has not been 
extensively studied in cutaneous HPV types. Recently, putative early promoters for different 
Beta-papillomaviruses have been identified: p92 in HPV38, p45 in HPV92, p7439 in HPV93 
and p256 in HPV96 (Vasiljevic et al., 2008). 
 
 
 
 
 
 
 
 
Figure 3. Gene organization in HPV31 (adapted from Longworth and Laimins, 2004). 
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1.1.4.1 Early proteins 
The early region encodes predominantly for proteins that are important in viral DNA 
replication, which occurs “early” in the viral life cycle. Six different ORFs have been 
described as E1, E2, E4, E5, E6 and E7. Additionally, E3 and E8 ORFs have been found in 
BPV 4 (bovine papillomavirus 4): E3 corresponds to a small putative gene of unknown 
function (Patel et al., 1987) whereas E8 may substitute the E6 gene, absent in BPV4 (Jackson 
et al., 1991).  
  
E1 
E1 is a DNA helicase/ATPase involved in initiating viral DNA replication (Hughes 
and Romanos, 1993). E1 binds weakly to AT-rich sequences near the origin of replication, 
controlling the episomal DNA replication (Frattini and Laimins, 1994). When E1 binds to E2 
protein, it forms a stable complex, enhancing the protein-DNA interaction. E1 also acts during 
replication by binding to DNA polymerase, recruiting cellular replication complexes and 
interacting with cyclins A and E (reviewed in Longworth and Laimins, 2004).  
 
E2 
E2 protein facilitates DNA replication (Ustav et al., 1993) and regulates viral 
transcription through site-specific binding to the early promoter (Frattini and Laimins, 1994). 
This protein increases viral DNA replication by recruiting the E1 protein to its binding site. 
When E2 is present at low concentrations, it binds to its recognition sequence and activates 
the early promoter. At high concentrations, E2 represses the early promoter activity by 
blocking the binding of cellular transcription factors (Steger and Corbach, 1997). Since the E1 
and E2 proteins are expressed from the early promoter, E2 effect on the promoter activity 
contributes to the control of viral copy number in undifferentiated cells. 
Unlike the early promoter, the late promoter is not negatively regulated by E2 protein. 
Thus, at late stages of viral life cycle E2 contributes to the amplification of viral DNA (Steger 
and Corbach, 1997). 
 
E4  
The E4 ORF is the most highly expressed HPV protein. E4 is translated together with 
the first 5 amino acids of E1 by formation of a spliced E1^E4 messenger RNA in productively 
infected keratinocytes (Doorbar et al., 1989). E4 expression is controlled by the HPV late 
promoter, activated in the differentiating cell layers of the epithelia. Thus, E4 is expressed at 
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late stages of the virus life cycle, during the viral genome amplification (Middleton et al., 
2003).  
Genital and cutaneous HPV E4 forms cytoplasmic networks that colocalize with 
keratin intermediate filaments in the cell. However, only high risk genital types induce 
collapse of the keratin skeleton facilitating the release of viral particles (Roberts et al., 1993). 
In addition, HPV11 and HPV16 E4 induce G2 arrest (reviewed in Longworth and Laimins, 
2004).  
 
E5 
The E5 protein is a strongly hydrophobic protein localized in the Golgi apparatus, 
endoplasmic reticulum, nuclear membrane and occasionally in cellular membranes of the host 
cell (Conrad et al., 1993).  Genital HPV types encode an E5 protein, whereas cutaneous types 
lack an E5 gene or a translation start codon (Schiffman et al., 2005). E5 is expressed in the 
early phase of infection. During malignant progression the HPV genome frequently integrates 
into the host genome, disrupting the E5 gene (DiMaio and Mattoon, 2001). E5 activates the 
epidermal growth factor (EGF) receptor, influencing cellular proliferation (Crusius et al., 
1998). HPV16 E5 has weak transforming activity in vitro; nevertheless, epidemiological and 
experimental evidences suggest that E5 activity enhances subsequent malignant progression 
in vivo (reviewed in Tsai and Chen, 2003). Targeted expression of HPV16 E5 in basal 
epithelial cells of transgenic mice induces skin tumors at a high frequency (Genther-Williams 
et al., 2005). In addition, estrogen-treated transgenic mice expressing HPV16 E5, E6 and E7 
develop a higher number of cervical cancers than transgenic mice that express HPV16 E6 and 
E7 but not E5 (Riley et al., 2003).  
Recently it has been demonstrated that E5 and E6 from both low and high risk HPV 
types cooperate in inducing koilocytosis in cell culture. Formation of koilocytes is inhibited 
after deletion of 20 amino acids in the carboxiterminal side of E5 protein, also in the presence 
of E6 protein, showing the key role of E5 in the formation of such structures (Krawczyk et al., 
2008). 
 
E6 
The E6 protein is composed of approximately 150 amino acids and contains two zinc-
binding domains with the motif Cys-X-X-Cys.  
In vitro experiments demonstrated that HPV16 E6 is able to transform rodent cells, 
and primary human mammary epithelial cells (Liu et al., 1999), while cooperates with E7 
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protein in inducing immortalization in primary human foreskin keratinocytes (Kiyono et al., 
1998). 
In mucosal high risk HPV types, E6 induces degradation of p53 tumor suppressor 
protein (Fig. 4, 5) by forming a trimeric complex together with the cellular ubiquitin ligase, 
E6-associated protein (E6AP) (Werness et al., 1990), resulting in inhibition of apoptotic 
signals (Munger et al., 1992; Scheffner et al., 1990). p53 regulates G1/S and G2/M cell cycle 
checkpoints. When p53 is degraded, the cell accumulates chromosomal aberrations and 
centrosomal abnormalities, contributing to malignant progression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. E6-mediated p53 degradation and its effect in cell cycle (adapted from Sterling and Tyring, 2001). 
 
E6 promotes telomerase activity by interacting with hTERT (Kiyono et al., 1998; 
Klingelhutz et al., 1996). This telomerase activity is a common feature observed in normal 
proliferating cells and in tumors, which allows an increase in the number of divisions that a 
cell can undergo.  
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High risk E6 gene can be also transcribed as E6* by alternative splicing (Pim et al., 
1994). This protein interacts with both E6 and E6AP and inhibits E6-mediated p53 
degradation (Pim et al., 1997).  
PDZ domain (acronym for Post synaptic density protein, PSD95, Drosophila disc 
large tumor suppressor, DlgA, and Zonula occludens-1, zo-1) is a structural protein domain 
present in signalling proteins of bacteria, yeast, plants and animals (Ponting, 1997). E6 
presents a PDZ binding motif in the C-terminal of the protein. It interacts with PDZ-
containing proteins (i.e. hDlg, MAGI or MUPP1) and targets them for degradation. This 
activity has only been found in mucosal HPV types and it is believed to play an important role 
in degradation of tumor suppressor proteins that contain PDZ domains (Lee and Laimins, 
2004). 
Cutaneous HPV E6 does not induce proteosome-mediated degradation of p53 or PDZ-
domain proteins (Elbel et al., 1997; Fei and de Villiers, 2008; Jackson et al., 2000; Pim et al., 
2002). However, they indirectly repress p53 function in both mucosal and cutaneous HPV by 
binding and consequently inhibiting p300/CBP (Hebner et al., 2007; Thomas and Chiang, 
2005), which activates p53 by acetylation (Lechner and Laimins, 1994).  
High risk E6 also binds and inactivates pro-apoptotic partners like Bak (Thomas and 
Banks, 1999) and Bax (Li and Dou, 2000) by targeting them for ubiquitin-proteosome 
degradation. Several cutaneous HPV E6 proteins inhibit UV-induced apoptosis by targeting 
pro-apoptotic Bak protein for degradation (Jackson et al., 2000; Underbrink et al., 2008). 
HPV20 and HPV8 E6 inhibit apoptotic response after ultraviolet irradiation of medium 
wavelengh or B irradiation (UVB) in primary foreskin keratinocytes, contributing to the 
oncogenic potencial of UV radiation and enhancing transformation in sun-exposed skin sites 
(Struijk et al., 2008).  
Interestingly, recent results indicate that HPV8 and 38 E6 are able to interact with the 
host cell endogenous E6AP protein (Bedard et al., 2008) and extend the lifespan of human 
keratinocytes by telomerase activation (Gabet et al., 2008). 
 
E7 
E7 is a nuclear protein considered to have the major transforming properties during 
high risk HPV infection. It shares similar gene sequences and transformation properties with 
the adenovirus E1A and SV40 large T antigen (reviewed in Lee and Cho, 2002). HPV E7s 
have three conserved regions: CR1, CR2 and CR3. E7 gene deletion experiments 
demonstrated that the CR2 region is responsible for the release of E2F from pRb whereas the 
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CR3 region contains two finger-like motifs that allows the E7 binding to pRb, p27KIP1, p21CIP1 
and p300/CBP (Liu et al., 2006). 
The tumor suppressor retinoblastoma protein (pRb) and related pocket proteins p107 
and p130 are the main cellular targets for HPV E7 (Dyson et al., 1989). pRb family is the 
main cell cycle repressor during epithelial differentiation. When unphosphorylated, pRb acts 
as transcription repressor by complexing to the transcriptional factors E2F/DP, involved in S 
phase progression and apoptosis (Fig. 5). When E7 binds to pRb, E2F is released, allowing 
the cell cycle progression and the constitutive activation of the repressed genes (Munger et 
al., 2001). In addition, E7 targets pRb degradation by ubiquitin proteosome pathway 
(Berezutskaya et al., 1997). Both low and high risk HPV E7s share the ability to bind to pRb 
and family members, although the affinity is much lower in the low risk types. 
 
Figure 5. Role of high risk E6 and E7 in HPV infection (adapted from Doorbar, 2006). 
 
Another activity of high risk E7 is interacting with histone deacetylases (HDACs), 
which helps in the repression effect of E2F. This inhibitory effect of E7 has been described to 
be crucial in the maintenance of the episomal viral genome (Hurford et al., 1997) although the 
cellular mechanisms involved in the interaction between E7 and HDAC are not yet fully 
understood. 
Cell cycle progression is controlled by cyclins, which form complexes with cyclin-
dependent protein kinases (CDK) (reviewed in Besson et al., 2008). E7 interferes with the 
activity of the CDK inhibitors p21CIP1 and p27KIP1 to override normal G1 checkpoint control 
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(Jones et al., 1997; Zerfass-Thome et al., 1996). It also contributes to cell cycle progression 
by activation of cyclins E and A (Arroyo et al., 1993), which are involved in pRb inactivation 
by phosphorylation. 
High risk HPV E7 expression leads to transformation of immortalized murine 
fibroblasts and to immortalization of primary human keratinocytes (Halbert et al., 1991). 
Centrosomal aberrations have been described as an effect of high risk HPV E7 expression 
(Duensing et al., 2000), inducing failures in chromosomal segregation, a normal feature in 
HPV-positive carcinomas. 
Low risk genital and cutaneous HPV E7 weakly interact with pRb (Schmitt et al., 
1994) and are unable to transform rodent cells unless they are combined with activated H-ras 
expression (Yamashita et al., 1993). However, single amino acid substitutions can increase 
the transforming properties of the low risk HPV6 E7 (Sang and Barbosa, 1992). It has been 
shown that low risk genital HPV1 E7 transforms a mouse fibroblast cell line (Schmitt et al., 
1994) and cutaneous HPV38 E7 inactivates pRb and deregulates cell cycle (Caldeira et al., 
2003). Moreover, cutaneous HPV5, 15, 17, 20 and 38 E6/E7 showed increased proliferation 
and aberrant differentiation when constitutively expressed in organotypic cultures of primary 
keratinocytes (Boxman et al., 2001).  
Smad peptides (Signalling Mother Against Decapentaplegic Peptide) are the 
molecules that control intracellular signalling of transforming growth factor-ß (TGF-ß). 
Interestingly, both high risk and low risk HPV E7 are able to inhibit the anti-proliferative 
effect of the TGF-ß by binding to Smad. In this way, E7 from different HPVs preserves 
keratinocyte proliferation, necessary for the productive viral life cycle (Habig et al., 2006). 
 
1.1.4.2 Late proteins 
The late genes L1 and L2 encode for viral structural proteins necessary for the viral 
capsid production.  
 
L1 
 The L1 ORF is the highest conserved region in all HPV types and codes for the major 
capsid protein, which is only expressed in terminally differentiated cells of the epithelia. L1 is 
the major structural component of HPV and it spontaneously self-assembles in pentamers, 
known as capsomeres. One virion capsid contains 360 L1 proteins organized in 72 
capsomeres (Baker et al., 1991; Modis et al., 2002).  
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The distinct tissue tropism of genital and cutaneous HPV types might be explained by 
the positive viral surface charge of L1 in genital types and negative charge of the cutaneous 
types, as recently demonstrated (Mistry et al., 2008). 
 
L2 
The L2 ORF encodes for the minor capsid protein and it is present as a single copy in 
the centre of the pentavalent capsomeres at the virion vertices (Buck et al., 2008; Modis et al., 
2002; Trus et al., 1997). Virus like particles (VLP) can assemble in vitro in the absence of L2. 
However, when L2 is present packaging occurs more efficiently (Stauffer et al., 1998) and the 
viral infectivity is increased (Roden et al., 2001). Additionally, L2 participates in the 
disruption of endosomal membranes and the subcellular trafficking of the incoming viral 
genome (Kamper et al., 2006). 
 
1.1.4.3 Upstream regulatory region 
The upstream regulatory region (URR) is located between the L1 and E6 genes of 
HPV genome. The URR contains the promoters responsible for early genes expression and 
sequences involved in transcription and replication. A number of binding sites for 
transcription factors present in the URR are found among all HPV types, as TFIID, Sp-1 and 
AP-1 (del Mar Pena and Laimins, 2001), NF-1 (Butz and Hoppe-Seyler, 1993), TEF-1 and 
TEF-2 (Ishiji et al., 1992), AP-2 (Kyo et al., 1997), Oct-1 (O'Connor and Bernard, 1995), 
Stat-1 (Chang and Laimins, 2000), YY1 and glucocorticoid responsive elements (Gloss et al., 
1987). 
 
1.1.5 HPV life cycle  
HPV life cycle is linked to the differentiation state of the infected host cell, the 
keratinocyte. The infection begins when virus particles gain access to proliferative basal cells 
of the epithelium (Fig. 6). The virus reaches epidermal basal cell layer through microlesions. 
However, the access is naturally occurring in the bulb of the hair follicle and in the 
transformation zones of the cervix and the anus where columnar and stratified epithelia meet 
each other (reviewed in Doorbar, 2005 and in Longworth and Laimins, 2004).  
The virus initially attaches to the cell surface via Heparin Sulphate 
Glycosaminoglycans (HSCG) (Giroglou et al., 2001; Joyce et al., 1999). Blocking of HSCG 
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in the cell surface by heparin sulphates inhibitors like DSTP27 is sufficient for avoiding HPV 
infection (Selinka et al., 2007).  
E1 and E2 proteins are expressed in undifferentiated basal layer cells and first 
suprabasal layers of the epidermis, where HPV genome is episomally maintained at low copy 
number (between 20 to 100 extrachromosomal copies per cell). E2 protein anchors the viral 
circular genome to mitotic chromosomes, ensuring segregation to daughter cells and regulates 
the early viral promoter (Frattini and Laimins, 1994).  
As an infected cell leaves the basal layer, the HPV E7 expression leads to induction of 
unscheduled re-entry into S-phase of the cell cycle (Cheng et al., 1995). In the upper 
suprabasal layers, induction of E1, E2, E4 and E5 genes expression necessary for replication 
is controlled by the late differentiation-specific promoter located in the E7 ORF.  
In the stratum granulosum, the capsid proteins L1 and L2 are expressed under the 
control of the late promoter and are spontaneously assembled into icosahedral capsids. Once 
the viral assembly occurs, mature viruses are released from the cornified layer of the 
epithelium, facilitated by the cytokeratin skeleton rearrangements induced by high levels of 
E4 protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Normal versus HPV infected epithelia. HPV life cycle (adapted from Frazer, 2004). 
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In low-grade lesions, the high risk HPV is presented in episomal copies in the host cell 
whereas during progression to high grade lesions or carcinomas the genome is often 
integrated into the host cell genome (reviewed in Pett and Coleman, 2007; Schwarz et al., 
1985). The integration usually occurs in the E2 ORF, disrupting the gene and releasing the 
repressing effect of E2 protein on E6 and E7 expression, leading to higher levels of these 
transforming proteins (Chan et al., 2007; Dowhanick et al., 1995).  
 
1.1.6 HPV and cancer 
HPV infection causes 5.2% of all cancers worldwide (Parkin and Bray, 2006). HPV is 
associated with cancer of the genital tract, skin and the head and neck region. The distribution 
of HPV positive cases is shown in table 1. 
 
 
 
 
 
 
Table 1. Percentage of HPV-positive tumors (Parkin and Bray, 2006). 
 
1.1.6.1 Cervical cancer 
Cervical cancer is the second most common cancer in women worldwide with 
approximately 493,000 new cases and 274,000 deaths per year (Parkin and Bray, 2006).  
Most of cervical cancer corresponds to SCC, whereas adenocarinomas are less 
common. Developing countries have the highest incidence in cervical cancer (83%) (Parkin et 
al., 2005), while the incidence in industrialized countries has decreased during the past 
decades, due to a highly effective screening program (Koong et al., 2006; Peto et al., 2004).  
HPV infection is linked to cervical carcinoma (zur Hausen et al., 1974) and it is 
known to be an essential factor in cervical and anogenital carcinogenesis (Walboomers et al., 
1999; zur Hausen, 1996; reviewed in zur Hausen, 2002).  
Anatomical distribution HPV positivity 
Cervix 100% 
Anus 90% 
Penis 40-50% 
Vulva, vagina 40% 
Oropharynx 14% 
Oral cavity 4% 
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HPV16 together with HPV18 infections accounts for approximately 70% of cervical 
cancers (IARC, 2005); other types demonstrated in cervical cancer are HPV31, 33, 35, 39, 45, 
51, 52, 56, 58, 59 and 66 (Clifford et al., 2003; IARC, 2005). Significant co-factors in HPV-
associated cancer include co-infection with Chlamydia or human immunodeficiency virus 
(HIV), smoking and parity (> 3 children). The role of hormonal contraceptives and nutrients is 
presently unclear (IARC, 2005). 
 
1.1.6.2 Head and neck cancer 
Head and neck squamous cell carcinoma (HNSCC) refers to mucosal malignancies 
arising from the lips, oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, maxillary 
sinus, nasal cavity, ethmoid sinus, and salivary glands. It is the fifth most common cancer in 
males and the eight most common in females (Parkin et al., 2005). The total number of new 
HNSCC cases is globally more than 600,000 annually, with 350,000 deaths per year. 
The etiology of HNSCC is considered multifactorial. Tobacco use and alcohol 
consumption are considered the main risk factors for this disease (Castellsague et al., 2004; 
Franceschi et al., 1990), and the incidence rates vary depending on different geographically 
customs. The mode of tobacco use varies depending on customs in different countries. 
Tobacco smoking is common in Europe, Australia and Latin America whereas chewing 
tobacco is the major exposure in India, Papua New Guinea and Southeast Asia. Alcohol 
increases the risk of oral cancer, regardless of the type of beverage (Parkin and Bray, 2006). 
Cancer risk is higher when tobacco and alcohol consumption are combined (Morse et al., 
2007). 
Viral agents also contribute to the development of HNSCC. Esptein-Barr virus is 
associated with nasopharyngeal cancer (Deyrup, 2008). HPV infection, mainly HPV16, has 
been demonstrated in oropharyngeal cancer (Loning et al., 1985; Syrjanen et al., 1983; 
Syrjanen et al., 1982; reviewed in Fakhry and Gillison, 2006; Kreimer et al., 2005).  
Oropharyngeal tumors are classified into two subgroups: tobacco and alcohol negative 
tumors associated with HPV infection and those associated with tobacco and alcohol 
consumption and HPV negative (Smith et al., 2004; Tachezy et al., 2005). However, a 
synergistic effect of HPV infection and alcohol/tobacco in the onset of the disease is still 
unclear (Smith et al., 2004). Tumors of never smokers and never drinkers contain more often 
HPV DNA than tumors of cases with tobacco and alcohol history. HPV DNA positivity varies 
depending on the anatomical localization of the tumor; tumors of oropharynx are more often 
HPV DNA positive (57%) than tumors of the oral cavity (25%) (Gillison et al., 2000; Miller 
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and Johnstone, 2001; Tachezy et al., 2005). The highest prevalence of HPV in HNSCC has 
been found in tonsillar cancer with HPV positivity in 40-75% of the cases (Dahlstrand and 
Dalianis, 2005). Interestingly, HNSCCs patients infected with HPV have a better prognosis 
when compared with HPV-negative patients (Fakhry and Gillison, 2006).  
 
1.1.6.3 Non melanoma skin cancer 
Non melanoma squamous skin cancer (NMSC) is the second most common cancer 
among Caucasian populations (Preston and Stern, 1992). Main risk factors described are UV 
light exposure, smoking, age, male sex, chronic skin ulcers, burn scars and 
immunosuppression (Alam and Ratner, 2001). Infection with HPV has been found in healthy 
individuals (Antonsson et al., 2000; Astori et al., 1998; Harwood et al., 2004) and it has been 
related to benign and malignant lesions of NMSC immunocompetent and immunosuppressed 
patients (Akgul et al., 2006; Biliris et al., 2000; de Jong-Tieben et al., 1995; de Villiers et al., 
1997; Kiviat, 1999; Shamanin et al., 1994).  
A number of cutaneous HPV types have been associated with multiple lesions in EV 
patients. These patients have an inherited disorder of cell-mediated immunity, and develop 
flat warts which in 40-60% of the cases lead to malignancy in sun-exposed sites (reviewed in 
Jablonska and Majewski, 1994). 
Immunosuppressed and solid organ transplant patients infected with HPV present 
warts that develop into squamous cell carcinoma (SCC), especially on sun-exposed skin sites 
(Akgul et al., 2006; Berkhout et al., 1995; de Villiers et al., 1997; Shamanin et al., 1994; 
Shamanin et al., 1996; Tieben et al., 1994). HPV is specially detected in sun-exposed sites in 
both lesion and control skin (Asgari et al., 2008; Forslund et al., 2007), what suggests that 
combined effect of viral infection and UV light may lead to persistent infection and malignant 
progression.  
Interestingly, a recent report in non-immunosuppressed patients showed that 12% of 
healthy skin contained HPV sequences whereas its presence was 26% in benign lesions, 22% 
in actinic keratoses, 18% in BCC and 26% in SCC. However, only infection with genus Beta 
papillomavirus of the subgroup 2 showed a direct correlation with disease (Forslund et al., 
2007). This observation demonstrates the involvement of HPV in skin SCC also in non-
immunosuppressed individuals. Individual involvement of cutaneous HPV types with the 
onset and development of skin SCC remain to be elucidated. 
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1.2 4-NQO 
Chemical carcinogens present in tobacco (e.g. DMBA and benzenes) need metabolic 
activation and are therefore rarely used in in vitro studies.  
4-nitroquinoline-1-oxide (4-NQO) is a quinoline derivative compound active when 
applied directly either to cells or whole organisms. It was initially developed with 
chemotherapeutic purposes (Nakahara et al., 1957) but it acts indeed as chemical carcinogen, 
inducing oral carcinogenesis in mice when applied in the drinking water and being widely 
used for studying oral carcinogenesis (Miyamoto et al., 2008; Srinivasan et al., 2008; Vered 
et al., 2005) and tumors of the head and neck region (Aubry et al., 2008).  
4-NQO is used as a model for studying genetic susceptibility to different types of 
cancers; it has been described that when lymphocytes are exposed to 4-NQO they are more 
sensitive in samples from melanoma patients than those from head and neck cancer patients or 
healthy subjects (Hsu TC, 1993). Recently, another study demonstrated that sensitivity to 4-
NQO reflects susceptibility to UV in the development of NMSC (Wang et al., 2007).  
Treatment with 4-NQO has been employed in mammalian cells as a model for DNA 
damage-induced carcinogenesis (Kyng et al., 2005; Ninomiya et al., 2004). 4-NQO has been 
characterized as UV-mimetic with respect to its genotoxic properties; it behaves very 
similarly to ultraviolet irradiation of short wavelengh or C irradiation (UVC) as DNA 
damaging agent. Both bulky 4-NQO adducts and UV-induced pyrimidine dimers are repaired 
by nucleotide excision repair mechanism (Snyderwine and Bohr, 1992). It induces a potent 
intracellular oxidative stress (Nunoshiba and Demple, 1993) and generates reactive oxygen 
species (ROS) such as superoxide radical or hydrogen peroxide (Arima et al., 2006; Hozumi, 
1969; Sugimura et al., 1968). 4-NQO causes bulky DNA adducts primarily at G and A bases 
(Bailleul et al., 1989; Galiegue-Zouitina et al., 1985), chromosomal aberrations (Darroudi et 
al., 1989), apoptosis when applied at high doses and cell cycle arrest in G0-G1 phases (Han et 
al., 2007).  
p16, cyclin D1 and p53 are altered during oral carcinogenesis (Opitz et al., 2001; Shah 
et al., 2007; Wayne and Robinson, 2006). Interestingly, these proteins have also been 
observed to change under experimental 4-NQO-induced oral cancer (Kanojia and Vaidya, 
2006).  DNA damage induced by 4-NQO treatment leads to increased levels of tumor 
suppressor p53 and up-regulation of p21CIP1 (Seo et al., 1999). In a 4-NQO mouse model, up-
regulation in expression of keratin 1, keratin 14, EGF receptor and a decrease in p16 
expression in tongue tumors have been reported as observed in human oral SCC (Tang et al., 
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2004), simultaneously with over-expression of apoptotic related Bcl-2 and Bax proteins 
(Nishimura, 1999). These similarities between human patients and mouse models treated with 
the carcinogenic agent points the suitability of 4-NQO as inducing agent for studying oral 
carcinogenesis.  
 
1.3 p53 gene family 
p53, p63 and p73 form a protein family that shares a similar gene structure, containing 
alternative splicing, initiation of translation and promoters sites. The basic structure of the 
family includes an N-terminal domain required for transcriptional activation, a DNA binding 
domain and an oligomerization domain in the C terminus. All the members have very similar 
sequences, especially in the DNA binding domain, which enable p63 and p73 to transactivate 
p53-responsive genes (reviewed in Irwin and Kaelin, 2001). However, each protein has 
specific functions that are not shared by all the family members (reviewed in Bourdon, 2007).  
 
1.3.1 p53 
p53 is a tumor suppressor protein. It acts as transcription regulator and plays a key role 
in cell cycle by regulating growth arrest, DNA repair and apoptosis. Mutations in the p53 
gene that unable it to bind its target DNA sequences have been observed in 50% of all the 
human tumors (Soussi and Beroud, 2001).  
DNA damage and other stress signals as UV radiation, osmotic stress, chemical agents 
and oncogene expression activate p53. Its expression is regulated by an E3 ubiquitin ligase, 
Mdm2, which recognizes the transactivation domain of the protein and inhibits its 
transcription.  
p53 regulates the transcription of genes encoding proteins involved in cell cycle arrest 
as p21CIP1, GADD45 and 14-3-3σ, avoiding replication of damaged DNA (Fig. 7).  Once 
growth arrest occurs, p53 activates the transcription of genes involved in DNA repair such as 
ribonucleotide reductase p53R2 (implicated in DNA replication and reparation) and the AP 
endonuclease, which forms part of the base excision repair machinery (reviewed in Bourdon, 
2007). In irreversible DNA-damaged cells, p53 can target them to apoptosis by activating the 
pro-apoptotic proteins Bax (Chipuk et al., 2004), Apaf-1 (Robles et al., 2001), PUMA 
(Nakano and Vousden, 2001) and NoxA (Shibue et al., 2003). 
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Figure 7. Role of p53 in G1 and G2/M growth arrest (modified from http://mol-biol4masters.org/). 
 
The p53 gene codes for nine different isoforms (p53, p53β, p53γ, ∆133p53, 
∆133p53β, ∆133p53γ, ∆40p53, ∆40p53β, ∆40p53γ) named depending on its promoter use (in 
exon 1 or in intron 4) and alternative splicing of intron 9 in the carboxiterminus side (β and γ 
forms) (reviewed in Bourdon, 2007). Although the function of the different forms still need to 
be further investigated, it has been shown that p53β binds preferably p21CIP1 and Bax target 
promoters, while p53 has a high affinity to Mdm2 (Bourdon et al., 2005). 
 
1.3.2 p63 
p63 gene is composed of 15 exons and codes for 6 protein isoforms (TAp63α, 
TAp63β, TAp63γ, ∆Np63α, ∆Np63β and ∆Np63γ). The transactivating isoforms, TAp63, are 
transcribed from the promoter located upstream of the exon 1 whereas truncated ∆Np63 forms 
lacking the transactivation domain are expressed under the control of the second promoter, 
located in the intron 3. The different C-terminal spliced proteins correspond to α, β and γ 
forms (reviewed in Candi et al., 2007). 
The role of p63 isoforms is still controversial. ∆Np63 plays a crucial role during 
embryogenesis, epithelial development and differentiation (McKeon, 2004). However, other 
reports defined TAp63 isoforms as the first appearing during development (Koster et al., 
2004). The more likely explanation is that both TA and ∆Np63 isoforms are required for 
development and their effect is exerted by protein counterbalance. In disease, the p63 gene is 
amplified in cervical carcinomas (Wang et al., 2001). 
The role of p63 isoforms in epidermal differentiation has been studied recently by 
iRNA in organotypic raft cultures (Truong et al., 2006). In this study, they demonstrated that 
failure in ∆Np63 isoforms expression abolishes proliferation and differentiation, whereas 
TAp63 isoforms expression has a minor contribution to epidermal differentiation.  
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1.4 Cell cycle control by cyclin-dependent kinase inhibitors  
Cell cycle progression is regulated by the activity of cyclin/CDK complexes (reviewed 
in Besson et al., 2008). Cell cycle inhibitor molecules (CDI) interact with these cyclin/CDK 
complexes.  CDI are classified into two gene families:  
• INK4 tumor suppressor family.  They inhibit cell cycle by avoiding CDK4 and CDK6 
union to cyclin D (reviewed in Sherr and Roberts, 1999). The INK4 family is formed by 
p16INK4a, p15INK4b, p18INK4c and p19INK4d proteins.  
• Cip/Kip family, refered to p21CIP1, p27KIP1 and p57KIP2 proteins. They bind to cyclins D, 
E, A and B and to CDK molecules, modulating the activity of these cyclin/CDK 
complexes (reviewed in Sherr and Roberts, 1999).  
p21CIP1 acts by binding to the complexes cyclin E/CDK2 and cyclin B/CDK1 and 
blocking the CDK kinase activity, inducing both G1 and G2 arrest (Agarwal et al., 1995). 
Moreover, p21CIP1 controls cellular proliferation by binding to proliferating cell nuclear 
antigen (PCNA) and inhibiting DNA synthesis (Luo et al., 1995). Its transcription is regulated 
by p53 (el-Deiry et al., 1993).  In addition, p21CIP1 activates pRb, linking both tumor 
suppressor pathways. The role of Cip/Kip proteins as tumor suppressors or oncogenes 
remains still controversial (reviewed in Besson et al., 2008). However, in pancreas, breast, 
prostate, ovary, cervix and brain tumors, p21CIP1 overexpression correlates with a poor 
prognosis (Roninson, 2002).  
 
1.5 The skin 
1.5.1 Skin organization 
The skin is a complex, multilayered organ that serves as the first barrier to the outside 
environment and prevents unnecessary loss of water from the organism. Both adherens 
junctions and desmosomes mediate cell-cell adhesion within the skin. It is composed of two 
parts, the dermis in the inner most layer and the epidermis as the outer layer (Elder et al., 
2005).  
The dermis is a connective tissue containing fibroblasts embedded in collagen and 
elastic fibers. It harbors the nerve receptors, hair follicles, sweat glands, sebaceous glands, 
apocrine glands, lymphatic vessels and blood vessels.  
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The epidermis consists primarily of cells with little connective tissue. It is a stratified, 
continually renewing epithelium, exhibiting progressive differentiation in a basal to 
superficial direction. It is comprised mainly of keratinocytes (90-95% of the cells) and also 
melanocytes, Langerhans and Merkel cells. The structure of an individual keratinocyte 
correlates with its position within the epidermis and its state of differentiation (reviewed in 
Houben et al., 2007). 
 
1.5.2 Epidermal layers 
Different cellular layers can be distinguished in the epidermis corresponding to 
progressive stages of differentiation: basal, spinous, granular and cornified layers (Fig. 8). 
Keratinocytes arise from stem cells in the basal layer of the epidermis and in the bulge region 
of the hair bulb, and move through a series of differentiation events until they are finally 
sloughed into the environment (Eckert et al., 1997). During epidermal differentiation, 
keratinocytes undergo dehydration, loss of proliferation properties, cell flattening and increase 
in size. The cells create and reorganize the organelles, change their plasma membrane 
properties, cell surface antigens and receptors and synthesize different proteins and lipids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Epidermal layers and protein expression pattern in the epidermis (adapted from Radtke and Raj, 2003). 
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The basal layer of keratinocytes is in contact with the basement membrane, which 
separates the epidermis from the dermis. Cells in the basal layer are the only keratinocytes in 
intact skin capable of mitosis and, as such, are the source of all other keratinocytes in the 
epidermis. They attach to the dermis through hemidesmosomes and to adjacent cells through 
desmosomes and adherens junctions (Borradori and Sonnenberg, 1996). Basal layers are 
columnar in shape and tipically express keratins 5 and 14 (Steinert, 1993). 
The first suprabasal keratinocyte layer is the stratum spinosum, with many 
desmosomal contacts between cells. Morphologically, spinous cells are larger and more 
flattened than basal cells. Suprabasal keratinocytes express differentiation-specific keratins 1 
and 10. Cells begin to produce late differentiation markers such as involucrin in the upper 
spinous layers followed by expression of loricrin and epidermis-specific transglutaminases in 
the upper stratum spinosum (Fuchs, 1993; Rossi et al., 1998).  
As keratinocytes differentiate further, they form the stratum granulosum. Distinct 
electron-dense keratohyalin granules characterize cells of this layer. They contain a late stage 
protein, the profilaggrin, the protein precursor of filaggrin. Filaggrin functions as an 
intermediate filament-associated protein, which aggregates keratin filaments in cornified cells 
(Ishida-Yamamoto et al., 1999).  Granular cells also contain lipid-filled granules. These lipids 
granules fuse with the plasma membrane and release their contents into the intercellular 
spaces in the transition zone between the stratum granulosum and stratum corneum. 
The uppermost epidermal layer is the stratum corneum. The corneocyte is a flattened 
cell that loses the nuclei, whose organelles have broken down, and which is metabolically 
inactive (reviewed in Candi et al., 2005). Macrofibrils are the basic structural unit of the 
cornified envelope. In this epidermal layer, the extracellular matrix is replaced by lipid 
lamellae, conferring hydrophobicity to the surface. Corneocytes attached by desmosomes are 
ultimately desquamated on the skin surface (Eckert et al., 1997). 
In palmar and plantar skin additional keratins, 6a, 6b, 9, 16, and 17 are expressed 
(Fuchs, 1993). 
 
1.5.3 The skin barrier 
The outermost layer of the stratified squamous epithelia, the stratum corneum, is 
responsible for skin impermeability. This layer is composed of dead cells (corneocytes) filled 
with keratins. They are embedded in a filaggrin matrix and surrounded by intercellular lipid 
lamellae structures. At the molecular level, a functional corneocyte contains loricrin, 
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involucrin attached to lipids and in the uppermost cell membrane free fatty acids, ceramides 
and cholesterol. A balanced composition of these elements is necessary for keeping an 
effective physical and water barrier function in the epidermis (reviewed in Candi et al., 2005). 
Loricrin constitutes 80% of the proteins in the cornified envelope. It acts as reinforcement 
together with small proline rich protein (SPR) in the lower part of the corneocyte cellular 
membrane (Hohl et al., 1991). 
Lipids are accumulated in the trans-Golgi of the cells in the granular layer and released 
as lamellar bodies (Wertz and van den Bergh, 1998), mostly composed of ceramides. The 
ceramides link to specific scaffold proteins, involucrin, envoplakin and periplakin in the 
cornified layer (Marekov and Steinert, 1998). This attachment occurs via transglutaminase 
enzymes that form ester bounds (reviewed in Kalinin et al., 2002).    
Several hereditary diseases involve impaired barrier function. These alterations in skin 
barrier can be caused by: 
• Protein alterations: as in the lamellar ichthyosis disease, where mutations in the 
transglutaminase 1 gene lead to aberrant crosslinking of the proteins in the cornified 
layer (Huber et al., 1995) or the Netherton syndrome, characterized by a severe skin 
barrier defect  induced by defects in  the serine protease inhibitor Kazal type 5 
(SPINK5) (reviewed in Sevilla et al., 2007). 
• Defects in lipid metabolism: as X-linked ichthyosis, with cholesterol sulphate 
accumulation in the intercellular spaces; nonbullous congenital ichthyosiform 
erythroderma with mutations in lipid lipoxygenase-3 or -12R that leads to aberrant lipid 
extrusion (reviewed in Elias et al., 2008 and in Sevilla et al., 2007) and the Chanarin–
Dorfman syndrome where lipid droplets accumulate into vacuoles in the epidermis 
(reviewed in Candi et al., 2005). 
 
1.5.4 Keratins 
 Keratins are the intermediate filaments that provide the structural integrity of the skin 
by interacting with the microfilaments and microtubules. Different keratin polypeptides have 
been described, 20 corresponding to epithelial cells and 10 to hair (reviewed in Moll et al., 
2008; Moll et al., 1982; Tseng et al., 1982; Wu et al., 1982). They can be classified into two 
classes, the acidic, type I (K10-K20) and basic-neutral, type II (K1-K9) based on amino acid 
sequence, charge, size, immunological properties and homologies with wool keratins (Sun, 
1984). Keratins form heterodimers between one acid and one basic keratin of similar 
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molecular weight. They are expressed in highly specific patterns related to the cell type, 
functional state and stage of cellular differentiation (table 2, fig. 8) (O'Guin et al., 1987). 
 
 
Table 2. Characteristic expression patterns of keratins. (Adapted from Moll et al., 2008). 
 
1.5.4.1 Keratin expression in simple epithelia 
The pair K8/K18 is the typical keratins expressed in simple epithelia. They appear 
firstly during embryogenesis and are present in simple epithelia as ductal, gastrointestinal and 
urothelial cells but not in differentiating keratinocytes (reviewed in Moll et al., 2008). 
Interestingly, since cancers tend to behave as simple epithelia, K8/K18 has been found in 
most cancers, except some differentiated SCC (Malzahn et al., 1998; reviewed in Moll, 1998). 
K7/K19 pair can be expressed in some simple ductal epithelia as bile and pancreatic 
ducts but its profile is not as well defined as K8/K18 (reviewed in Moll et al., 2008).  
 
1.5.4.2 Keratin expression in stratified epithelia 
The K5/14 pair of keratin filaments is expressed in the basal cells of epidermis and 
mucosal non-keratinizing stratified squamous epithelia (Moll et al., 2008). As basal cells of 
the epidermis begin to differentiate, they down-regulate their expression and begin to produce 
differentiation-specific keratins.  
K6/K16 are typically found in hyperproliferative tissue as nails, mucosa, palmoplantar 
epidermis and skin wounding (Moll et al., 1982; Sun et al., 1983). They are highly expressed 
after injury and UV exposure, in squamous metaplasia and poorly differentiated SCCs (Moll, 
1998). K6/K16 are rarely found in cervix adenocarcinomas and invasive breast carcinomas. 
K17 is restricted to basal/myoepithelial cells and shares the same expression profile in healthy 
and carcinoma tissue as the K6/K16 pair. 
 Simple epithelia Stratified epithelia 
Type II/type I keratins 
K8/ 
K18 
K7/ 
K19 
K5/ 
K14 
 
K15 
K6/ 
K16 
K1/ 
K10 
K4/ 
K13 
Non-keratinizing 
stratified squamous 
epithelia 
Some 
basal 
cells 
K19 in 
many basal 
cells 
Basal 
cell layer 
Basal 
cell layer 
Suprabasal 
layers 
Focal, 
suprabasal 
layers 
Suprabasal 
layers 
Epidermis   
Basal 
cell layer 
Basal 
cell layer 
 
Suprabasal 
layers 
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The K1/K10 pair is expressed in the suprabasal layers of the epidermis and is the main 
keratins associated with differentiation and keratinization. In normal skin, they are expressed 
from the first suprabasal layer throughout the surface of the tissue (Boukamp et al., 1990; 
Stoler et al., 1988) and provide mechanical integrity to the epidermis. K9 is a very specific 
keratin that couples with K1; it is only present in the palm and sole in terminally 
differentiating keratinocytes (Moll et al., 1987).  
The pair K4/K13 is expressed in suprabasal mucosal squamous epithelial cells, 
involving non-keratinizing epithelia (intern organs) but not epidermis (Mischke et al., 1990).  
K77 expression is restricted to secreting cells of eccrine sweat gland ducts, what 
makes it a suitable marker for secreting epithelia (Langbein et al., 2005). 
 
1.5.4.3 Keratin expression in squamous cell carcinoma 
Keratin expression profile deeply changes during disease depending on the keratin 
type, being therefore a very important tool for diagnostic in tumor pathology.   
SCC mainly expresses stratified-epithelia keratins but may retain expression of 
simple-epithelia types too. Most SCCs and mesotheliomas, but not adenocarcinomas, strongly 
express K5/K14 and K17 (McDonald et al., 1998). The K6/16 pair, associated with 
hyperproliferative tissue, is generally up-regulated in SCC (McGowan and Coulombe, 1998). 
Histological examinations in SCCs revealed focal expression of K1/K10 depending on its 
level of maturation and keratinisation. High differentiated tumors focally express K4/K13 as 
well as K1/K10 in horn pearls formations. Considering the epidermal origin of HNSCC 
results surprising that focal K4/K13 expression has been found in this disease, especially in 
poorly differentiated carcinomas (Moll, 1998). 
K1/K10 are present in 50% of oral and pharyngeal SCC (Moll, 1998). In contrast, low 
differentiated SCC expresses typical keratins for simple epithelia, as K8/K18 and K19. In the 
case of oral SCC, K8/K18 expression is used as a marker for poor prognosis (Fillies et al., 
2006). 
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1.5.5 Differentiation markers 
1.5.5.1 Involucrin 
Involucrin is a soluble protein localized in the cytoplasm of granular and cornified 
cells (Mansbridge and Knapp, 1987; Murphy et al., 1984) of stratified squamous epithelia and 
primary keratinocyte organotypic cultures (Boukamp et al., 1990; Watt et al., 1987). This 
protein consists of repeating peptide units with a high Gly and Asp amino acid content. It is 
an early component during the cornified envelope formation, getting crosslinked to other 
proteins and thus forming a scaffold structure. Involucrin localizes in the cell membrane and 
is the substrate for lipid (mainly ceramides) attachment, being a crucial component of the 
lipid envelope (Marekov and Steinert, 1998). Involucrin expression has been demonstrated to 
be crucial for maintenance of epidermal barrier function (reviewed in Sevilla et al., 2007). 
 
1.5.5.2 Loricrin 
 Loricrin is expressed in granular layer cells during cornification as aggregates in the 
cytoplasm. It is the main component of the cornified layer and plays a key structural role as 
reinforcement protein and maintenance of barrier function (Candi et al., 1995; Segre, 2006). 
Its sequence is very rich in Gly, Ser and Cys residues and the protein lacks an ordered 
structure, providing elasticity to the cornified layer. Loricrin crosslinks with other loricrin 
molecules and to a lesser extends to SPR proteins, forming the scaffold of the cornified 
envelope (reviewed in Candi et al., 2005).  
 
1.6 Aim of the project 
The etiology of cancer of the oral cavity and esophagus is multifactorial with alcohol 
and tobacco consumption considered to be the main risk factors. Mucosal high risk HPV 
plays an important role in the pathogenesis of a subset of HNSCC, particularly those that arise 
from the lingual and palatine tonsils within the oropharynx. The smaller proportion of 
smokers in patients with HPV DNA positive tumors suggests that these tumors might form a 
distinct epidemiological entity.  
Cutaneous HPV20 is associated with benign and malignant lesions in the skin disease 
EV. It has been demonstrated in a number of NMSC as well as in esophageal carcinoma and 
in HNSCC patients. 
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Chemical carcinogens present in tobacco need metabolic activation and therefore are 
rarely used in in vitro studies. In our studies, we combined HPV20 with a chemical 
carcinogen that would act as a co-factor for investigating the immortalization and 
transformation properties of this virus. 4-NQO is considered as an UV-mimetic with respect 
to its genotoxic properties. It has been largely applied as model for oral carcinogenesis and it 
is active when applied directly either to cell culture or whole organisms.  
The aim of the project was studying the cooperation between HPV20 and the chemical 
carcinogen 4-NQO in the pathogenesis of malignant tumors by characterization of: 
• The HPV20 promoter activation profile under the context of 4-NQO treatment together 
with HPV20 E6, E7 or E6/E7 expression. 
• The expression of cellular proteins involved in cell cycle control, proliferation and 
differentiation (p53, ∆Np63α, PCNA and p16) in keratinocytes expressing HPV20 E6 
and treated with 4-NQO. 
• The cell cycle profile, apoptosis rates and effect on life span of primary keratinocytes 
treated with 4-NQO combined with HPV20 E6 expression. 
• Epidermal morphology; differentiation and proliferation markers expression pattern; 
effect in cellular proteins p53, ∆Np63α and p21CIP1; skin barrier functionality and lipid 
organization in organotypic cultures expressing HPV20 E6 and treated with 4-NQO.  
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2 Materials 
2.1 Equipment 
 
 
 
 
 
Cell culture 
Incubator for cell culture Forma Scientific, Ohio, USA 
Laminar flow hood The Baker Company Inc., Sanford, USA 
Neubauer cell counting chamber Brand GmbH, Wertheim, Germany 
Tissue grinder (Dounce) Sigma-Aldrich, Taufkirchen, Germany 
Centrifuges 
Floor centrifuge for large volumes (up to 
500 ml) RC5C 
Sorvall Instruments, USA 
High speed refrigerated centrifuge  1-15K Sigma, Osterode, Germany 
Non-refrigerated bench top centrifuge 5415  Eppendorf, Hamburg, Germany 
Refrigerated centrifuge Megafuge for 
conical tubes 1.0R 
Heraeus Sepatech, Hanau, Germany 
Freezers 
Freezer 4°C and -20°C Premium Liebherr, Ochsenhausen, Germany 
Freezer -80°C Hera  Kendro Laboratory, Hanau, Germany 
Liquid nitrogen  freezer Chronos Biosafe, Griesheim, Germany 
Gel electrophoresis, UV visualization and film developing  
Electrophoresis chamber for DNA and 
RNA 
Owl Separation Systems, Inc. Portsmouth, USA 
Electrophoresis power supplier Power Pac  Bio-Rad, München, Germany 
Film developing hyperprocessor Amersham Biotech, Freiburg, Germany 
Protein Minigel Wet Transfer System  Bio-Rad, München, Germany 
SDS-PAGE electrophoresis equipment Bio-Rad, München, Germany 
UV transilluminator 366 nm Konrad Benda, Wiesloch, Germany 
UV transilluminator 254 nm Bio-Rad, Milan, Italy 
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Microscopes, microtome and cryostat 
Binocular microscope Wilovert S Helmut Hund GmbH, Wetzlar, Germany 
Cryostat Leica CM3050S Leica, Nussloch, Germany 
Fluorescence camera F-View II firewire Soft Imaging System Münster, Germany 
Fluorescence microscope Leitz DM RBF Leitz Instruments, Wetzlar, Germany 
Light camera Colorview II Olympus, Hamburg, Germany 
Microtome Leica RM2235 Leica, Nussloch, Germany 
Transmission electron microscope EM 900 Zeiss, Oberkochen, Germany 
Ultramicrotome  Leica Ultracut UCT for 
electron microscopy sectioning 
Leica, Nussloch, Germany 
Other equipment 
Balance PB 602  Mettler- Toledo, Greifensee, Switzerland 
Bunsen burner Integra Biosciences, Chur, Switzerland 
Cytofluorograph 30-L  Ortho Diagnostics, Westwood, USA 
Gas chromatograph HP5890  Agilent Technologies, Waldbronn, Germany 
Flow cytometer FACScalibur Becton Dickinson, Heidelberg, Germany 
Block heater Gebr. Liebisch, Bielefeld, Germany 
Magnetic stirrer Heidolph Instruments, Schwabach, Germany 
Mass spectrometer HP5973 Agilent Technologies, Waldbronn, Germany 
Microwave oven B. Braun, Melsungen, Germany 
pH meter WTW, Weilheim, Germany 
Platform shaker Str6 Stuart Scientific, United Kingdom 
Scanner Perfection 4990 PHOTO Epson, Tokyo, Japan 
Shaking water bath 3047 Köttermann, Hänigsen, Germany 
Sonicator Bioruptor™ Diagenode, Liege, Belgium 
Spectrophotometer Ultrospec 3000pro Amersham Pharmacia Biotech, Freiburg 
SpeedVac concentrator Savant Instruments Inc., Farmingdale, NY, USA 
Thermocycler GeneAmp PCR 9700 Applied Biosystems, Darmstadt, Germany 
Vacuum pump Pfeiffer, Asslar, Germany 
Vortex Genie 2 Bender & Hobein AG, Zurich, Switzerland 
Water bath  Julabo Labortechnik, Seelbach, Germany 
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2.2 Consumables 
Bacterial culture 
Bacterial culture plates Greiner bio-one, Solingen, Germany 
 
Cell culture 
Cell culture plates  Greiner bio-one, Solingen, Germany 
Cell scrapers Corning Costar GmbH, Bodenheim, Germany 
Cryo tubes Nunc, Invitrogen, Karlsruhe, Germany 
Organotypic culture transwells inserts 3 µm  Neolab, Heidelberg, Germany 
Organotypic culture trays  Neolab, Heidelberg, Germany 
 
Sterile filtration 
Bottle Top Filter 500 ml, 0,22 µm Corning Costar GmbH, Bodenheim, Germany 
Filter Millex 0,22µm and 0,45 µm Millipore, Schwalbach, Germany 
Filter Puradisc for viruses, 0,45 µm Whatman, Madistone, USA 
 
Western blot 
BioMax MR film, Kodak Kodak, Stuttgart, Germany 
Cuvettes for protein cuantification Greiner bio-one, Solingen, Germany 
Nitrocellulose membrane Whatman Optitran, Dassel, Germany 
Whatman 3MM paper Whatman, Madistone, USA 
 
Other consumables 
Capillary columns for gas chromatography 
HP 5MS 
Agilent Technologies, Waldbronn, Germany 
Centrifugation tubes 1,5 ml and 2 ml Eppendorf, Hamburg, Germany 
Centrifugation tubes 15 ml and 50 ml BD FalconTM, New Jersey, USA 
Microscope Slides Super-Frost® Plus Menzel-Gläser, Braunschweig, Germany 
Parafilm M Greiner, Frickenhausen, Germany 
QIAshredder™ columns Qiagen, Hilden, Germany 
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2.3 Reagents 
Bacterial culture  
Ampicillin Sigma-Aldrich, Taufkirchen, Germany 
Bacto-agar Invitrogen, Karlsruhe, Germany 
Trypton AppliedChem GmbH, Darmstadt, Germany 
Yeast extract Difco, Beckton and Dickinson, USA 
 
Cell culture 
Adenine Sigma-Aldrich, Seelze, Germany 
Cholera toxin Sigma-Aldrich, Taufkirchen, Germany 
Dimethyl sulfoxide Sigma-Aldrich, Taufkirchen, Germany 
Dulbecco´s modified Eagle´s medium 
(DMEM) 1x  
Sigma-Aldrich, Taufkirchen, Germany 
Dulbecco´s modified Eagle´s medium 
(DMEM) 10x 
Promocell, Heidelberg, Germany 
Earl´s salt solution Sigma-Aldrich, Taufkirchen, Germany 
Epidermal growth factor (EGF) R & D systems, Wiesbaden, Germany 
Fetal calf serum (FCS) PAA laboratories, Pasching, Germany 
Geneticin  Calbiochem, Darmstadt, Germany 
Ham´s F-12 medium Invitrogen, Karlsruhe, Germany 
Hepes Sigma-Aldrich, Taufkirchen, Germany 
Hydrocortisone Merck, Darmstadt, Germany 
Insulin Sigma-Aldrich, Taufkirchen, Germany 
Keratinocyte medium 2 Promocell, Heidelberg, Germany 
Keratinocyte medium supplements 2 Promocell, Heidelberg, Germany 
Keratinocyte EpiLife medium Cascade Biologics, Mansfield, UK 
Keratinocyte medium supplements HKGS  Cascade Biologics, Mansfield, UK 
Mitomycin C Roche, Mannheim, Germany 
4-Nitroquinoline-1-oxide 99% Sigma-Aldrich, Taufkirchen, Germany 
OPTI-MEM medium Gibco, Invitrogen, Germany 
Penicillin 10,000 units/ml /streptomycin 
10 mg/ml (P/S) 
Sigma-Aldrich, Taufkirchen, Germany 
Polybrene (Hexadimethrine bromide) Sigma-Aldrich, Taufkirchen, Germany 
Materials 
 
 
43 
Rat tail collagen type I 4mg/ml BD Biosciences, Heidelberg, Germany 
Roswell Park Memorial Institute medium 
(RPMI) 
Sigma-Aldrich, Taufkirchen, Germany 
Transfection reagent FuGENE HD Roche, Mannheim, Germany 
Transfection reagent LipofectamineTM  Invitrogen, Karlsruhe, Germany 
Transfection reagent LipofectamineTM 
2000 
Invitrogen, Karlsruhe, Germany 
Transfection PlusTM Reagent  Invitrogen, Karlsruhe, Germany 
Trypan blue dye  Sigma-Aldrich, Taufkirchen, Germany 
Trypsin-EDTA Sigma-Aldrich, Taufkirchen, Germany 
 
Gas chromatography- mass spectrometry 
Chloroform Sigma-Aldrich, Taufkirchen, Germany 
Dimethoxypropane Sigma-Aldrich, Taufkirchen, Germany 
Oleic acid Campro Scientific, Berlin, Germany 
Palmitic acid  CDN, Pointe-Claire, Quebec, Canada 
Stearic acid CDN, Pointe-Claire, Quebec, Canada 
Sulfuric acid H2SO4 Sigma-Aldrich, Taufkirchen, Germany 
Toluene Sigma-Aldrich, Taufkirchen, Germany 
 
DNA and RNA  
Agarose Gibco, Invitrogen, Karlsruhe, Germany 
Bromophenol blue Serva, Heidelberg, Germany 
Deoxynocleosidetriphosphate (dNTP) Qiagen, Hilden, Germany 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Taufkirchen, Germany 
Ethidium bromide 95% (EtBr) Carl Roth GmbH, Karlsruhe, Germany 
Isoamylalcohol Merck, Darmstadt, Germany 
Isopropanol J.T. Baker, Deventer, Holland 
Random hexamers Qiagen, Hilden, Germany 
RNase inhibitor RNasin® Promega, Mannheim, Germany 
Xylene cyanol Sigma-Aldrich, Seelze, Germany 
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Immunohistochemistry and electron microscopy 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
5´ bromo-2-deoxyuridine (BrdU) Calbiochem, Darmstadt, Germany 
Citric acid Merck, Darmstadt, Germany 
3,3´-diaminobenzidine substrate (DAB) BD Biosciences, Heidelberg, Germany 
4´, 6- Diamidino-2-phenylindole 
dihydrochloride (DAPI)  
Serva, Heidelberg, Germany 
Eosin Y-solution 0,5% Merck, Darmstadt, Germany 
Eukitt® Kalo GmbH, Freiburg, Germany 
Fluoromount-G™ Southern Biotech, Biozol, Eching, Germany 
Glutaraldehyde solution 25% Sigma-Aldrich, Taufkirchen, Germany 
Haematoxylin Merck, Darmstadt, Germany 
Hoechst 33258 dye Invitrogen, Karlsruhe, Germany 
Hydrogen peroxide H2O2 Serva, Heidelberg, Germany 
Lead citrate Merck, Darmstadt, Germany 
Meyers´ hemalaum solution Carl Roth GmbH, Karlsruhe, Germany 
Oil red O  Sigma-Aldrich, Taufkirchen, Germany 
Paraffin Paraplast® Plus Ted Pella  Inc., Redding, CA, USA 
Paraformaldehyde (PFA) Merck, Darmstadt, Germany 
Resin Araldite® 506 epoxy  Sigma-Aldrich, Taufkirchen, Germany 
Sodium cacodylate trihydrate 
(CH3)2AsO2Na·3H2O 
Serva, Heidelberg, Germany 
Sodium citrate dihydrate C6H5Na3O7·2H2O Merck, Darmstadt, Germany 
Streptavidin Alexa 488-conjugated Invitrogen, Karlsruhe, Germany 
Sulforhodamide 101 dye (SR101) Eastman Kodak, Sttutgart, Germany 
Tissue-Tek O.C.T Sakura Finetek, Tokyo, Japan 
Triethyl-phosphate 60%  (C2H5)3PO4 Sigma-Aldrich, Taufkirchen, Germany 
Trypsin powder Biochrom AG, Berlin, Germany 
Uranyl acetate Merck, Darmstadt, Germany 
Xylol Sigma-Aldrich, Taufkirchen, Germany 
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Protein extraction and Western blot 
Ammonium persulfate (NH4)2S2O8 (APS) Merck, Darmstadt, Germany 
Protein quantification reagent BioRad Laboratories, Munich, Germany 
1,4-dithio-DL-threitol (DTT) Sigma-Aldrich, Taufkirchen, Germany 
Western blotting detection reagent ECL Amersham Biotech, Munich, Germany 
β-Mercaptoethanol (ß-ME) Sigma-Aldrich, Taufkirchen, Germany 
Nonidet NP40 10% Roche, Mannheim, Germany 
Non-fat milk powder Carl Roth GmbH, Karlsruhe, Germany 
Pefabloc® AEBSF Roche, Mannheim, Germany 
Polyacrylamide Carl Roth GmbH, Karlsruhe, Germany 
Protease inhibitor cocktail 100x Sigma-Aldrich, Taufkirchen, Germany 
Restore™ Western Blot Stripping Reagent Perbio Science, Rockfold, USA 
Sodium dodecyl sulfate C12H25SO4Na 
(SDS) 
Gerbu, Gaiberg, Germany 
Sodium orthovanadate Na3VO4 Merck, Darmstadt, Germany 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich, Taufkirchen, Germany 
Triton X 100 Applichem, Darmstadt, Germany 
Tween®20 Serva, Heidelberg, Germany 
Urea Fluka, Deisenhofen, Germany 
 
Methanol J.T. Baker, Deventer, Holland 
Phosphate buffered saline (PBS) 10x Invitrogen, Karlsruhe, Germany 
Phenol Merck, Darmstadt, Germany 
Sodium acetate CH3COONa Merck, Darmstadt, Germany 
Sodium bicarbonate NaHCO3 Merck, Darmstadt, Germany 
Other reagents  
Ammonium acetate CH3COONH4 Merck, Darmstadt, Germany 
Ammonium chloride NH4Cl Merck, Darmstadt, Germany 
Calcium chloride CaCl2 Fluka Chemie AG, Buchs, Switzerland 
Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt, Germany 
Glycerol Fluka, Deisenhofen, Germany 
Hydrochloric acid HCl Sigma-Aldrich, Seelze, Germany 
Magnesium chloride MgCl2 Merck, Darmstadt, Germany 
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Sodium carbonate Na2CO3 Merck, Darmstadt, Germany 
Sodium citrate dihydrate   
C6H8O7Na3· 2H2O 
Merck, Darmstadt, Germany 
Sodium chloride NaCl J.T. Baker, Deventer, Holland 
Sodium fluoride NaF Merck, Darmstadt, Germany 
Sodium hydroxide NaOH Merck, Darmstadt, Germany 
Sodium orthovanadate NaVPO4 Merck, Darmstadt, Germany 
Sodium phosphate, monobasic NaH2PO4 Merck, Darmstadt, Germany 
Sodium phosphate, dibasic Na2HPO4 Merck, Darmstadt, Germany 
Sucrose Merck, Darmstadt, Germany 
Trishydroxymethylaminomethan (Tris) Sigma-Aldrich, Taufkirchen, Germany 
 
2.4 Software 
Basic Local Alignment (BLAST) 
 
National Center for Biotechnology 
Information, Bethesda, MD, USA 
Cellquest Pro 4  Becton Dickinson, Heidelberg, Germany 
ClustalW Conway Institute UCD, Dublin, Ireland 
ImageQuant 5.0 Molecular Dynamics, Sunnywale, CA, USA 
OligoAnalyzer 3.1. Integrated DNA Technologies, Leuven, 
Belgium 
 
2.5 Commercial kits 
Kit Used for Company 
BrdU 
Immunohistochemistry 
System 
Immunohistochemistry 
staining of cells that 
incorporated BrdU. 
Merck, Darmstadt, Germany 
Cytofix/Cytoperm™ Fixation and permeabilization 
of FACS samples. 
BD Biosciences, Heidelberg, 
Germany  
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Keratinocyte Detach kit2-
125 
Trypsinization of primary 
keratinocytes. 
Promocell, Heidelberg, 
Germany 
JetQuick Gel Extraction 
Spin Kit/250 
Purification of DNA from 
agarose gels. 
Genomed GmbH, Löhne, 
Germany 
JetQuick PCR Purification 
Spin Kit/250 
Cleaning and purification of 
DNA after PCR or enzymatic 
digestion. 
Genomed GmbH, Löhne, 
Germany 
JetQuick Plasmid Miniprep 
Spin Kit/250 
Small scale plasmid DNA 
purification from bacteria. 
Genomed GmbH, Löhne, 
Germany 
Dual-Luciferase® Reporter 
(DLR™) Assay System kit 
Measurement of promoter 
activity by luciferase reporter 
gene. 
Promega, Mannheim, 
Germany 
RNeasy® mini kit 50 Purification of RNA from cell 
extracts. 
Qiagen, Hilden, Germany 
Qiagen Plasmid purification 
kit 
Large scale plasmid DNA 
purification from bacteria. 
Qiagen, Hilden, Germany 
Vectastain®ABC Elite® kit Immunohistochemistry 
Avidin-Biotintylated enzyme 
complex.  
Vector Laboratories, 
Burlingame, CA, USA 
 
2.6 Solutions 
Nucleic acids preparation and manipulation 
Solution Final concentrations Components 
DEPC-H2O. Store at RT. 0,1% 
Dissolve in 
DEPC 
ddH2O, incubate o/n 37°C 
DNA loading buffer 5x. Aliquot 
and store at -20°C. 
40% (w/v) 
20 mM 
0,05% (w/v) 
0,05% (w/v) 
Dissolve in 
Sucrose 
EDTA 
Bromophenol blue 
Xylene cyanol 
dH2O 
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Electrophoresis buffer 50x (EP 
buffer). Store at RT. 
2 M 
0,25 M 
0,05 M 
Dissolve in 
Tris base 
CH3COONa 
EDTA 
dH2O 
Adjust pH 7,8 
TE buffer 10x. Store at RT. 100 mM 
10 mM 
Dissolve in 
Tris-HCl pH 8,0 
EDTA 
dH2O 
TE buffer 1x. Store at RT. 10% 
Dissolve in 
TE buffer 10x 
dH2O 
 
Protein extraction 
Solution Final concentrations Components 
Organotypic culture protein 
extraction buffer. Store at 4°C. 
50 mM  
5 mM  
10 mM 
10 mM 
0,5% 
Dissolve in 
 
 
1x 
2 mM 
1 mM 
Tris 
EDTA 
NaCl 
NaF 
NP40 
dH2O 
Adjust pH 8,0, Store at 4°C 
Just before use add: 
Protease inhibitor cocktail 
DTT 
NaVPO4 
Monolayer cell culture protein 
extraction buffer (RIPA). Store 
at 4°C. 
100 mM 
150 mM 
1 mM 
1% 
0,1% 
 
1x  
2mM 
1mM 
Tris-HCl pH 8,0 
NaCl 
EDTA 
NP40 
SDS 
Just before use add: 
Protease inhibitor cocktail 
DTT 
Pefabloc AEBSF 
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Sodium orthovanadate 10 M. 
Aliquot and store at -20°C. 
 
10 M 
Dissolve in 
NaVPO4 
H2O 
1. Adjust pH 10 
2. Boil and cool down 
Repeat steps 1-2 until the solution 
becomes colorless. 
Urea 12 M/Mercaptoethanol 
0,8% buffer  
Aliquot and store at -20°C. 
12 M 
0,8% (v/v) 
Dissolve in 
Urea 
β-ME 
dH2O 
 
SDS-polyacrylamide gel electrophoresis buffers 
Solution Final concentrations Components 
Blotting buffer 10x. Store at 
RT. 
250 mM 
2 M 
Dissolve in 
Tris 
Glycine 
dH2O 
Adjust pH 8,3-8,7 
Blotting buffer 1x. Prepare fresh 
just before use. 
10% 
20% 
Dissolve in 
Blotting buffer 10x 
Methanol 
dH2O 
Loading buffer 5x. Aliquot and 
store at -20°C. 
10% (w/v) 
0,3 M 
50% (v/v) 
Dissolve in 
 
0,5% (w/v) 
5% (v/v) 
Dissolve in 
SDS 
Tris-HCl pH 6,8 
Glycerol 
dH2O 
Heat 10 min 40-50°C 
Bromphenol blue 
ß-ME 
dH2O 
Running buffer 5x. Store at RT. 120 mM 
1,25 M 
5% (w/v) 
Dissolve in 
Tris 
Glycine 
SDS 
dH2O 
Running buffer 1x. Prepare 
fresh just before use. 
20% 
Dissolve in 
Running buffer 5x 
dH2O 
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TBS buffer 10x. Store at RT. 0,2 M 
1,36 M 
Dissolve in 
Tris 
NaCl 
H2O 
Adjust pH 7,6-8,0 
TBS-T buffer 1x. Prepare fresh 
just before use. 
10% 
0,1% 
Dissolve in 
TBS buffer 10x 
Tween20 
dH2O 
 
SDS-polyacrylamide gel  
Solution Final concentrations Components 
Stacking gel. Prepare fresh just 
before use. 
Polyacrylamide concentration 
varies depending on the size of 
the protein of interest, ranging 
between 10-15%. 
10-15% (v/v) 
25% (v/v) 
1% (v/v) 
1% (v/v) 
0,1% 
Dissolve in 
Polyacrylamide 
Tris-HCl 0,5 M, pH 8,8 
SDS 10% 
APS 10% 
TEMED 
dH2O 
Resolving gel. Prepare fresh just 
before use. 
7,5% (v/v) 
25% (v/v) 
1% (v/v) 
1% (v/v) 
0,1% 
Dissolve in 
Polyacrylamide 
Tris-HCl 0,5 M, pH 6,8 
SDS 10% 
APS 10% 
TEMED 
dH2O 
 
Cell culture 
Solution Final concentrations Components 
Adenine 18 mM. Filter sterilize, 
aliquot and store at -20°C. 
18 mM 
Dissolve in 
Adenine 
HCl 0,05 M 
Stir 1 h at RT 
Cholera toxin stock 0,83 mg/ml. 
Store at 4°C.  
0,083% (v/v) 
Dissolve in  
Cholera toxin 
dH2O 
Cholera toxin 0,83 µg/ml. Filter 
sterilize, aliquot and store at 
4°C. 
0,1% (v/v) 
0,1% (w/v) 
Dissolve in 
Cholera toxin stock 0,83 mg/ml 
BSA 
Hepes-buffered Earl´s salt 25 mM 
 
 
Materials 
 
 
51 
EGF stock solution 1 mg/ml. 
Store at -20°C. 
0,1% (w/v) 
Dissolve in 
EGF 
dH2O 
EGF solution 1 µg/ml. Filter 
sterilize, aliquot  and  store  at   
-20°C. 
0,1% (v/v) 
0,1% (w/v) 
Dissolve in 
EGF stock solution 1 mg/ml 
BSA 
Hepes-buffered Earl´s salt 25 mM 
FCS.  Aliquot   and   store   at    
-20°C. 
500 ml Heat inactivate at 56°C, 30 min 
Freezing medium for cell line 
storage in liquid nitrogen. 
90% 
10% 
Corresponding cell medium 
DMSO 
Hydrocortisone stock 5 mg/ml. 
Store at -20°C. 
0,5% (w/v) 
Dissolve in 
Hydrocortisone 
Ethanol 100% 
Hydrocortisone 0,8 µg/ml. Filter 
sterilize,  aliquot  and  store  at  
-20°C.  
0,8% (v/v) 
5% (v/v) 
Dissolve in 
Hydrocortisone stock 5 mg/ml 
Heat inactivated FCS 
Hepes-buffered Earl´s salt 25 mM 
Insulin 0,5 mg/ml. Filter 
sterilize,  aliquot  and  store  at  
-20°C. 
0,05% (w/v) 
Dissolve in 
Insulin 
HCl 5 mM 
Reconstitution buffer 10x.  
Filter sterilize, aliquot and store 
at -20°C. 
260 mM 
2 M 
Dissolve in 
NaHCO3 
Hepes 
NaOH 50 mM 
 
Immunohistochemistry/ immunofluorescence 
Solution Final concentrations Components 
Citrate buffer. Prepare fresh just 
before use. 
18% 
82% 
Dissolve in 
Citric acid 0,1 M 
C6H5Na3O7 ·2H2O 0,1 M 
dH2O 
Adjust pH 6,0 
H2O2/methanol 3%. Store at 
4°C. 
3% 
Dissolve in 
H2O2 
Methanol 
Oil red O stock solution. Store 
at RT. 
0,5% (w/v) 
Dissolve in 
oil red O  
Triethyl-phosphate 60% 
Oil red O working solution. 
Prepare fresh just before use. 
60% (v/v) 
Dissolve in 
oil red O stock solution 
dH2O  
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4% Paraformaldehyde. Prepare 
fresh just before use. 
4% (w/v) 
Dissolve in 
 
PFA 
dH2O  
Stir at 60°C 
Adjust pH 7,2 with NaOH 
PBS/0,5% Triton buffer. Store 
at 4°C. 
0,5% 
Dissolve in 
Triton X-100 
PBS 
Trypsin solution 10x. Store at 
4°C for 14 days. 
1% (w/v) 
10 mM 
Dissolve in 
Trypsin 
CaCl2 
Tris-HCl 50 mM pH 7,8 
 
 
2.7 Bacteria 
2.7.1 Strain 
 
 
 
Lipid preparation 
Solution Volumes Components 
Folch reagent 200 ml 
100 ml  
Chloroform 
Methanol 
Trans-methylation reagent 39 ml 
20 ml 
5 ml 
2 ml 
Methanol 
Toluene 
Dimethoxypropane 
conc.H2SO4  
Cell line Genotype Company 
E.coli One Shot® TOP 10 F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 
∆lacX74 recA1 araD139 ∆(araleu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen, 
Karlsruhe, 
Germany 
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2.7.2 Medium 
Medium Composition 
LB medium (Luria Bertani) 1% trypton 
1% NaCl 
0,5% yeast extract 
Dissolve in dH2O and autoclave. 
LB agar plates 1% trypton 
1% NaCl 
0,5% yeast extract 
1,5% bacto-agar 
Dissolve in dH2O, autoclave and pour in bacterial culture 
plates. 
Ampicillin Stock solution: 100 mg/ml. Filter sterilize aliquot and store at 
-20°C. 
Final concentration: 100 µg/ml LB-medium. 
 
2.8 Mammalian cell lines 
2.8.1 Cell lines and mediums 
 
Cell line Properties Medium 
H1299  Non small-cell lung carcinoma cell line 
(Ji et al., 1999). ATCC Nr: 5803™ 
500 ml RPMI medium 
10% heat inactivated (56°C) FCS 
100 U/ml penicillin, 10 µg/ml 
streptomycin 
HFK Primary human foreskin keratinocytes. 
Cascade Biologics, Mansfield, UK. 
500 ml Epilife medium 
5 ml HKGS supplements 
100 U/ml penicillin, 10 µg/ml 
streptomycin 
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Oral 
KER16  
Oral keratinocyte cell line immortalized 
with HPV16. 
Kindly provided by Prof. Dr. Steinberg  
(Department of Operative Dentistry and 
Periodontology, Dental School, 
University of Heidelberg, Germany). 
500 ml Keratinocyte medium 2 
10% heat inactivated (56%) FCS 
Keratinocyte medium supplements 2 
100 U/ml penicillin, 10 µg/ml 
streptomycin 
J23T3 Primary murine fibroblasts. Kindly 
provided by Prof. Dr. Laimins 
(Department of Microbiology-
Immunology, Feinberg School of 
Medicine, Chicago, USA). 
500 ml DMEM medium 
10% heat inactivated (56%) FCS 
100 U/ml penicillin, 10 µg/ml 
streptomycin 
Phoenix Human embryonic kidney 293T-based 
amphotrophic packaging cell line.  
Kindly provided by Prof. Dr. Alonso 
(Department of cell differentiation, 
DKFZ, Heidelberg, Germany). 
500 ml DMEM medium 
10% heat inactivated (56°C) FCS 
100 U/ml penicillin, 10 µg/ml 
streptomycin 
NIKS Spontaneous immortalized near-diplod 
human foreskin keratinocyte cell line 
(Allen-Hoffmann et al., 2000). 
For INCOMPLETE MEDIUM: 
270 ml Ham´s F-12 medium 
90 ml DMEM 
5% heat inactivated (56°C) FCS 
4 ml of 0,8 µg/ml hydrocortisone 
4 ml of 0,83 µg/ml cholera toxin 
4 ml of 0,5 mg/ml insulin 
4 ml of 18 mM adenine 
100 U/ml penicillin, 10 µg/ml 
streptomycin  
For COMPLETE MEDIUM:  
Add freshly 4 ml of 1 µg/ml EGF  
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2.9 Plasmids 
Plasmid Properties Source 
pcDNA3.1.(+) Cloning vector. Invitrogen, Karlsruhe, Germany. 
pcDNA3.1.(+)- 
HPV20 E6-flag 
Expresses HPV20 N-
terminal flag-tagged 
E6. 
Gift from Dr. Fei (Division of tumor virus 
characterization, DKFZ, Heidelberg, Germany). 
pcDNA3.1.(+)- 
HPV20 E7-flag 
Expresses HPV20 N-
terminal flag-tagged 
E7. 
Gift from Dr. Fei (Division of tumor virus 
characterization, DKFZ, Heidelberg, Germany). 
pcDNA3.1.(+)-
wtp53 
Expresses wtp53. Gift from Dr. Fei (Division of tumor virus 
characterization, DKFZ, Heidelberg, Germany). 
pcDNA3.1.(+)-
p53R248W 
Expresses p53R248W. Gift from Dr. Fei (Division of tumor virus 
characterization, DKFZ, Heidelberg, Germany). 
pcDNA3.1.(+)-
TAp63α 
Expresses TAp63α. Gift from Prof. Dr. G. Melino (Biochemistry 
IDI-IRCCS laboratory, University of Rome, 
Italy). 
pcDNA3.1.(+)-
∆Np63α 
Expresses ∆Np63α. Gift from Prof. Dr. G. Melino (Biochemistry 
IDI-IRCCS laboratory, University of Rome, 
Italy). 
pGL3 basic Basic firefly luciferase 
reporter cloning vector. 
Promega, Mannheim, Germany. 
pGL3 basic-
HPV20URR 
Contains HPV20URR. Gift from Dr. Fei (Division of tumor virus 
characterization, DKFZ, Heidelberg, Germany). 
pRL-β-actin Renilla luciferase 
reporter plasmid. 
Contains the minimal 
β-actin promoter. 
Promega, Mannheim, Germany. 
pLXSN Retroviral vector. Gift from Prof. Dr. A. Alonso (Department of 
cell differentiation, DKFZ, Heidelberg, 
Germany). 
pLXSN16 
E6/E7 
Expresses HPV16 E6 
and E7 proteins. 
Gift from Prof. Dr. A. Alonso (Department of 
cell differentiation, DKFZ, Heidelberg, 
Germany). 
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pLXSN-GFP Expresses GFP protein. Gift from Prof. Dr. A. Alonso (Department of 
cell differentiation, DKFZ, Heidelberg, 
Germany). 
 
2.10 Primers 
DNA primers were purchased from Sigma-Aldrich (Taufkirchen, Germany) or DKFZ 
oligonucleotide synthesis core facility (Dr. Hunziker). PCR primers were obtained in desalted, 
lyophilised form and were dissolved in water. After cloning, all constructs were sequenced in 
the DKFZ sequencing core facility and verified by multiple alignment against the 
corresponding GeneBank sequence using the program ClustalW (EMBL-EBI, Heidelberg, 
Germany).   
Primer Melting T° 
Primers for pcDNA3.1.(+) vector.  
HPV20 E6 Forward (Kozak sequence) 
 
              Bam HI                                                      
5’- AAG GAT CCA CCA TGG CTA CAC CTC CTT CTT CAG AAG ACA G -3’ 
 
67°C 
HPV20 E6Flag Forward (Kozak sequence) 
 
              Bam HI                                                     Flag 
5’- AAG GAT CCA CCA TGG ACT ACA AGG ACG ACG ACG ACA AGG CTA CAC CTC -3’ 
 
69°C 
HPV20 E6 Reverse  
 
               Xba I 
5’- GCT CTA GAG CTT ATT GAA AAT GCT TAC ACA GCC -3’ 
 
60°C 
HPV20 E7 Forward (Kozak sequence) 
 
               Bam HI                                                     
5’- AAG GAT CCA CCA TGA TTG GTA AAG AGG CTA CAT TGC AAG-3’ 
 
65°c 
HPV20 E7Flag Forward (Kozak sequence) 
 
               Bam HI                                                    Flag 
5’- AAG GAT CCA CCA TGG ACT ACA AGG ACG ACG ACG ACA AGA TTG GTA AAG-3’ 
 
67°C 
HPV20 E7 Reverse  
 
                  Xba I 
5’- TGC TCT AGA GCA TTA GGA TCC GCC ATG TTT GCA G -3’ 
 
65°C 
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Primers for pLXSN vector.  
HPV20 E6 Forward (Kozak sequence) 
 
               Eco RI                                                     
5´TTA GAA TTC ACC ATG GCT ACA CCT CCT TCT TCA GAA GAC AG- 3´ 
 
67°C 
HPV20 E6Flag Forward (Kozak sequence) 
 
               Eco RI                                                     Flag 
5´TTA GAA TTC ACC ATG GAC TAC AAG GAC GAC GAC GAC AAG GCT ACA C- 3´ 
 
64°C 
HPV20 E6 Reverse  
 
                Bam HI    * 
5´TTA GGA TCC TTA TTG AAA ATG CTT ACA CAG CCT ACA G 3´ 
 
60°C 
 
RT-PCR primers.  
GAPDH forward 
 
5'- GAA GGT GAA GGT CGG AGT -3' 
 
53°C 
GAPDH reverse 
 
5'- GAA GAT GGT GAT GGG A -3' 
 
47°C 
 
Constructs: 
(a) pcDNA3.1.(+)-HPV20 E6: containing the Kozak sequence. It was amplified by PCR 
from pcDNA3.1.(+)-HPV20 E6 and cloned into the multiple cloning site at Bam HI 
and Xba I restriction sites of pcDNA3.1.(+) vector. 
(b) pcDNA3.1.(+)-HPV20 E6-flag: containing the Kozak sequence and a Flag-tag in N-
terminal. It was amplified by PCR from pcDNA3.1.(+)-HPV20 E6 and cloned into the 
multiple cloning site at Bam HI and Xba I restriction sites of pcDNA3.1.(+) vector. 
(c) pcDNA3.1.(+)-HPV20 E7: containing the Kozak sequence. It was amplified by PCR 
from pcDNA3.1.(+)-HPV20 E7 and cloned into the multiple cloning site at Bam HI 
and Xba I restriction sites of pcDNA3.1.(+) vector. 
(d) pcDNA3.1.(+)-HPV20 E7-flag: containing the Kozak sequence and a Flag-tag in N-
terminal. It was amplified by PCR from pcDNA3.1.(+)-HPV20 E7 and cloned into the 
multiple cloning site at Bam HI and Xba I restriction sites of pcDNA3.1.(+) vector. 
(e) pLXSN-HPV20 E6: containing the Kozak sequence. It was amplified by PCR from 
pcDNA3.1.(+)-HPV20 E6 and cloned into the multiple cloning site at Eco RI and Bam 
HI restriction sites of pLXSN vector. 
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(f) pLXSN-HPV20 E6-flag: containing the Kozak sequence and a Flag-tag in N-
terminal. It was amplified by PCR from pcDNA3.1.(+)-HPV20 E6 and cloned into the 
multiple cloning site at Eco RI and Bam HI restriction sites of pLXSN vector. 
 
2.11 Enzymes 
Antibody Company Buffer 
Antarctic alkaline phosphatase New England Biolabs, Ipswich, USA 10x AP buffer 
Bam HI Invitrogen, Karlsruhe, Germany 10x Buffer 2 
Cla I Fermentas, St. Leon-Rot, Germany 10x Buffer 1 
DNase I RNase-free RQ1 Promega, Mannheim, Germany 10x DNase buffer  
Eco RI Invitrogen, Karlsruhe, Germany 10x Buffer 3 
Proof start Taq DNA 
polymerase                                                                            
Qiagen, Hilden, Germany 10x Taq buffer 
Superscript II reverse 
transcriptase 
Invitrogen, Karlsruhe, Germany 5x Superscript II 
RT buffer 
T4 DNA-ligase Invitrogen, Karlsruhe, Germany 5x DNA ligase 
buffer 
Xba I Invitrogen, Karlsruhe, Germany 10x Buffer 2 
Xho I Invitrogen, Karlsruhe, Germany 10x Buffer 1 
 
2.12 Antibodies 
  Dilution used 
Antibody against Company Western 
blot 
IHC 
Paraffin  
IHC 
Cryo  
β-actin MP biomedicals, Eschwege, Germany 1:10000   
Cingulin Progen, Heidelberg, Germany   1:100 
Cytokeratin 4 Progen, Heidelberg, Germany   1:2000 
Cytokeratin 10  Progen, Heidelberg, Germany 1:5000   
Cytokeratin 13 Progen, Heidelberg, Germany  1:3000  
Cytokeratin 14 Progen, Heidelberg, Germany 1:80000 1:2000  
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Cytokeratin 77 Prof. Langbein (DKFZ)  1:2000  
Desmoplakin I/II Prof. Langbein (DKFZ)   1:50 
Flag M2 Stratagene, CA, USA 1:500   
GFP (JL-8) BD Biosciences, Heidelberg, Germany 1:1000   
Guinea pig-Cy3 Jackson ImmunoResearch, PA, USA  1:500 1:500 
Involucrin Sigma-Aldrich, Taufkirchen, Germany 1:500 1:100  
Loricrin Covance, Münster, Germany  1:500  
Mouse-Cy3 Jackson ImmunoResearch, PA, USA  1:500 1:500 
Mouse-
Horseradish 
peroxidase (HRP) 
Promega, Mannheim, Germany 1:5000   
p16 (50.1) Santa Cruz Biotechnology, CA, USA 1:500   
p21 OP 64 Calbiochem, Darmstadt, Germany 1:500   
p21 (WA-1) Progen, Heidelberg, Germany  1:500  
p53 (DO-1) Santa Cruz Biotechnology, CA, USA 1:500   
p53 (Bp53-11) Progen, Heidelberg, Germany  1:500  
p63 (4A4) Santa Cruz Biotechnology, CA, USA 1:1000 1:100  
p63α (H-129) Santa Cruz Biotechnology, CA, USA 1:1000   
PCNA (PC-10) Santa Cruz Biotechnology, CA, USA 1:1000 1:500  
Rabbit- HRP Promega, Mannheim, Germany 1:5000   
Rabbit-alexa 488  Molecular Probes Inc., USA  1:1000 1:1000 
 
2.13 Markers 
Markers were purchased from Fermentas GmbH (St. Leon-Rot, Germany).  
Marker Size range 
GeneRuler™ DNA Ladder mix 100-10000 bp 
PageRuler™ Prestained Protein Ladder 170-10 kDa 
RiboRuler™ High Range RNA Ladder 200-6000 bp 
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3 Methods 
3.1 Bacterial manipulation 
3.1.1 Bacterial culture 
Plasmid DNA preparation was performed in E. coli TOP 10 bacteria strain. Cells were 
grown in LB media liquid or on LB agar plates at 37°C (Sambrook, 1989). Bacteria were 
selected by ampicillin resistance in medium/agar containing 100 µg/ml ampillicin for all the 
plasmids used. The inoculation of bacterial cultures as well as the plating was carried out 
under semi sterile conditions using a Bunsen burner.   
 
3.1.2 Bacterial stocks 
Clones of interest were stored by freezing plasmid-containing bacterial culture. 
Exponent growing bacterial culture were pelleted by centrifugation at 1,000 rpm for 5 min at 
RT and resuspended in 1 ml LB media containing 15% glycerol, keeping them at -70°C. 
 
3.1.3 Bacterial transformation 
Ligated DNA (2 µl) (see 3.2.6.3) was transformed into 50 µl competent bacteria (E. 
coli, One Shot®, Top 10, Invitrogen) and kept 30 min on ice. After pipeting the ligated DNA, 
bacteria were exposed to heat shock at 42°C during 30 seconds and kept on ice for 2 min. 
Subsequently, pre-warmed SOC media (250 µl) was added to the cells and they were 
incubated at 37°C by shaking at 200 rpm for 1 h. Transformed bacteria were plated in agar 
plates containing 100 µg/ml ampicillin and incubated overnight at 37°C. Colonies were 
picked and bacteria were grown overnight at 37ºC by shaking for small scale preparations of 
plasmid DNA (see 3.2.1). 
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3.2 DNA  
3.2.1 Small scale preparation 
 DNA mini plasmid preparation was performed with the JetQuick Plasmid Miniprep 
Spin Kit (Genomed) according to manufacturer´s instructions. Bacterial cultures (4 ml) were 
pelleted at 12,000 x g for 3 min and resuspend in 250 µl G1 solution (50 mM Tris-HCl pH 
8,0, 10 mM EDTA, 100 µg/ml RNase A). Cells were lysated by adding G2 solution (250 µl) 
(200 mM NaOH, 1% SDS). After 5 min incubation at RT, neutralization was induced by 
adding G3 solution (350 µl) (contains acetate and guanididine hydrochloride) and 
homogenized by inverting the tube. Lysated cells were centrifuged and supernatant containing 
plasmid DNA was loaded in a spin column, centrifuged at 12,000 x g for 1 min, discarding 
the flow-through. Sample reconstitution was achieved by addition of G4 solution (500 µl) 
(contains ethanol, NaCl, EDTA and Tris-HCl) and centrifugation at 12,000 x g for 1 min, 
discarding the flow-through. Samples were centrifuged at 12,000 x g for 1 min and DNA was 
eluted from the column by addition of 50 µl of  pre-warmed (37°C) TE buffer pH 8,0 and 
centrifugation at 12,000 x g for 2 min. 
 
3.2.2 Large scale preparation 
DNA maxi plasmid preparation was performed according to manufacturer´s 
instructions (Qiagen Plasmid Maxi Purification). Bacteria were grown for 12-16 h in 400 ml 
medium containing 100 µg/ml ampicillin and incubated on agitation at 220 rpm at 37°C. 
Bacteria were pelleted by centrifugation at 6,000 x g for 15 min at 4°C and resuspended in P1 
buffer (10 ml) (50 mM Tris-HCl pH 8,0, 10 mM EDTA, 100 µg/ml RNase A) by pipetting up 
and down. Cells were lysed by addition of P2 buffer (200 mM NaOH, 1% SDS), mixed and 
incubated 15-25 min at RT. The lysis was neutralized with chilled P3 buffer (10 ml) (3 M 
potassium acetate, pH 5,5), vigorously inverted 4-6 times and incubated on ice for 20 min. 
Samples were centrifuged at 20,000 x g for 30 min at 4°C and supernatant was promptly 
removed and centrifuged again at 20,000 x g for 15 min at 4°C. Qiagen-tip columns were 
equilibrated with Buffer QBT (10 ml) (750 mM NaCl, 50 mM MOPS pH 7, 15% isopropanol, 
0,15% triton X-100) and allowed to empty by gravity flow. Lysates were applied to the 
Qiagen-tip columns and cleared by filtration.  Columns were washed twice with Buffer QC 
(30 ml) (1 M NaCl, 50 mM Tris-HCl pH 8,5, 15% isopropanol) and DNA was eluted by 
addition of Buffer QF (15 ml) (1,25 M NaCl, 50 mM Tris-HCl pH 8,5, 15% isopropanol). 
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DNA precipitation was performed by adding 10,5 ml isopropanol to the eluted DNA and 
centrifugation at 15,000 x g for 30 min at 4°C. DNA was washed with 70% ethanol (5 ml) and 
centrifuged at 15,000 x g for 15 min at 4°C. Pelleted DNA was air dried in a SpeedVac 
concentrator and allowed to dissolve overnight at 4°C in TE buffer, pH 8,0. 
 
3.2.3 Determination of nucleic acid concentration 
The DNA or RNA concentration was determined photometrically by measuring the 
absorbance at 260 nm. The spectrophotometer was calibrated using the same solution as the 
solvent for the correspondent nucleic acid. The concentration was calculated as follows: 
 
 
 
 
 
The purity of the preparation was determined by calculating the ratio 
OD260nm/OD280nm. DNA was considered free of protein contamination when the range was 
between 1,7-2,0. Pure RNA ratio should be in the range of 1,9-2,1. 
 
3.2.4 Agarose gel electrophoresis 
For a 1 % (w/v) gel, 1 g agarose was dissolved in 100 ml EP buffer and was brought to 
boil in a microwave oven. The solution was allowed to cool down and was poured into the 
casting gel. Once agarose gel had solidified, the electrophoresis tray was filled with EP buffer 
and the casting gel was placed in it. DNA loading buffer was added to the samples, loaded 
into wells  and runned  at 100 V.  The DNA was  stained  with  ethidium bromide solution 
(0,5 µg/ml) for 10 min and visualized under UV light. 
 
3.2.4.1 DNA isolation from agarose gels 
DNA fragments generated by PCR or by restriction digestion were separated by 
electrophoresis depending on their sizes on 0.8-1.5% agarose gels at 100V. Subsequently, the 
agarose gel was incubated in ethidium bromide solution (0,5 µg/ml) for 10 min, analyzed 
under UV light (366 nm) and the fragment of interest cut from the gel. 
Single-stranded DNA (µg/ml) = 33 x OD260 x dilution factor 
Double-stranded DNA (µg/ml) = 50 x OD260 x dilution factor 
RNA (µg/ml) = 40 x OD260 x dilution factor 
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The DNA extraction from the agarose fragment was performed using the JetQuick Gel 
Extraction Spin Kit from Genomed according to manufacturer´s instructions. Agarose 
fragment was dissolved in L1 buffer (contains NaClO4, sodium acetate and TBE solubilizer), 
with 300 µl L1/100 mg gel slice. Samples were incubated 15 min at 50°C in a water bath, 
inverting the tubes every 3 min to ensure agarose solubilization. Samples were placed in a 
JetQuick spin column and centrifuged at 12,000 x g for 1 min. Supernatant was discarded and 
silica filter was washed twice with 500 µl of L2 buffer (contains ethanol, NaCl, EDTA and 
Tris-HCl), discarding the flow-through. DNA was eluted by adding 50 µl 10 mM Tris-HCl 
pH 8,0 and centrifugation at 12,000 x g for 2 min.  
 
3.2.5 Polymerase Chain Reaction (PCR) 
For cloning, suitable primer pairs were designed to incorporate appropriate restriction 
enzyme sites followed by sequences that were complementary to the ends of the desired 
insert. Primers were designed with the presence of two bases preceding the restriction enzyme 
site to improve the efficiency of restriction enzyme digestion of the fragment (Dieffenbach et 
al., 1993). 
Final concentrations of the reagents in an example reaction contained 100 ng of 
template DNA, 0,5 µM forward and reverse primers, 200 µM of dNTPs, 2,5 units of Proof 
Start Taq Polymerase and the correspondent enzyme buffer in a final volume of 50 µl. 
Annealing temperatures were adapted for each reaction, depending on the primers 
used and were calculated with computer analysis using the program OligoAnalyzer 3.1 (see 
appropriate melting temperature (Tm) in section 2.9). Elongation time was different for each 
reaction and was calculated depending on the lengh of the amplified fragment (1 kb/min). An 
example PCR thermocycle protocol was: 
 
Cycles Time Temperature Step 
1 x 4 min 94 °C Denaturation 
30 sec 94° C Denaturation 
45 sec Temperature depending on primer´s Tm Annealing 
 
30 x 
variable 72°C (time depending on fragment´s lengh, 1kb/min) Elongation 
1 x 10 min 72°C Elongation 
 ∞ 4°C  
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3.2.6 Cloning  
3.2.6.1 Digestion of DNA using restriction enzymes 
Vector (10 µg) or PCR product (200 ng) was cut with 10 U enzyme/µg DNA for 1 h at 
37°C in the corresponding buffer. Enzyme was inactivated by incubation at 65°C during 20 
min. 
DNA was purified using the JetQuick PCR Purification Spin Kit according to 
manufacturer´s instructions. H1 buffer (400 µl) (contains guanidine hydrochloride and 
isopropanol) was added to 100 µl PCR product. Spin column was loaded with the H1 buffer-
PCR product mixture and centrifuged at 12,000 x g for 1 min. Flow-through was discarded 
and column was washed twice by adding 500 µl H2 buffer (contains ethanol, NaCl, EDTA 
and Tris-HCl) and centrifugation at 12,000 x g for 1 min. DNA was eluted by adding 10 mM 
Tris-HCl pH 8,0 and centrifugation at 12,000 x g for 2 min.  
Restricted fragments volumes were too low to be quantified espectrophotometrycally. 
Instead, quantification was performed by agarose gel electrophoresis, comparing the intensity 
of the bands to the known concentration of the marker bands. 
 
3.2.6.2 Dephosphorylation of DNA 
In order to avoid vector recircularization, phosphate groups were removed by 
phosphatase treatment. After restriction and purification, 1 µg of digested plasmidic DNA was 
incubated with 5 U of antartic alkaline phosphatase and its corresponding buffer for 1 h at 
37°C. The solution was incubated 10 min at 65°C for inactivating the enzyme.  After 
purification with the JetQuick PCR Purification Spin Kit (see 3.2.6.1), the vector was 
quantified by electrophoresis. 
 
3.2.6.3 Ligation 
The ratio between the molarity of the vector and fragment was calculated according to 
the size of the insert. The ligation reaction was prepared by mixing 20 fmoles of linearized 
and dephosphorylated plasmid with 60 fmoles of the cut DNA fragment with compatible 
ends, 5 U of T4-ligase and 1x T4-ligase buffer in a final volume of 20 µl. The ligation was 
carried out overnight at 14°C and ligase was inactivated by incubation at 65°C during 10 min. 
The DNA molarity was calculated as follows:  
 
Fmoles = ng/µl : kb x 0.66 
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Efficiency of ligation was controlled by electrophoresis of the reaction mixture before 
and after T4-ligase incubation, comparing the amount of linearized vector and fragment 
before and after ligation. Ligation mix was used for bacterial transformation (see 3.1.3).  
 
3.2.6.4 Analysis of transformed clones 
After transformation (see 3.1.3) colonies were selected and plasmid DNA was 
extracted. Small scale DNA preparation (20 µl) was restricted with the appropriate enzymes 
in a volume of 50 µl as described (see 3.2.6.1). Clones harbouring the insert of correct size 
were sequenced and large scale DNA preparations were performed (see 3.2.2). 
 
3.3 RNA  
3.3.1 RNA isolation from cultured cells 
Prior to extraction, surfaces and equipment were extensively cleaned with ethanol and 
rinsed with DEPC-treated water. RNA isolation from 145 mm diameter cell culture plates was 
performed using the Qiagen RNeasy® mini kit, following manufacturer´s instructions. 
Briefly, cells were washed and lysed directly in the cell culture plate with 600 µl RLT buffer. 
Lysates were homogenized by pipetting into a QIAshredder™ spin column and centrifugation 
at 12,000 x g for 2 min. Homogenized lysate (corresponding to the flow-through) was 
combined with 1 vol 70% ethanol and the samples were mixed by inverting the tubes several 
times. Samples were transferred to an RNeasy spin column and centrifuged at 8,000 x g for 15 
sec. Flow-through was discarded. Column was washed by addition of 700 µl RW1 buffer and 
centrifugation at 8,000 x g for 15 sec, discarding the flow-through. RPE buffer (500 µl) was 
added to the column and centrifugated at 8,000 x g for 15 sec. Flow-through was discarded 
and again 500 µl RPE buffer were added, followed by centrifugation at 8,000 x g for 2 min. 
Column was centrifuged at 10,000 x g for 1 min to eliminate any possible carryover of the 
buffers. Total RNA was eluted in 50 µl RNase-free water. Each sample (2 µl) was separated 
by electrophoresis in 1% agarose gel (see 3.2.4) and possible RNA degradation was 
controlled by visualizing intact 28S, 18S and 5S rRNA bands. 
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3.3.2 DNAse I treatment 
DNAse I treatment was performed to prevent cellular DNA contamination in the PCR 
reaction. Total RNA (2 µg) was incubated for 30 min at 37°C with 2 units of DNAse I (RQ1 
RNase-Free DNase I, Promega, Mannheim, Germany) and its corresponding DNase I buffer 
in a final volume of 10 µl. Reaction was stopped by adding 1 µl of  DNAse I stop solution 
provided with the enzyme and 10 min incubation at 65°C.  
 
3.3.3 cDNA synthesis by Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR) 
Total RNA was used as substrate for single strand cDNA synthesis. RNA (2 µg) was 
mixed with 2 µl of 50 µM random hexamers, 0,4 µl of 25 mM dNTPs in 12 µl final volume. 
Samples were incubated at 70°C for 10 min to minimize RNA secondary structure, shortly 
spinned and placed 1 min on ice. Subsequently, 4 µl 5x Superscript II RT buffer, 0,5 µl 
RNase  inhibitor  RNasin®  and  2 µl 0,1 M DTT were  added  to each  tube.  Mix was placed 
2 min at 25°C and 1 µl Superscript II reverse transcriptase was added. Samples were 
incubated 10 min at 25°C (necessary for pre-incubation of random hexamers). 
Retrotranscription was performed for 50 min at 42°C followed by heat inactivation for 15 min 
at 70°C. Genes of interest were amplified by PCR as previously described (see 3.2.5). Control 
of DNA contaminations was done by performing RT-PCR reactions without reverse 
transcriptase, where retrotranscription from mRNA to cDNA does not happen and, therefore, 
DNA amplification after PCR must correspond to DNA contamination.  
 
3.4 Protein  
3.4.1 Protein extraction 
3.4.1.1 Passive lysis buffer 
For HPV20 promoter activity studies, cells were lysed with passive lysis buffer 
contained in the Dual-Luciferase® Reporter (DLR™) Assay System kit. Cells growing in six-
well plates were washed twice with ice cold PBS. Pre-chilled passive lysis buffer (200 µl) was 
applied in the wells, gently rotated at 4°C, and cells were scraped while kept on ice. 
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Subsequently, the samples were centrifuged at 10,000 rpm for 10 min at 4 ºC to pellet the 
undissolved material. Samples were stored at -70 ºC until use.  
 
3.4.1.2 RIPA  buffer 
 For protein isolation from monolayer cultured cells, medium was removed from the 
cell culture plates and centrifuged for 2 min at 1,000 rpm and 4°C, discarding the supernatant. 
Cells were washed twice with ice cold PBS and 150 µl fresh RIPA buffer (see 2.6) was 
applied per 106 cells.  
Cells were scraped from the cell culture plate while kept on ice and samples were 
incubated in severe agitation for 5 min at 4°C. Sonicator was filled with ice and water, tubes 
were submerged and sonicated during 5 min (30 sec cycles). Extracts were centrifuged  at 
10,000 rpm for  10 min  at 4°C  to  pellet  undissolved  material and stored  at  -70°C.  
 
3.4.1.3 Organotypic culture protein isolation 
Epithelial cell cultures were isolated by loosen the keratinocyte culture from the 
surrounding transwell with the help of a scalpel. Then, the epidermal layer was separated 
from the collagen matrix, mixed with 150 µl of organotypic culture protein extraction buffer 
(see 2.5) and lysed manually in a chilled glass tissue grinder (Dounce).  Lysates were cleared 
by centrifuging at 10,000 rpm for 10 min at 4°C and proteins were stored at -70°C.  
 
3.4.2 Protein quantification 
Protein concentration was measured using a protein quantification reagent (BioRad 
Protein Assay), following the Bradford method (Bradford, 1976). This is a colorimetric assay 
method based on the change in absorbance of the Coomassie Brilliant Blue G-250 dye, which 
shifts from 465 nm to 595 nm when it binds to proteins. The increase of absorbance at 595 nm 
is proportional to the amount of dye coupled to proteins. 
Protein samples (2 µl) were mixed with 20 µl of urea-β mercaptoethanol buffer and 
boiled at 95°C for 5 min. The BioRad Protein Assay reagent was prepared by diluting it 1:5 
with dH2O and added to the protein mixture. Absorbance was measured at 595 nm. BSA at 
given concentration was used as reference. 
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3.4.3 SDS-polyacrilamide gel electrophoresis 
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
SDS denatures the proteins and covers them with equal negative charges, allowing them to 
migrate in an electric field. Proteins were mixed with SDS-loading buffer (1x final 
concentration) and heated for 5 min at 95 ºC before loading. 
Polyacrylamide gels contained an upper stacking gel that concentrates the samples in 
the gel, ensuring that all proteins in the sample enter the lower resolving gel simultaneously. 
The lower resolving gel had a 10-15% polyacrilamyde concentration, depending on the size of 
the proteins of interest.  
The electrophoresis was run at 100 V in 1x protein running buffer (see 2.6) until the 
bromophenol blue dye of the sample buffer (corresponding to 6,7 kDa) had run out of the gel.  
 
3.4.4 Western blot 
3.4.4.1 Transfer of proteins onto nitrocellulose membrane 
To transfer proteins from a polyacrylamide gel onto a nitrocellulose membrane a 
Protein Minigel Wet Transfer System (BioRad) was used. All the components of the blotting 
sandwich were soaked in 1x blotting buffer (see 2.6) and placed avoiding the formation of air 
bubbles as follows: a sponge pad, two sheets of Whatman filter, the nitrocellulose membrane, 
the polyacrylamide gel, two sheets of Whatman filter paper and a sponge pad. This sandwich 
was placed in the anode part of the cassette, the cuvette was filled with 1x blotting buffer and 
the proteins were allowed to transfer at 4°C at 100 V for 1.30 h or 30 V overnight. 
 
3.4.4.2 Immunoprobing of nitrocellulose membranes 
After the transfer, the membrane was washed in TBS-T buffer (see 2.5) and incubated 
on a platform shaker for 1 h in blocking buffer (5 % w/v non-fat milk powder in TBS-T). 
Primary antibody was added to blocking buffer at the appropriate concentration (see listed 
antibodies 2.12) and incubated overnight at 4°C on a platform shaker. The membrane was 
subsequently washed in TBS-T (3 x 15 min) and then exposed to a secondary antibody diluted 
in blocking buffer for 1 h at RT.  After membrane washing in TBS-T (3 x 15 min), proteins 
were detected using a Western blotting detection reagent (ECL system, Amersham Biotech) 
following manufacturer´s instructions. Signals were visualized on autoradiograph ECL film. 
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For anti-Flag antibody, all steps were carried out in TBS buffer and the blocking 
buffer composition consisted in 3% non-fat powder milk in TBS. 
 
3.4.4.3 Densitometric analysis  
After Western blot, X-ray films were quantified by using the ImageQuant 5.0 
software. 
 
3.5 Cell culture  
3.5.1 Culturing of cell lines 
Cells were grown in an incubator at 37 °C in a 5 % carbon dioxide / 95 % humidity 
atmosphere. For cell detachment, medium was removed, cells were washed with PBS/EDTA 
and incubate in trypsin/EDTA solution. Trypsin was inactivated by adding cell culture media 
containing FCS. Cells were centrifuged at 1,000 rpm for 10 min at RT, counted and seeded 
onto new plates. Primary foreskin keratinocytes are too sensitive to normal trypsin/EDTA; 
instead, Keratinocyte Detach Kit2-125 (Promocell) was used. Cells were washed with Hepes 
solution, trypsinized and reaction was blocked by adding a trypsin neutralizer following the 
protocol provided by the supplier (Hepes solution, trypsin and trypsin neutralizer contained in 
the kit).  
H1299 cells were split 1:5 and medium was changed every 3 days. One vial of primary 
foreskin keratinocytes was initially plated in 3 T-75 flasks and cells were refed every 3 days 
and split 1:2.  Phoenix cells were split 1:10 and medium was change every second day. Oral 
keratinocytes immortalized with HPV16 (oral KER16) were split 1:3 and medium was 
replaced every 3 days. NIKS were maintained as subconfluent cultures on a mitomycin C-
treated J23T3 fibroblast feeder layer in NIKS medium. Mitomycin C irreversibly damages 
DNA, arresting the fibroblast cell cycle. J23T3 fibroblasts were treated with 8 µg/ml 
mitomycin C for 2-4 h at 37°C. Cells were then washed with PBS/EDTA, trypsinized and 
split 1:3 in incomplete NIKS medium. Next day, NIKS cells were plated over the treated 
J23T3 cells. After one day, medium was changed to complete NIKS medium and cells were 
refed every 3 days.  
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3.5.2 Cell lines cryopreservation 
Cells (106-107) were pelleted by centrifugation at 1,000 rpm for 10 min at RT and 
resuspended in 0,5 ml medium containing 10% DMSO. Cryotubes were placed immediately 
in a -80 °C freezer. After one week, the cells were transferred to liquid nitrogen containers. 
Cells were thawed by warming them in at 37 °C, centrifugated at 1,000 rpm for 5 min at RT 
and seeded in fresh medium. 
 
3.5.3 Determination of cell number and viability  
Cells were counted with the help of a hemocytometer (Neubauer cell counting 
chamber, depth 0,1 µl) and an optical microscope Wilovert S. 
Trypan blue dye (0,02%) was used to distinguish dead cells and calculating cell 
viability. This vital dye is negatively charged and does not interact with the cell unless the 
membrane is damaged. Therefore, all the cells which exclude the dye are viable whereas 
stained ones correspond to dead cells.  
 
3.5.4 Transient transfection 
 H1299, Phoenix and oral KER16 cell lines were plated one day prior transfection at 
2,5x104 cells/cm2, 2x104 cells/cm2 and 3x104 cells/cm2 respectively. Transfection was 
performed using Plus Reagent- Lipofectamine following manufacturer´s instructions. Plus 
Reagent enhances the transfection efficiency while lipofectamine is a mixture of 2,3-
dioleyloxy- N- [2(spermine-carboxamido)ethyl]- N,N- dimethyl-1 - propanaminiumtrifluoro-
acetate (DOSPA) -a polycationic synthetic lipid- and phosphatidyl-ethanolamine -a fusogenic 
lipid. This lipid mixture spontaneously associates with nucleic acids (negatively charged), 
forming lipoplexes. Mixture lipid-DNA results in the formation of structures that fuse and 
pass through the plasma membrane, delivering the DNA into the cell.  
DNA was dissolved in OPTI-MEM medium (10 µl/cm2) and combined with Plus 
Reagent (1,2 µl/cm2), following by incubation for 15 min at RT. Lipofectamine (0,8 µl/cm2) 
was added to the this preparation, mixed and incubated for 15 min at RT. Medium was 
removed from the cells and the complexed DNA mixture was carefully spread drop-wise over 
the cells. After 3 h, normal cell culture medium without penicillin/streptomycin was added 
and cells were returned to the incubator for 24 h.  Moreover, oral KER16 were treated in two 
different forms in order to compare best protocol for Lipofectamine reagent: in a subset of the 
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cells the medium was removed and replaced for OPTI-MEM 3 h prior transfection whereas in 
the other subset the medium was not replace before the transfection procedure.   
Oral KER16 were also transfected with Lipofectamine 2000 and FuGENE HD reagent 
in order to choose the method with highest transfection efficiency. Cells were plated one day 
prior transfection at a density of 3x105 cells per 35 mm diameter cell culture plate. For 
Lipofectamine 2000, 2 µg DNA were diluted in 250 µl OPTI-MEM, gently mixed and 
incubated for 5 min at RT. Then, diluted DNA was combined with 10 µl Lipofectamine 2000 
plus 250 µl OPTI-MEM and incubated for 20 min at RT.  Medium was removed from the 
cells and the  complexed DNA  mixture  was carefully spread drop-wise over the cells. After 
3 h, normal cell culture medium without penicillin/streptomycin was added and cells were 
returned to the incubator for 24 h.  Similarly to the Lipofectamine protocol, two variants of 
the protocol were done; one where medium was replaced by OPTI-MEM 3 h prior 
transfection and other with no medium replacement until the transfection was performed. For 
FuGENE HD transfection, 2 µg DNA were diluted in 100 µl OPTI-MEM and incubated for 
15 min with FuGENE HD reagent. Different FuGENE HD reagent (µl):DNA (µg) ratios were 
used (3:2, 4:2, 5:2, 6:2, 7:2) in order to optimize the protocol for best transfection efficiency. 
The mix was added drop-wise over the cells fed with 2 ml normal cell culture medium 
without penicillin/streptomycin. Proteins were extracted 24 h after transfection. 
 
3.5.5 Luciferase assay 
The luciferase dual reporter assay was used to investigate the promoter activity of the 
HPV20, cloned upstream of the reporter gene Firefly Luciferase. One day prior transfection, 
2,5x105 H1299 cells or 2,5x105 oral KER16 cells were plated in 6-well plates.  
H1299 cells were co-transfected with the Firefly reporter construct pGL3-HPV20 
URR (1 µg/well), together with the pRL-β-actin Renilla reporter plasmid (0,1 µg/well) and 
with or without wtp53, mutp53R248W, TAp63α ∆Np63α plasmids (1 µg/well), or HPV20 E6 
(2 µg/well). 
Oral KER16 were co-transfected with the Firefly reporter construct pGL3-HPV20 
URR (1 µg/well), together with the pRL-β-actin Renilla reporter plasmid (0,1 µg/well) and 
HPV20 E6 (2 µg/well) and/or HPV20 E7 (2 µg/well). After 24 h cells were lysed and stored 
at -70°C (see 3.4.1.1). Promoter activity was quantified by adding the Firefly Luciferase 
substract Luciferase Assay Reagent II (LAR II) (100 µl) to 20 µl of lysed extract generating a 
luminescent signal. After quantifying the Firefly luminescence, the reaction is quenched and 
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the Renilla luciferase reaction was initiated simultaneously by adding Stop & Glo® Reagent 
(contains coelenterazine, the substract for Renilla luciferase) (100 µl) to the same sample. All 
experiments were performed in triplicates. 
 
3.5.6 Retroviral production 
Retroviruses were used to create stable cells expressing the gene of interest. These 
vectors integrate in the host cell genome, ensuring continuous gene expression.  Phoenix™ 
amphotrophic cell line (Orbigen Inc., San Diego, Ca, USA) is a helper free packaging cell line 
derived from human embryonic kidney cell line 293-T transformed with adenovirus type 5 
(Ad5) and polyomavirus SV40. PhoenixTM cells contain the retroviral genes gag, pol and env, 
the retroviral origin of replication and the RNA Ψ packaging signal necessary for producing 
retroviral particles. Retroviruses produced from these cells can infect the target cells and 
integrate into the host genome. However, they are replication deficient because they lack the 
corresponding viral machinery. 
High titers of recombinant retroviruses were produced by transfecting subconfluent 
PhoenixTM with 21 µg retroviral DNA using Lipofectamine reagent (see 3.5.4). One day prior 
transfection 29x105 cells were plate in a 145 cm2 cell culture plate. Maximal retroviral 
production is achieved 30 h post-transfection (Pear, 1997). Therefore, 24 h post-transfection 
the medium containing retroviruses was collected (named supernadant 1), new medium was 
added and collected again 48 h after transfection (named supernadant 2). Viral supernatants 
were kept at -70°C until used. 
 
3.5.6.1 Transduction of target cells 
HFK and NIKS target cells were subconfluent at the time of infection. Polybrene was 
added at a final concentration of 6 µg/ml to the viral supernatant to increase retroviral gene 
transfer (Davis et al., 2002). Viral supernatant collected 48 h after transfection (supernadant 
2) was filtered (Whatman Puradisc filter, 0,45 µm) to remove any cell debris and added to the 
cells, replacing the medium after 3 h. After 24 h, supernadant 1 was filtered and applied to 
the cells. Medium was replaced after 3 h and cells were incubated overnight. Cells that 
incorporated the retrovirus in their genome were selected by antibiotic resistance contained in 
the retroviral vector. The cells were trypsinized and plated in medium containing geneticin 
sulphate (G418) (100 µg/ml). Uninfected cells were exposed to the antibiotic to determine the 
end point of selection: when all uninfected cells were dead we assumed that all surviving cells 
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in the transduced sample corresponded to cells that had incorporated the retrovirus in the 
genome (5-7 days).   
Retroviral transduction into NIKS was done in subconfluent cells without feeder layer. 
Stable clones were propagated on fresh mytomicin C-treated feeder layer in NIKS medium, 
expanded (4 to 8 passages) and used for organotypic raft cultures.  
 
3.5.6.2 Study of life span 
Growth of primary keratinocytes retrovirally transduced was monitored. Cells were 
passaged when the confluency was approximately 80%. The population doubling (PD) 
corresponds to a two-fold increase in the total number of cells in a culture and it is used to 
study the growth rate and life span of cells. PD was calculated considering the split ratio and 
the number of cells until they died. 
 
3.5.7 Organotypic raft cultures 
 HPV life cycle is linked to the differentiation of stratified squamous epithelia 
(reviewed in Longworth and Laimins, 2004). Organotypic culture is a three-dimensional 
system that develops well-ordered epithelia, thus offering an opportunity to analyze the 
cellular mechanisms of tissue formation, such as cell-cell interactions and the regulation of 
proliferation and differentiation. It is a very useful tool to investigate the role of individual 
viral genes or full viral life cycle (reviewed in Stark et al., 2004). In this model, cells are 
nourished by diffusion from below.  Keratinocytes are plated on a matrix of collagen type I, 
extracted from rat tail tendon. To serve as functional dermal equivalents, the collagen gels 
contain viable fibroblasts which produce extracellular matrix components comparable with 
the in vivo situation (Fig. 9).  
 
                                 
                       Epidermal cells 
                    
     Collagen-fibroblast matrix 
 
Figure 9. Schematic illustration of the organotypic culture system. 
Methods 
 
74 
When using HFK it is necessary that the HPV used extend the life span of the cells in 
order to have sufficient cell generations to form differenting epithelia. In our studies we used 
NIKS cells that display normal differentiation properties in organotypic cultures, mimicing 
the natural host of HPV.  
 
3.5.7.1 Preparation of dermal equivalent matrix 
Collagen mix (in a proportion 8:1:1 rat tail collagen type 1, reconstitution buffer and 
10x DMEM) was prepared on ice by resuspending 3x105 fibroblast in 10x DMEM followed 
by adding  the reconstitution buffer (see composition in section 2.6)  and finally mixing by 
pipetting with rat tail collagen type I with the help of a disposable pipet. Collagen mix (2 ml) 
was placed in a filter insert and allowed to solidify by incubation at 37°C for 1 h in a humified 
incubator. Collagen dermal equivalents composed of collagen mix and embedded J23T3 
fibroblasts (Davy, 2005) were maintained in complete immersion in NIKS medium without 
EGF in 6-well-deep plates for four days.  
 
3.5.7.2 Raft cultures  
Stably transduced pLXSN-, pLXSN- HPV20 E6-Flag or pLXSN-HPV16 E6/E7 NIKS 
cells were seeded onto collagen dermal equivalents (1x106 cells/ transwell). Medium was 
replaced with complete NIKS medium 24 h later and cells were cultured for 5 days. Medium 
was added to the level of the collagen matrix, thus restricting nourishment to diffusion from 
below. This air-lift procedure was defined as the start of the culture time. From this moment, 
incomplete NIKS medium was replaced every second day. BrdU (50 µg/ml) was added 12 h 
prior to harvest on day 14 in all the samples. Rafts were either fixed overnight in 4% formalin 
followed by embedding in paraffin (for immunohistochemistry and immunofluorescence), or 
embedded in Tissue Tek-OTC and subsequently snap frozen in liquid nitrogen vapour (for 
barrier function studies), or fixed in resin (for electron microscopy analyses). Organotypic raft 
cultures were repeated at least 3 times for each stable cell line. 
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3.5.7.3 Barrier function analyses 
 
Lucifer yellow penetration assay 
To assess the functionality of the stratum corneum in the epidermal equivalents, 
outside-in epidermal barrier was investigated. Lucifer Yellow (1mM) dissolved in PBS (pH 
7,4) was placed over the epidermal surface of the organotypic raft cultures for 1 h as 
previously described (Koch et al., 2000). Raft cultures were subsequently embedded in Tissue 
Tek-OCT and snap frozen in liquid nitrogen. Serial sections were cut at -20°C using a cryostat 
Leica CM3050S at a thickness of 5 µm and air dried for 15 min before storage at -70°C. 
Cryosections were counterstained with Hoechst dye 33258 and penetration of the dye was 
assessed by immunofluorescence microscopy observation (microscope Leitz DM RBF and 
firewire fluorescence camera F-View II). 
 
Biotin uptake assay 
To examine whether the viral-containing organotypic rafts had an increased inside-out 
permeability due to alterations in tight junctions (present in the stratum granulosum), Biotin 
uptake was examined.  Biotin was added at a final concentration of 2 mg/ml to the raft culture 
media as previously described (Furuse et al., 2002). After 30 min, epidermal equivalents were 
washed with PBS, embedded in Tissue Tek-OCT, snap frozen in liquid nitrogen and stored at 
-70°C. Serial sections were cut at -20°C using a cryostat Leica CM3050S and air dried for 15 
min before storage at -70°C. Sections were defrosted at RT for 15 minutes and then 
rehydrated with PBS for another 15 minutes. To follow the penetration of the Biotin, sections 
were stained with Alexa 488- labelled streptavidin and nuclei were counterstained with 
Hoechst 33258 dye. Samples were analyzed using a Leitz DM RBF microscope and 
fluorescent staining was visualized using a F-View II firewire fluorescence camera. 
 
3.6 Immunohistochemistry 
 Embedding in paraffin (Paraffin Paraplast® Plus) and cutting of organotypic cultures 
was performed in the Department of Cellular and Molecular Pathology (Prof. Dr. H.-J. 
Gröne). 
Samples were fixed overnight in 4% formalin, dehydratated in increasing ethanol 
solutions and embedded in paraffin for 1 h at 60°C. Blocks were cut by sequential sections of 
5 µm thickness using a microtome (Leica RM2235), placed on microscope slides Super-
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frost® Plus, and allowed to dry for 1 h at 65°C. Slides were kept at RT until use. Sections of 
rafts were deparaffinized 3x 5 min in xylene. Rehydratation was performed by incubation in a 
serial grade of ethanol solutions 100%, 95%, 80%, 70% and 50% for 5 min each. All the 
incubation steps were performed placing the slides in a wet chamber in order to avoid the 
drying of the samples.  Leaking of the solutions was prevented by encircling the tissue 
samples using a Pap Pen Liquid Blocker creating a water repellent barrier around the tissue. 
 
3.6.1 Haematoxylin-eosin staining 
 Morphological study of the organotypic culture sections was done by haematoxylin-
eosin staining visualization. The staining was performed in the Department of Cellular and 
Molecular Pathology (Prof. Dr. H.-J. Gröne).  
Haematoxlyin is a basic dye which colours basophilic structure in blue (nucleic acid-
containing structures, such as cell nucleus and ribosomes). Acidic eosin Y colours proteins 
and most of the cytoplasm in pink.  
Samples were fixed in formalin, embedded in paraffin, and sectioned as described (see 
3.6). After deparaffinization and rehydratation, samples were dipped into hematoxylin for 10 
sec and washed with tap water for 10 min. Eosinic staining was performed by quick dipping 
into eosin solution followed by washing 10 min in tap water. Samples were dehydrated 
through changes in ethanol solutions with increasing concentrations (95%-100%-100%, 5 min 
each), incubated 2x5 min in xylol, and mounted using Eukitt® solution. 
Immunohistochemical staining was documented using a digital colour camera Colorview II.   
 
3.6.2 Fluorescence microscopy immunohistochemistry 
Histological examination was performed on sections (5 µm) of paraffin-embedded raft 
cultures. Serial sections were stained for keratins 4, 10, 13, 14, 16 and 77, loricrin, involucrin, 
desmoplakin I/II, PCNA, BrdU, cingulin and p63. After deparaffinization and rehydratation, 
antigen retrieval was achieved by heating at 98ºC during 15 min in 10 mM citrate buffer (pH 
6,0) (see 2.5). Slides were cooled and washed in H2O and PBS. Samples were trypsinized 
(0,001% trypsin in 0,05 M Tris-HCl) for 15 min at 37ºC, followed by washing in PBS. Tissue 
sections were blocked in 1% BSA/PBS for 1 h. The respective primary antibody was added 
and incubated overnight in a humid chamber. The following day slides were washed 3x5 min 
in PBS. Mouse and guinea pig primary antibodies were detected using Cy3–conjugated-goat  
anti-mouse and Cy3-conjugated-goat anti-guinea pig, respectively. Rabbit primary antibody 
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was detected with Alexa 488 goat anti-rabbit. Secondary antibodies were incubated for 40 
min in the dark and counterstained with Hoechst 33258 dye. Incorporated BrdU was detected 
using streptavidin-Alexa 488 and counterstained with Hoechst 33258 dye. Samples were 
washed in H2O and mounted using Fluoromont G. 
 All slides were examined using a Leitz DM RBF microscope whereas fluorescent 
staining was visualized using an F-View II firewire fluorescence camera. 
 
3.6.3 Light microscopy immunohistochemistry. Avidin-Biotin-peroxidase 
Complex 
p53 and p21CIP1 protein localization was visualized by light microscopy using the 
Vectastain®ABC Elite® system, were the avidin binds with high affinity to secondary 
antibody coupled to Biotintylated horseradish peroxidase. DAB is used as substrate for the 
peroxidase enzyme, giving a brownish color to positive cells.  
Samples were treated as described for fluorescence microscopy immunohistochemistry 
(see 3.6.2) with the exception that before blocking, endogenous peroxidase activity was 
quenched by incubation with 3% hydrogen peroxide in methanol for 15 min at RT. Slides 
were incubated overnight with the primary antibody in a wet chamber, 3x5 min washed in 
PBS and incubated with Biotintylated anti-mouse secondary antibody for 30 min. After 
washing for 5 min in PBS, ABC reagent was added for 30 min. Samples were exposed to 
DAB as substrate for peroxidase until the desired colour intensity was obtained. Sections were 
counterstained with Meyers´ hemalaum, dehydrated through changes in ethanol solutions with 
increasing concentrations (95%- 100%- 100%, 5 min each), incubated 2x5 min in xylol, and 
mounted using Eukitt® solution. Immunohistochemical staining was documented using a 
digital colour camera Colorview II.   
 
3.6.4 Lipid staining 
Cryosections were stained for lipid visualization using oil red O (Koopman et al., 
2001). Tissue samples were fixed in 3,7% formaldehyde for 1 h, washed in PBS for 5 min and 
incubated with a oil red O working solution (see composition in section 2.6) for 30 min. 
Nuclei were counterstained with Meyers´ hemalaum, samples then dehydrated in aqueous 
solution with increasing alcohol content and slides mounted using Fluoromont G. 
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3.7 Electron microscopy 
 Electron microscopy was performed in the Department of Cellular and Molecular 
Pathology (Prof. Dr. H.-J. Gröne). Organotypic cultures were isolated from the transwell 
inserts and fixed in Karnovsky solution (2% paraformaldehyde and 0,5% glutaraldehyde) for 
2 h  at  4°C. Samples were  rinsed in  1 M  cacodylate  buffer and  subsequently  fixed   in    
2% osmium tetroxide for 1 h. The specimens were dehydrated in increasing concentrations of 
ethanol and embedded in Araldite® epoxy resin. Ultrathin sections were performed in a 
ultramicrotome Leica Ultracut UCT and were stained  with 0,7% lead citrate for 5 min and 
1% uranyl acetate for 10 min. Samples were visualized by transmission electron microscopy 
(EM 900, Zeiss). 
 
3.8 Gas chromatography- mass spectrometry 
Lipid composition of the skin equivalents was studied by gas chromatography-mass 
spectrometry (GC-MS). Analysis was performed in the Deparment of Toxicology (Prof. Dr. 
R. Owen). Samples were mixed with the internal fatty acid standards for palmitic acid, stearic 
acid and oleic acid at 250 µg/ml in methanol. Then, 3 ml of Folch reagent (see 2.6) was 
added, whirly mix for 2 min and centrifuged at 2,000 x g for 10 min at 4°C. Supernatant was 
removed and samples dried under a stream of nitrogen gas. Pellet was resuspend with 900 µl 
heptane and 900 µl trans-methylation reagents (see 2.6) and incubated at 80°C for 60 min. 
Two phases could be distinguished in the samples and the upper heptane phase, corresponding 
to the fatty acids, was carefully removed for further analysis. 
 Analyses were performed using a HP 5973 mass selective detector coupled to a HP 
5890 gas chromatograph. Sample volumes of 1 µl of the hexane phase were injected into the 
gas chromatograph. Separation was achieved using a HP 5MS capillary column (30 m × 0,25 
mm I.D, 0,25 µm film thickness). Helium  was used  as carrier gas with a linear velocity of 
0,9 ml/s.  The oven  temperature  program  was:  initial  temperature  100°C,  100-160 °C  at  
4 °C/min, 160-270°C at 2°C/min. The GC injector had a temperature of 250°C whereas the 
transfer line temperature was held at 280°C. The mass spectrometer parameters for EI mode 
were: ion source temperature: 230°C; electron energy: 70 eV; filament current: 34,6 µA; 
electron multiplier voltage: 1200 V. Standard curves of authentic standards were generated 
under similar conditions in the range of 5-100 µg/ml. 
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Three samples of each raft type were analyzed for lipid composition and comparisons 
between groups were performed by t-test. Multiplicity of testing was accounted by adjusting 
p-values according to stepdown Bonferroni method (significance at p<=0.05). 
 
3.9 Flow cytometry 
Flow activated cells sorting (FACS) distinguishes cells according to their size, 
structure, cell surface properties and internal composition. Aspirated cells from the sample 
move in a laminar flow and pass through a laser beam. The light is refracted by the cell 
depending on its size and granularity and the refraction can be used to determine the latter two 
properties of a cell. When the cells are stained, fluorescent is measured for every single cell 
and different populations can be established and isolated. 
 
3.9.1 Determination of cell cycle profile 
 For cell cycle analysis, cells of interest were trypsinized, washed twice in PBS and 
pellet was fixed in 4 ml 80% ethanol at -20°C for at least 24 h. Cells were stained with 5 µM 
DAPI and 5 µM SR101 in 0,2 M Tris-HCl buffer as previously described (Stohr et al., 1978). 
DAPI binds to the A-T bases of DNA and the intensity of the fluorescence emitted reflects the 
number of bonds and, therefore, the DNA content in labelled nuclei. For a typical DNA 
histogram, one peak represents the G1 and another (with twice the channel value due to 
double DNA content) represents the G2/M phase of the cell cycle. UV illumination was used 
for fluorescence excitation of DAPI and SR101 was used as protein counterstain for 
discriminating unspecific DAPI staining. Analysis was performed according to Dean and Jett 
(1974), with a cytofluorograph 30-L. 
 
3.9.2 GFP measurement 
 After GFP retroviral transduction, HFK cells were trypsinized and centrifuged at 1,000 
rpm for 5 min at 4°C. Pellet was washed with PBS and cells were fixed using the 
Cytofix/Cytoperm™ kit following manufacturer´s instructions. Cells were washed in PBS and 
analyzed on flow cytometer. Settings were adjusted with untransduced cells and the forward 
and side scatter were set for keeping the autofluorescence of the cells in the first decade. 
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4 Results 
4.1 Characterization of HPV20 promoter activity in H1299 cells 
Previous work in our group demonstrated the HPV20 promoter activation by p53 
family members TAp63α and ∆Np63α through interaction with AP-1 c-Jun protein (Fei et al., 
2006; Fei et al., 2005).  
In order to study the influence of p53 family on HPV20 URR activity, luciferase 
reporter assays were performed. H1299 cells (a p63-null non-small cell lung cancer cell line) 
were transiently transfected with the corresponding vectors. wtp53, mutp53R248W, TAp63α 
and ∆Np63α cloned in pcDNA3.1.(+) vector were individually co-transfected with pGL3-
HPV20 URR, that contains the luciferase gene under the control of the HPV20 promoter. In 
addition, pRL-β-actin reporter plasmid, which contains the gene for Renilla luciferase from 
the β-actin promoter, was co-transfected as control for normalizing the transfection efficiency. 
Protein expression was confirmed by Western Blot analysis.  
 
4.1.1 Effect of wtp53 and mut p53R248W expression on HPV20 promoter 
 The p53 tumor suppressor gene is one of the most frequently mutated genes in human 
cancers (Hollstein et al., 1991). It plays a critical role in activating genes involved in cell 
cycle arrest and apoptosis (see 1.3.1) and it is targeted for degradation by high risk HPV E6 
(see 1.1.4.1). mutp53R248W is a common “hot spot” mutation in non-melanoma skin cancer 
(Ziegler et al., 1993).  
Under the context of wtp53 expression, HPV20 URR was 4-fold activated comparing 
to its basal activity in H1299 cells, suggesting that wtp53 up-regulation in the cell could 
promote protein viral gene expression. Interestingly, mutp53R248W expression did not 
influence HPV20 promoter activity. This is probably because the mutation in residue 248 
enables p53 binding to the viral promoter and therefore it can not modify its activity (Fig. 10). 
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Figure 10. Luciferase reporter assays show that ectopically expressed wtp53 activates HPV20 promoter, 
whereas p53mutR248W over-expression does not significantly influence it. 
 
4.1.2 Effect of TAp63α and ∆Np63α expression on HPV20 promoter  
p63 protein is a member of the p53 family. Different protein isoforms have been 
described. TA isoforms contains a transactivation domain in N-terminus, whereas in ∆N 
isoforms it is partially deleted. C-terminal spliced proteins correspond to α, β and γ forms 
(reviewed in Candi et al., 2007). 
∆Np63α has been shown to be over-expressed  in SCC of skin, head and neck, cervix 
and lung, in transitional cell carcinomas as well as certain lymphomas and thymomas (Hall et 
al., 2000; Hibi et al., 2000; Irwin and Kaelin, 2001; Quade et al., 2001; Wrone et al., 2004; 
Yang et al., 2004). In this study, we confirmed that HPV20 promoter is activated by 
ectopically expressed ∆Np63α (37 fold) as well as TAp63α (25 fold) proteins (Fig. 11), in 
accordance with previous reports from our group (Fei et al., 2005; Fei et al., 2006). 
 
 
 
 
 
 
 
 
Figure 11. Luciferase reporter assays show that expression of ∆Np63α or TAp63α highly activates HPV20 
promoter. 
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4.1.3 Effect of HPV20 E6 expression on HPV20 promoter 
In order to study the influence of HPV20 E6 expression on its own viral promoter, co-
transfection experiments with HPV20 E6 and HPV20 promoter were performed. pRL-β-actin 
reporter plasmid was co-transfected as control for transfection efficiency. Luciferase activity 
measurements demonstrated that Flag-tagged and non-Flag-tagged HPV20 E6 induce an up-
regulation of HPV20 URR (1,5 fold) when compared with the promoter basal activity or with 
the empty vector pcDNA3.1.(+). Thus, we demonstrated that HPV20 promoter activity is 
directly or indirectly influenced by its own viral protein HPV20 E6. Additional simultaneous 
expression with a Flag-tag does not modify HPV20 E6 functionality in promoter activation 
(Fig. 12). 
 
Figure 12. Luciferase reporter assays show that ectopically expressed HPV20 E6 protein directly activates 
HPV20 promoter activity.  
 
4.1.3.1 E6 protein does not influence the activation of HPV20 promoter by wtp53 
wtp53 and HPV20 E6 activate HPV20 promoter (see 4.1.1 and 4.1.3). However, when 
wtp53 was co-transfected together with HPV20 E6 and HPV20 URR, promoter activation 
levels were similar to those observed when wtp53 was co-transfected with the empty vector. 
Taken together, these results indicate that although HPV20 E6 activates HPV20 URR, it does 
not influence the HPV20 URR activation promoted by wtp53 (Fig. 13 A). That is probably 
because E6 protein from cutaneous HPV types does not directly interact with p53. 
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Figure 13. A. Luciferase reporter assays demonstrate that HPV20 promoter activitation by wtp53 it is not 
influenced by HPV20 E6 expression. B. Western blot from protein extracts after transient transfection in H1299 
cells. wtp53 is not degraded when expressed together with HPV20 E6. ß-actin was used as loading control. 
 
E6 protein of high risk HPV types binds to p53 and targets it for degradation (Munger 
et al., 1992; Scheffner et al., 1990). Cutaneous HPV20 E6 does not promote wtp53 
degradation. When HPV20 E6 was co-transfected together with wtp53 and HPV20 URR, no 
difference in p53 expression was observed, indicating that HPV20 E6 does not degradate 
wtp53 (Fig. 13 B).  
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4.1.3.2 E6 protein does not influence the activation of HPV20 promoter by TAp63α 
TAp63α highly up-regulates (15 fold) HPV20 promoter (see 4.1.2) and this effect is 
decreased when expressed together with HPV20 E6 (13 fold) and Flag-tagged HPV20 E6 
(11,5 fold) (Fig. 14 A). However, TAp63α protein levels were not altered in the presence of 
HPV20 E6 (Fig. 14 B). 
 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
Figure 14. A. HPV20 E6 expression decreases the HPV20 promoter up-regulation by TAp63α as demonstrated 
by luciferase reporter assays. B. Western blot of protein extracts after transient transfection in H1299 cells shows 
that TAp63α levels are not modified when co-expressed together with HPV20 E6. 
 
4.2 Effect of 4-NQO in immortalized oral keratinocytes 
4.2.1 Standardization of transfection conditions  
Keratinocytes were used in order to mimic the natural host cell infected by HPV. 
Primary foreskin keratinocytes were transiently transfected but the efficiency was too low to 
detect reliable luciferase reading and hence were not used for those experiments (data not 
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shown). HPV16 E6/E7 immortalized oral keratinocytes (oral KER16) were used for further 
characterization of HPV20 in cells treated with 4-NQO. 
Efficiency of transfection was compared by GFP expression levels with different 
methods (lipofectamine, lipofectamine 2000 and FuGENE reagents) and protocols (depending 
on the cell culture medium used before transfection and the ratio reagent: DNA) (see 3.5.4). 
Fluorescence microscopy allowed quick evaluation of cell survival and morphology as well as 
determination of transfection efficiency by cell counting (Fig. 15). 
The results showed that when medium was replaced by OPTI-MEM medium 3 h prior 
transfection using either LipofectamineTM 2000 or LipofectamineTM - PlusTM Reagent the 
efficiency was higher than when the medium was not replaced. However, both methods 
showed very low transfection efficiency (20%) and altered cell morphology (cells were 
increased in size and had an irregular shape).  
 
Figure 15. GFP expression levels in oral KER16 by different transfection methods.  
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When FuGENE HD was used, cell morphology remained intact and best efficiency 
(80%) was achieved when ratio FuGENE HD reagent (µl): DNA (µg) was 4:2, 5:2, 6:2 and 
7:2. Following manufacturer´s instructions, we chose the ratio 4:2, where only 4 µl of 
FuGENE HD reagent pro 2 µg DNA were able to give 80% transfection efficiency.  
Optimal DNA concentration for promoter activation studies was determined by 
transfection of different DNA amounts (1, 2, and 3 µg of pGL3-HPV20 URR) using the 
FuGENE HD reagent at ratio 4:2. When 2 µg of plasmid were transfected, a linear 
progression in the promoter activity was observed. Thus, this plasmid concentration was used 
for further luciferase reporter assays in oral KER16 (Fig. 16). 
 
 
 
 
 
 
 
Figure 16. Luciferase reporter assay. Dose-dependent HPV20 URR activation in oral KER16. 
 
4.2.2 Optimization of 4-NQO doses for treatment of keratinocytes  
Optimal concentration of 4-NQO for treatment of keratinocyte cells needed to be 
established. 4-NQO is a synthetic chemical poorly soluble in water and organic solvents 
(DMSO or EtOH) have to be used for concentrated stocks. We dissolved the chemical 
following manufacturer´s instructions in a final concentration of 2 mM 4-NQO in 0,05% 
DMSO and treated the cells overnight with different concentrations of the chemical (Fig. 17). 
DMSO control was applied at a concentration of 0,015%, corresponding to the concentration 
of DMSO that the 30 µM 4-NQO sample contained. Viability was measured in triplicates by 
counting live cells (unstained) in comparison to dead cells (uptake trypan blue dye) in a 
Neuenbauer chamber.  
Cells remained viable (96-98%) when treated with 0,015% DMSO, 2µM 4-NQO or 
10µM 4-NQO. When 4-NQO was applied at 30 µM final concentration, cells changed to a 
rounded and shiny morphology and viability decreased to 85% (Fig. 17). 
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                                                                                                              4-NQO 
Figure 17. 4-NQO toxicity assay. Death cells were quantified by trypan blue uptake. 
 
4.2.3 Effect of  4-NQO on cell cycle 
Cell cycle profile was determined by measuring DNA content in samples treated 
overnight with varying concentrations of 4-NQO (Fig. 18 A). The first peak corresponds to 
G1 population, where cells have a haploid DNA content. Second peak represents cells in 
G2/M phase (with double DNA content). Populations with less than one copy of the genome 
(sub-G1) are considered apoptotic cells whereas populations between G1 and G2/M peaks 
correspond to cells in S phase. 4-NQO was applied at different concentrations and the results 
showed that low dose treatment (≤ 3 µM) promotes entry into S-phase and G2/M as 
previously observed (Heron-Milhavet et al., 2001). 4-NQO induces G1 arrest and apoptosis 
when applied at high doses (Han et al., 2007). In agreement with this report, we  observed  G1 
arrest when  4-NQO was  applied  at 6, 9 and 12 µM. In  addition,  4-NQO induced apoptosis 
at a concentration 12 µM, as observed in the cell cycle analysis by the appearance of a sub-G1 
population (Fig. 18 A and B).  
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Figure 18.  A. Cell cycle profile of 4-NQO treated oral KER16 measured by FACS analysis. B. Percentage of 
cells in G1, S and G2/M phases.  Apoptotic cells correspond to sub-G1 population.  
 
4.2.4 Influence of  4-NQO on HPV20 promoter activity 
The viral promoter activity is often influenced by cellular factors, environmental 
factors and its own proteins. In order to study the promoter behavior of HPV20 when 
combined with 4-NQO, luciferase reporter experiments were performed. Oral KER16 were 
transiently transfected with either pGL3-HPV20 URR alone or in combination with Flag-
tagged HPV20 E6 and/or E7  oncoproteins.  4-NQO was applied at  a final  concentration  of 
3 µM  4 h after transfection. Proteins were extracted 20 h after transfection using passive lysis 
buffer (see 3.4.1.1). Measurement of luciferase activity showed that DMSO alone does not 
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modify the HPV20 promoter activity whereas 4-NQO enhances it in cells transfected with the 
empty plasmid pcDNA3.1.(+) as well as cells expressing Flag-tagged HPV20 E6, Flag-tagged 
-E7 and Flag-tagged E6/E7, further contributing to the up-regulation induced by the 
respective viral proteins (Fig. 19). 
 
 
 
 
 
 
 
 
 
 
                                  pcDNA3.1(+)           + HPV20 E6-flag         + HPV20 E7-flag   + HPV20 E6-flag/E7-flag 
 
Figure 19. Luciferase activity assays show that 4-NQO enhances HPV20 promoter activity in oral KER16. 4-
NQO further increases the promoter activation induced by HPV20 E6-flag, E7-flag and E6-flag/E7-flag proteins. 
 
4.2.5 Influence of 4-NQO together with Flag-tagged HPV20 E6 on 
endogenous expression of ∆Np63α, p53, PCNA and p16 
Oral KER16 were transiently transfected with Flag-tagged HPV20 E6 and 
subsequently treated with 4-NQO as described (see 3.2.5). Proteins of interest were 
demonstrated by Western Blot. Bands were quantified using the software program 
ImageQuant 5.0 (Molecular Dinamics, USA). Flag-tagged HPV20 E6 expression was 
demonstrated by antibody against Flag-tag (Fig. 20 A).  
∆Np63α protein was highly increased after Flag-tagged HPV20 E6 transfection. 
DMSO did not alter ∆Np63α levels whereas 4-NQO up-regulated ∆Np63α in both control 
vector and Flag-tagged HPV20 E6 samples. Interestingly, tumor suppressor gene p16 was 
HPV20 URR + + + + + + + + + + + + 
pcDNA3.1.(+) + + + - - - - - - - - - 
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also similarly up-regulated when Flag-tagged HPV20 E6 expression was combined with 4-
NQO treatment (Fig. 20 B).  
Our group has previously demonstrated an up-regulation of p53 in transgenic mice 
expressing HPV20 E6/E7 when chronically exposed to UV (Michel et al., 2006). In the 
present in vitro study p53 was over-expressed after Flag-tagged HPV20 E6 transfection and 
this effect was enhanced when incubated with the UV-mimetic 4-NQO.  
It has been described that the transcription of the proliferation marker PCNA is 
increased after treatment with 4-NQO (Li et al., 2005). However, no significant difference in 
PCNA expression was observed in 4-NQO treated samples after Western blot quantification 
(Fig. 20 B).  
 
Figure 20. A. Western blot analysis of cellular proteins of oral KER16 after transfection with HPV20 E6-flag. B. 
Quantification of protein bands normalized to ß-actin using the densitometer software ImageQuant 5.0.  
 
4.3 HPV20 E6 expression and/or 4-NQO treatment do not increase the 
life span of primary keratinocytes   
HPV16 and 18 immortalize primary keratinocytes (Durst et al., 1989; Kaur and 
McDougall, 1989). E6 or E7 from high risk genital HPV16 or 18 individually immortalize 
keratinocytes weakly whereas the effect is synergistic when E6 and E7 are co-expressed 
(Romanczuk et al., 1991). However, low risk genital HPV and cutaneous HPV are not able to 
immortalize cells (reviewed in Munger and Howley, 2002), although an enhancement in life 
span after retroviral transduction of certain HPV types has been observed (Caldeira et al., 
2003; Schaper et al., 2005). In this study, we characterize the effect of Flag-tagged HPV20 E6 
and HPV16 E6/E7 proteins in the presence of 4-NQO in the keratinocytes life span. 
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Transfection efficiency is very low in primary keratinocytes (HFK). Therefore, cells were 
transduced with retroviral vectors that integrate in the host genome and ensure stable protein 
expression. HFK transduced with the empty pLXSN retroviral vector were used as control. 
Flag-tagged HPV20 E6 gene was cloned into pLXSN retroviral vector with a Kozak sequence 
upstream of the starting methionine and was Flag-tagged at N-terminus. Gene expression was 
controlled by the SV40 constitutive promoter contained in the pLXSN retroviral vector. 
Transduction efficiency was 28%, as determined by measurement of GFP fluorescence in 
FACS analysis (Fig. 21 A). Neomycin phosphotransferase expression (present in the pLXSN 
plasmid) was shown by RT-PCR and Western blot in the transduced cells (Fig. 21 B and C). 
Flag-tagged HPV20 E6 expression was demonstrated by RT-PCR (Fig. 21 C).  
 
 
 
Figure 21. A. Measurement of GFP transduction efficiency. Cells were sorted by its fluorescence in a 
FACScalibur and population of transduced cells estimated in 28%. B. Western blot analyses of proteins from 
cells transduced with empty vector (pLXSN) or vector containing GFP (pLXSN-GFP). Cells containing pLXSN 
vector expressed the neomycin phosphotransferase (NPT) protein. β-actin was used as loading control. C. RT-
PCR of normal HFK (control) and HFK stably transduced with empty vector (pLXSN) or pLXSN-HPV20 E6-
flag.  Cells containing pLXSN vector transcribed the NPT gene.  GAPDH was used as housekeeping gene 
internal control. 
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After selection in geneticin (G418) antibiotic cells were exposed to 4-NQO. At 3 µM 
4-NQO concentration all the cells died. We decided to reduce the chemical concentration to 
minimize cell death, choosing 1 µM as final concentration for long term chemical treatment in 
HFK cells. Stable clones containing the empty pLXSN vector, Flag-tagged HPV20 E6 or 
HPV16 E6/E7 were monitored in presence/absence of 1 µM 4-NQO. Cells were maintained 
for 5-6 passages. HPV16 E6/E7 transduced cells (used as positive control) had a higher 
growth rate and survived until they experiment was stopped at passage 15. When pLXSN and 
Flag-tagged HPV20 E6 transduced cells were treated with 1 µM 4-NQO, they died within the 
first 10 days.  Interestingly, cells transduced  with  pLXSN-HPV16 E6/E7  and treated  with  
1 µM 4-NQO survived for only three days after the treatment started (Fig. 22). In summary, 
Flag-tagged HPV20 E6 expression did not extend the life span of HFK. Moreover, cell death 
was decreased in 4-NQO treated transduced cells. 
Figure 22. Life span of HFK stably transduced with pLXSN empty vector, HPV20 E6-flag or HPV16 E6/E7 
alone or in combination with 1 µM 4-NQO treatment. 
 
4.4 Organotypic cultures 
The HPV life cycle is linked to the differentiation of the stratified squamous 
epithelium. NIKS is a near-diploid keratinocyte cell line that differentiates in culture similar 
to in in vivo situation, stratifies normally, presents the same expression profile of molecular 
markers as healthy skin and is non-tumorigenic in nude mice (Allen-Hoffmann et al., 2000). 
These cells have been widely used in organotypic culturing techniques, which mimic the 
natural environment and conditions for HPV infection.  
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4.4.1 Epidermal morphology of organotypic cultures 
Organotypic cultures of NIKS cells stably transduced with empty pLXSN vector, 
Flag-tagged HPV20 E6 or HPV16 E6/E7 were expanded and grown in the air-medium 
interphase. During the 14 days growth under these conditions, the epithelial surface became 
whiter and passed from a shiny and wet to a dry and mat appearance.  
Sections from paraffin-embedded rafts were stained with haematoxylin/eosin (HE). 
Morphological examination by light microscopy revealed that NIKS cells transduced with the 
pLXSN empty vector developed into normal differentiating epithelia, containing the stratum 
basale, stratum spinosum, stratum granulosum and stratum corneum corresponding to normal 
skin layers (Fig. 23).  
 
Figure 23.  HE staining of organotypic raft culture based on NIKS cells stably transduced with pLXSN empty 
vector. Epidermal layers can be distinguished: stratum basale (SB), stratum spinosum (SS), stratum granulosum 
(SG) and stratum corneum (SC). Magnification 200x. 
 
Flag-tagged HPV20 E6 expression resulted in unorganized epithelia with poorly 
differentiated parabasal layers of the stratified epithelia. The regular orientation and 
stratification of cells was disturbed (Fig. 24). The basal cell layer was present but was not as 
regular as in the control culture harboring the empty retroviral vector pLXSN (Fig. 23). 
Parabasal layers were poorly differentiated, the stratum spinous and stratum granulosum were 
poorly developed with an increase in apoptotic cells and fat droplets and, insofar, giving rise 
to morphological features of squamous epithelia. In contrast to control epidermis, the stratum 
corneum was thin and less compact. Foamy-cell-like structures were also found in the 
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uppermost differentiating layers (Fig. 24 a). The upper parts of Flag-tagged HPV20 E6 
epidermis presented large vacuolated structures and unnucleated eosinophilic inclusions 
resembling dyskeratotic cells (Fig. 24 b). Basophilic flat oval and compact nuclei present in 
all parabasal layers indicate a high DNA content (Fig. 24 c). Bubble-like cavernae structures 
were evidenced in the considerable thinner cornified layers (Fig. 24 d), suggesting failures in 
adherence and cell junctions. Some areas of Flag-tagged HPV20 E6-expressing rafts formed 
circular basket-like cysts (Fig. 24 e). The increased number of apoptotic cell residues in the 
upper epidermis is interpreted as a consequence of the increased number of keratinocytes 
entering the disorganized stratum corneum. 
 
Figure 24.  HE staining of HPV20 E6-flag expressing raft culture. It presents (a) foamy-like cells in the 
uppermost layers, (b) vacuolated structures with eosinophilic inclusions, (c) basophilic and compact nuclei, (d) 
cell bubbling in the cornified layer and (e) basket-like cysts. Magnification 200x. 
 
Control HPV16 E6/E7 containing rafts showed a highly dysplastic and disorganized 
epidermal morphology. The stratum corneum was reduced in comparison to pLXSN control 
and only stratum basale could be distinguished. Abundant mitotic figures were found in 
suprabasal layers as described in cervical cancer (Babawale et al., 2005) and organotypic raft 
cultures of HPV16 and HPV18-immortalized keratinocytes (Blanton et al., 1991) (Fig. 25). 
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Figure 25. HE staining of HPV16 E6/E7 raft culture. Magnification 200x. 
 
All three lines were additionally treated with 4-NQO. The chemical was dissolved in 
the NIKS medium at 3 µM final concentration and applied during the 14 days air-lifted 
organotypic culture growing. HE staining did not show any obvious difference in morphology 
and staining when compared to the untreated samples (Fig. 26). Prolonged treatment of these 
cultures with 4-NQO was not possible because of the limited life span of the organotypic raft 
cultures. 
 
 
Figure 26. HE staining of pLXSN, HPV20 E6-flag and HPV16 E6/E7 organotypic cultures. 4-NQO was added 
to the medium at 3 µM final concentration for 14 days. Magnification 200x. 
 
4.4.2 Verification of Flag-tagged HPV20 E6 expression in organotypic 
cultures 
Flag-tagged HPV20 E6 gene transcription was demonstrated by RT-PCR of cDNA 
from monolayer cultures (Fig. 27 A). Moreover, Western blot analysis of proteins extracted 
from organotypic cultures showed Flag-tagged HPV20 E6 expression by anti-Flag 
immunodetection (Fig. 27  B). Interestingly, after 4-NQO treatment Flag-tagged HPV20 E6 
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protein was up-regulated as demonstrated by Western blot (Fig. 27 B); in this way, the 
addition of 4-NQO might enhance viral protein expression and/or stability. 
 
 
 
 
 
 
 
Figure 27. A. RT-PCR of transduced NIKS cells grown in monolayer. GAPDH was used as reference gene. B. 
Western blot of raft total lysates. HPV20 E6-flag protein was detected by anti-Flag antibody. ß-actin was used as 
loading control. 
 
4.4.3 Flag-tagged HPV20 E6 alters the expression of p21
CIP1
, p53 and ∆Np63α 
proteins 
Our group has previously demonstrated the degradation of HPV20 E6 under 
simultaneous ectopic expression with wtp53 in the lung carcinoma cell line H1299 (Fei and 
de Villiers, 2008). In the organotypic culture system, we studied the effect of Flag-tagged 
HPV20 E6 expression on the endogenous p53 levels. Duplicate organotypic cultures were 
harvested for protein extraction and paraffin embedding. Protein expression levels and 
distribution were monitored by immunohistochemistry staining and Western blotting.  
Expression of Flag-tagged HPV20 E6 in the organotypic cell cultures led to an increase 
of endogenous p53 as demonstrated by Western blot analyses (Fig. 28 A and B). HPV16 E6 
mediates the degradation of p53 and it is therefore not detectable as shown in the 
immunohistochemistry and Western blot staining of HPV16 E6/E7 samples (Fig. 28 A, B and 
C). 4-NQO treatment induced the down-regulation of p53 protein levels in pLXSN control 
sample and the up-regulation of p53 protein levels in Flag-tagged HPV20 E6  when compared 
to its counterpart cultures not treated with 4-NQO (Fig. 28 A and B). Immunohistochemical 
staining of Flag-tagged HPV20 E6 cultures confirmed an up-regulation of endogenous p53 
seen not only in the basal compartment, but extending into all suprabasal layers. Although 
differences in p53 levels were found between samples treated and untreated with 4-NQO, the 
protein distribution pattern was not altered in 4-NQO-treated samples as observed by 
immunohistochemistry staining (Fig 28 C).  
p53 acts as tumor suppressor through up-regulation of the cyclin kinase inhibitor p21CIP1 
(reviewed in Thomas and Laimins, 1998). p21CIP1 is degraded by proteosomes in normal 
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primary keratinocytes (Banerjee et al., 2006). Our results showed an up-regulation in p53 
levels in organotypic cultures expressing Flag-tagged HPV20 E6. Therefore, an up-regulation 
of the p53 downstream target p21CIP1 in Flag-tagged HPV20 E6 rafts was expected. 
In our system, p21CIP1 expression in the pLXSN control rafts was not restricted to the 
basal cell layer only, but was evident through all strata (Fig. 28 D). This distribution is not 
surprising in view of the immortalized nature of the NIKS keratinocytes cells (Allen-
Hoffmann et al., 2000). p21CIP1 expression was up-regulated in Flag-tagged HPV20 E6 
cultures, as demonstrated in both Western blot analyses of the proteins extracted from the 
organotypic cultures and in the immunohistochemistry staining (Fig. 28 A, B and D). In 
HPV16 E6/E7 rafts, p21CIP1 was up-regulated in comparison to pLXSN control. p21CIP1 
localization and expression levels were not altered when 4-NQO was applied to the medium 
of pLXSN, Flag-tagged HPV20 E6 and HPV16 E6/E7 organotypic cultures. 
∆Np63α is a p53 family member involved in skin proliferation and differentiation 
commonly over-expressed in SCC (Hibi et al., 2000; Mills, 2006) that acts as a dominant 
negative of p53. Immunofluorescence staining of p63α indicated a moderate up-regulation of 
∆Np63α protein levels by Flag-tagged HPV20 E6 (Fig. 28 E). This expression was, as in the 
pLXSN control organotypic cultures, not confined to the basal compartment, but extended 
through the suprabasal layers. Western blot analyses however indicated a clear up-regulation 
of the ∆Np63α protein level by Flag-tagged HPV20 E6 compared to the pLXSN control 
cultures. HPV16 E6/E7 also highly up-regulated p63α expression throughout the suprabasal 
layers (Fig. 28 E). pLXSN control culture treated with 4-NQO showed up-regulated levels of 
∆Np63α protein by Western blot (Fig. 28 A and B) whereas no inffluence was found in Flag-
tagged HPV20 E6 or HPV16 E6/E7. ∆Np63α protein expression pattern did not differed in 4-
NQO treated versus 4-NQO untreated samples (Fig. 28 E). 
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Figure 28. A. Western blot of proteins extracted from organotypic cultures. ß-actin was used as loading control. 
B. Quantification of protein bands normalized to ß-actin by densitometry. Immmunohistochemistry staining of 
p53 (C) and p21CIP1 (D) revealed their up-regulation in HPV20 E6-flag rafts. Nuclei were counterstained with 
Meyers´hemalaum.
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Figure 28. E. p63 immunofluorescence profile indicates expression in basal and parabasal layers, being slightly 
up-regulated in HPV20 E6-flag organotypic culture. Dotted lines indicate separation from collagen raft. Nuclei 
were counterstained with Hoechst 33258 dye. Magnification 200x. 
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4.4.4 Profiles of epidermal markers differ in Flag-tagged HPV20 E6 and 
HPV16 E6/E7-expressing organotypic cultures 
4.4.4.1 Keratin pattern 
Keratins are main components of the architecture of epithelial cells. These 
intermediate filaments present a characteristic profile in healthy epithelia that change during 
tumor development. Alterations in expression levels and profiles are useful tools for 
histological diagnosis and tumor classification (reviewed in Moll et al., 2008). Since 
epidermal morphology was altered in Flag-tagged HPV20 E6 cultures, modified expression of 
keratins could be expected.  Cytokeratin 10 and 14 were detected by immunofluorescence 
staining and Western blot. 
 
Cytokeratin 14 
Cytokeratin 14 expression is a marker for undifferenciated cells, strictly confined in 
healthy skin to the outer sheath of the hair follicle (reviewed in Stark et al., 1987) and basal 
compartment (reviewed in Moll et al., 2008), as found in the pLXSN control organotypic 
culture (Fig. 29 C). However, immunofluorescence staining showed extended cytokeratin 14 
expression into all suprabasal layers in Flag-tagged HPV20 E6-expressing organotypic 
cultures, with a prominent staining of dyskeratotic cells. This expression was more restricted 
to the lower suprabasal layers in the HPV16 E6/E7-expressing cultures. 4-NQO treatment did 
not additionally alter the cytokeratin 14 expression and localization in any of the samples 
investigated (Fig. 29 C). Western blot analysis of organotypic cultures extracts confirmed the 
up-regulation of cytokeratin 14 in Flag-tagged HPV20 E6 compared with the pLXSN control 
in both samples treated and untreated with 4-NQO (Fig. 29 A and B).  
 
 
Figure 29. A. Western blot of proteins extracted from organotypic cultures. ß-actin was used as loading control. 
B. Quantification of protein bands normalized to ß-actin using the densitometer software ImageQuant 5.0.  
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Figure 29. C. Immunofluorescence staining showed that Cytokeratin 14 was confined to the basal membrane in 
the pLXSN control raft whereas HPV20 E6-flag kept its expression along the epidermis, especially in the 
dyskeratotic cells. HPV16 E6/E7 cultures showed extended cytokeratin 14 expression into the suprabasal layers, 
becoming more pronounced after 4-NQO treatment. Dotted lines indicate separation from collagen raft. Nuclei 
were counterstained with Hoechst 33258 dye. Magnification 200x. 
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Figure 29. D. Immunofluorescence staining of cytokeratin 10 showed delayed expression in HPV20 E6-flag, 
HPV20 E6-flag treated with 4-NQO and more pronouncedly in HPV16 E6/E7 rafts. Dotted lines indicate 
separation from collagen raft. Nuclei were counterstained with Hoechst 33258 dye. Magnification 200x. 
 
Cytokeratin 10 
Cytokeratin 10 is expressed very early in differentiation, when keratinocytes leave the 
basal proliferative stratum and enter the suprabasal compartment, representing sensitive 
indicators for the onset of the epidermal differentiation program (reviewed in Moll et al., 
2008).  
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Cytokeratin 10 is localized in the suprabasal compartment beginning in the first 
suprabasal cell layer in normal epidermis, as observed in the pLXSN control raft (Fig. 29 C). 
In contrast to the pLXSN control, in HPV16 E6/E7 cytokeratin 10 expression pattern was 
delayed until the 5-6th suprabasal layer. Cytokeratin 10 expression was regularly delayed in 
rafts expressing Flag-tagged HPV20 E6, starting only from the second or third suprabasal 
layer. Interestingly, when 4-NQO was applied to the medium, a further delay in the 
expression pattern was observed in Flag-tagged HPV20 E6 rafts but not in pLXSN control or 
HPV16 E6/E7 samples (Fig. 29 D).  
At Western blot level, cytokeratin 10 was up-regulated in Flag-tagged HPV20 E6 in 
comparison to pLXSN control and HPV16 E6/E7 (Fig. 29 A and B) whereas the cytokeratin 
10 protein levels were reduced in the Flag-tagged HPV20 E6 samples treated with 4-NQO 
(Fig. 29 A, B and D).  
 
Other cytokeratins 
 Keratins 4 and 13 are typically expressed in non-cornified mucosal stratified 
epithelium. Those keratins were not expressed in pLXSN, Flag-tagged HPV20 E6 or HPV16 
E6/E7-expressing cultures irrespective of 4-NQO treament (data not shown), indicating that 
Flag-tagged HPV20 E6, HPV16 E6/E7 expression and/or 4-NQO treatment did not altered the 
cornifing nature of the NIKS raft cultures. 
 
4.4.4.2 Late differentiation markers  
To further confirm the defective development of the epidermis, expression of late 
differentiation markers was studied. 
Involucrin and loricrin are important components of the epidermal barrier (reviewed in 
Steinert, 2000). In Flag-tagged HPV20 E6 cultures, involucrin expression was only slightly 
delayed whereas levels of loricrin were somewhat reduced and expression restricted to the 
uppermost epidermal layers. 4-NQO altered involucrin expression in Flag-tagged HPV20 E6 
rafts, producing a further delay in its expression profile. Loricrin expression was markedly 
reduced in Flag-tagged HPV20 E6 samples when combined with the chemical treatment. 
Immunofluorescence staining of pLXSN control revealed the involucrin specific membrane-
associated honeycomb texture and an expanded distribution commonly seen in regenerating 
epidermis (Watt et al., 1987) (Fig. 30 A). Loricrin expression was concentrated strongly in 
the stratum granulosum of pLXSN control rafts (Fig. 30 B) as described in healthy skin (Hohl 
et al., 1993). 
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Involucrin expression was highly decreased and delayed and loricrin was extremely 
faint or no longer visible in HPV16 E6/E7 expressing rafts (Fig. 30 A and B). No significant 
differences in involucrin and loricrin expression pattern were observed when the samples 
were treated with 4-NQO.  
 
Figure 30. Immunofluorescence staining of late differentiation markers.  A. Involucrin (red) expression was 
decreased in HPV20 E6-flag, HPV20 E6-flag treated with 4-NQO and much more pronouncedly in HPV16 
E6/E7. Dotted lines indicate separation from collagen raft. Nuclei were counterstained with Hoechst 33258 dye. 
Magnification 200x. 
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Figure 30. Immunofluorescence staining of late differentiation markers.  B. Loricrin (green) expression pattern 
was similar in pLXSN control vector and HPV20 E6-flag raft, being restricted to last uppermost layers, very 
reduced in HPV20 E6-flag + 4-NQO and absent in HPV16E6/E7. However, HPV20 E6-flag contained a much 
lower amount of protein compared to pLXSN control. Dotted lines indicate separation from collagen raft. Nuclei 
were counterstained with Hoechst 33258 dye. Magnification 200x. 
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4.4.5 Proliferation measured by PCNA staining and BrdU incorporation 
Proliferating cells were identified by PCNA staining and BrdU incorporation assay. 
PCNA is an auxiliary protein of DNA polymerase that is specifically expressed in cells during 
the S phase and it is used as a marker for cellular proliferation (Kelman, 1997). As 
keratinocytes proliferate from the stratum basale, PCNA-positive cells were observed only in 
this layer in pLXSN control and Flag-tagged HPV20 E6 organotypic cultures (Fig. 31 C). 
Western blot analysis showed a decrease in PCNA expression in the Flag-tagged HPV20 E6 
samples (Fig. 31 A and B).  p21CIP1 and p53 down-regulate PCNA (Luo et al., 1995; Mercer 
et al., 1991). This PCNA down-regulation in Flag-tagged HPV20 E6 cultures is probably due 
to the simultaneous up-regulation of p21CIP1 and p53 leading to a down-regulation of PCNA 
synthesis rather than a decreased proliferation rate per se (Fig. 31 A and B). In HPV16 E6/E7 
epidermis PCNA staining was not only found in the stratum basale but also in the stratum 
spinosum, indicating hyperproliferation of abnormally differentiated keratinocytes (Fig. 31 
C).  
BrdU incorporation shared a similar labeling pattern with PCNA. No difference in 
BrdU incorporation was observed in Flag-tagged HPV20 E6-expressing cultures when 
comparing the pLXSN control, whereas unscheduled DNA synthesis in the differentiating 
compartment was demonstrated under the expression of HPV16 E6/E7 (Fig. 31 D). Both 
PCNA and BrdU incorporation studies demonstrated that proliferation rates are not modified 
when 4-NQO is added to the media. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Proliferation levels showed to be similar in pLXSN control vector and HPV20 E6-flag, as 
demonstrated by BrdU incorporation and  PCNA expression A. Western blot of raft total lysate. ß-actin was used 
as loading control. B. Quantification of protein bands normalized to ß-actin by densitometry.  
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Figure 31. Proliferation levels showed to be similar in pLXSN control vector and HPV20 E6-flag, as 
demonstrated by BrdU incorporation and  PCNA expression C. Immunofluorescence staining of PCNA. Dotted 
lines indicate separation from collagen raft. Nuclei were counterstained with Hoechst 33258 dye. Magnification 
200x. 
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Figure 31. Proliferation level showed to be similar in pLXSN control vector and HPV20 E6-flag, as 
demonstrated by BrdU incorporation and PCNA expression. D. BrdU incorporation assay measured by 
immunofluorescence. Dotted lines indicate separation from collagen raft. Nuclei were counterstained with 
Hoechst 33258 dye. Magnification 200x. 
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4.4.6 Electron microscopy 
In order to confirm the aberrant differentiation found in Flag-tagged HPV20 E6 
expressing cultures (see 3.4.1 and 3.4.4), ultrastructural morphology was analyzed by 
transmission electron microscopy. In normal skin epidermis, the synthesis of keratin filaments 
starts in the stratum basale and continues into the stratum granulosum (Fuchs, 1993). In the 
stratum corneum cells become anucleated and compact. In accordance with these 
observations, ultrastructure analysis by transmission microscopy of the pLXSN control 
epidermis showed keratin accumulation in the stratum spinosum, small electro-dense granules 
in the stratum granulosum and compact stratum corneum where corneocytes can not be 
individually distinguished (Fig. 32 A). In Flag-tagged HPV20 E6 epidermis the stratum 
spinosum was not distinguishable. Stratum granulosum appeared thicker than in the pLXSN 
control, it was disorganized, with fewer keratin granules that highly differ in size from each 
other as well as accumulated of lipid droplets (Fig. 32 A and C). Moreover, Flag-tagged 
HPV20 E6 presented apoptotic figures in the upper granulosum and corneum strata (Fig. 32 
C).  
Intercellular spaces were not widened and the ultrastructure of desmosomes appeared 
normal in both pLXSN control and Flag-tagged HPV20 E6 samples (Fig. 32 B). 
 
 
 
Figure 32. Ultrastructural analysis of raft cultures by electron microscopy. A. HPV20 E6-flag sample showed 
lipid accumulation and aberrant apoptotic bodies in the granular and cornified layer. Arrowheads indicate lipid 
droplets. Magnification 10 µm.   
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Figure 32. Ultrastructural analysis of raft cultures by electron microscopy. B. Desmosomes (*) were similar in 
pLXSN control and HPV20 E6-flag rafts and intercellular spaces (arrows) did not differ between both samples. 
Magnification 1 µm. C. Detail of Flag-tagged HPV20 E6 raft ultrastructure with lipid droplets (arrowheads), 
abnormal granules of different sizes in the stratum granulosum and apoptotic cell in the stratum corneum.  
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4.4.7 Loss of barrier function 
4.4.7.1 Lipid quantification 
Free fatty acids, ceramides and cholesterol are the main lipid constituents involved in 
maintenance of epidermal barrier function (Coderch et al., 2003). We thus determined the 
levels of free fatty acids and cholesterol by Gas Chromatography-Mass Spectrometry (GC-
MS). Differences in composition were observed between pLXSN control and Flag-tagged 
HPV20 E6 rafts (Fig. 33): pentadecanoic acid, linoleic acid, cis-10-Heptadecanoic acid, cis-
10-Pentadecanoic acid, arachidonic acid, stearic acid, palmitoleic acid, oleic acid and total 
content of fatty acid were significantly increased in Flag-tagged HPV20 E6 organotypic 
cultures as determined by GC-MS whereas nervonic acid was significantly decreased. 
 
Figure 33. Lipid content analyzed by GC-MS. Content of individual fatty acids, cholesterol and total lipids was 
measured as µg/g raft tissue. 1. Erucic acid. 2. Behenic acid. 3. Arachidic acid. 4. Pentadecanoic acid. 5. Linoleic 
acid. 6. Nervonic acid. 7. cis-10-Heptadecanoic acid. 8. cis-10-Pentadecanoic acid. 9. Lignoceric acid. 10. 
Arachidonic acid. 11. cis-11-Eicosenoic acid. 12. Myristic acid. 13. Stearic acid. 14. Palmitoleic acid. 15. 
Palmitic acid. 16. Elaidic acid. 17. Oleic acid. 18. Total fatty acids. 19. Cholesterol. 20. Total lipids. * indicates 
significance calculated by stepdown Bonferroni method (p<=0.05). 
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4.4.7.2 Lipid droplets accumulate in organotypic cell cultures expressing Flag-tagged 
HPV20 E6  
Flag-tagged HPV20 E6 expression induced changes in lipid composition (see 3.6.1) 
and lipid accumulation in the organotypic cultures as observed by electron microscopy (see 
3.5). Therefore, lipid accumulation was suspected and staining with Oil Red O was 
performed. Both pLXSN control, as well as Flag-tagged HPV20 E6 showed intense lipid 
accumulation in the cornified layers. In addition, lipid droplets were seen in single cells of the 
basal compartment of Flag-tagged HPV20 E6 cultures at higher magnification (Fig. 34). 
 
 
 
 
 
 
 
 
 
Figure 34. Lipid staining of cryosections. Lipids were detected by Oil Red O staining (red) and nuclei were 
counterstained with Meyers´ hemalaum. At magnification of 200x the cornified layer showed an intense lipid 
accumulation in both pLXSN control vector and HPV20 E6-flag rafts. HPV20 E6-flag presented accumulation 
of lipid droplets in the basal layer (see square detail).  
 
4.4.8 Skin permeability assay 
Stratum corneum is formed by ordered synthesis of different keratins and proteins in 
each stratum and it is crucial to develop the skin barrier function. The aberrant differentiation 
in Flag-tagged HPV20 E6 organotypic cultures (extended cytokeratin 14 expression, delay in 
cytokeratin 10 and involucrin expression; see 3.4.1 and 3.4.4), the altered lipid composition 
(see 3.6) and lipid accumulation (see 3.5 and 3.6) suggested a perturbed skin barrier. To 
examine this hypothesis, we performed skin permeability assay by Lucifer yellow penetration 
and Biotin uptake assays. Moreover, the presence of tight junctions was evaluated by cingulin 
staining. 
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4.4.8.1 The outside-in barrier is not functional in Flag-tagged HPV20 E6 rafts 
The outside-in permeability of the stratum corneum was analyzed by its ability to take 
up a liquid dye. Lucifer yellow placed on top of the epithelia could not pass through the 
stratum corneum in control tissue. However, the dye penetrated through the epidermis in 
Flag-tagged HPV20 E6-expressing epidermis, demonstrating the defective skin barrier 
function (Fig. 35).  
 
Figure 35. Lucifer yellow penetration assay showed that stratum corneum of pLXSN control raft was able to 
retain the dye whereas in Flag-tagged HPV20 E6 it diffused across the stratum corneum into the dermal 
equivalent. Dotted lines indicate basement membrane. Nuclei were counterstained with Hoechst 33258. 
Magnification 200x. 
 
4.4.8.2 Increased permeability of tight junctions: altered inside-out barrier in Flag-
tagged HPV20 E6 epithelia 
In order to study how Flag-tagged HPV20 E6 expression affects the inside-out barrier 
function in stratifying epithelia, Biotin solution was added to the feeding medium of the raft 
cultures 30 min before harvesting. In pLXSN control tissue, Biotin moved up to the stratum 
granulosum (Fig. 36 A), where it was halted due to the presence of tight junctions, marked by 
cingulin staining (Fig. 36 B). However, Biotin penetrated the granular layer in Flag-tagged 
HPV20 E6-expressing epidermis and was able to reach the stratum corneum (Fig. 36 A). This 
observation was confirmed by the fact that Flag-tagged HPV20 E6 rafts were negative for 
cingulin staining (Fig. 36 B), indicating that the Biotin was not retained by the tight junctions 
and could reach the uppermost part of the tissue. Thus, tight junctions were disrupted in Flag-
tagged HPV20 E6 samples and inside-out barrier was no longer functional. 
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Figure 36. A. Biotin uptake assay. Inside-out barrier was functional in pLXSN control raft cultures whereas 
Biotin diffusion showed impaired barrier in HPV20 E6-flag raft culture. Dotted lines indicate basement 
membrane. Nuclei were counterstained with Hoechst 33258. Magnification 400x. B. Tight junction staining by 
localization of cingulin. In HPV20 E6-flag cultures the tight junctions were disrupted, in contrast to pLXSN 
control. Insert in merged picture shows detail of the upper stratum granulosum where tight junctions localise. 
Dotted lines indicate basement membrane. Magnification 200x. 
 
4.4.9 Cell-cell communication: desmosomal distribution 
Desmosomes are cell-to-cell adhesion structures that attach the cell surface adhesion 
proteins to intracellular keratin filaments (Langbein et al., 2002). Differences in keratin 
expression profile and failure in barrier function suggested possible modifications in 
desmosome structure and/or localization. In order to examine the cellular distribution of 
desmosomes, desmoplakin staining was performed. This protein is an obligate component of 
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functional desmosomes which anchors intermediate filaments to desmosomal plaques in cell-
to-cell adhesion complexes (Green et al., 1990) and altered formation has been described in 
high-grade squamous intraepithelial lesions of the cervix (Alazawi et al., 2003). 
Immunofluorescence showed a similar distribution of desmosomes in Flag-tagged 
HPV20 E6 compared to control rafts as demonstrated by desmoplakin I/II staining (Fig. 37). 
Interestingly, desmoplakin staining made the presence of multilobular and pleomorfic nuclei 
more evident in Flag-tagged HPV20 E6 organotypic culture (Fig. 37, arrows).  
Figure 37. Study of desmosomal distribution by immunofluorescence staining showed correct desmosomal 
formation in HPV20 E6-flag and pLXSN control samples. Arrows indicate multilobular nuclei in HPV20 E6-
flag raft cultures. Dotted lines indicate basement membrane. Nuclei counterstained with Hoechst 33258. 
Magnification 200x. 
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5 Discussion 
Squamous cell cancer of the oral cavity is the third most common cancer in developing 
countries whereas esophageal cancer corresponds to the fifth most common cancer in males 
worldwide (Opitz et al., 2002). Oropharyngeal and esophageal cancer are considered 
multifactorial, alcohol consumption and tobacco-use being the main risk factors (Castellsague 
et al., 2004; Franceschi et al., 1990; Ogden, 2005; Warnakulasuriya et al., 2005). Smokers 
have a 4-7 times higher incidence for oropharyngeal and esophageal tumors than non-
smokers. When tobacco is combined with alcohol consumption, the risk is further increased 
19-fold (Zheng et al., 1997). On the other hand, oropharyngeal and esophageal cancer patients 
infected with high risk HPV and with no alcohol or tobacco-use history have also been 
described (Loning et al., 1985; Syrjanen et al., 1983; Syrjanen et al., 1982). Epidemiological 
differences between patients suggest the existence of two groups in the etiology of these 
malignancies corresponding to either viral infection or alcohol/tobacco consumption (Smith et 
al., 2004).  
HPV may cooperate with carcinogens in the development of oropharyngeal and 
esophageal tumors. It has been reported in nude mice that the early region of HPV16 is able to 
immortalize oral keratinocytes but only after 6 months of chronic exposure to the tobacco 
carcinogen Benzo[a]pyrene (BaP) (Li et al., 1992). Oral keratinocytes isolated from these 
mice containing the HPV16 early region and exposed to BaP presented a malignant 
phenotype in organotypic raft culture (Park et al., 1995). Moreover, it has been demonstrated 
that organotypic keratinocyte cultures exposed to BaP shown an increase in HPV16, 18 and 
31 viral titers (Alam et al., 2008). In addition, increased cervical cancer risk has been reported 
in smoking women (Nischan et al., 1988; Stockwell and Lyman, 1987), as well as enhanced 
tumor progression (Phillips and Ni She, 1993) and invasive cervical cancer (Vaccarella et al., 
2008). BaP and other tobacco compounds such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) have been found in the cervical mucus of smoker patients with cervical 
dysplasia (Holly et al., 1993). This anatomical co-localization of both virus and carcinogen 
allows their interaction in the genital tract. 
Cutaneous HPV have been found in skin SCC and HNSCC. Possible mechanisms 
through which genus Beta papillomaviruses types are involved in pathogenesis of disease are 
slowly evolving. Earlier epidemiological evidence high-lighted UV-irradiation as being an 
important co-factor in the development of pre- or malignant skin lesions (Brash et al., 1991). 
In vivo and in vitro studies describing interactions of cutaneous HPV E6 and E7 genes with 
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cellular proteins confirm these data by indicating a necessity for additional UV-irradiation in 
the pathogenesis of skin disease in the presence of HPV (Dong et al., 2008; Jackson et al., 
2000; Michel et al., 2006; Struijk et al., 2008; Underbrink et al., 2008).  
HPV20 belongs to the Genus Beta papillomavirus and it has been detected in NMSC 
(de Villiers, 1998; Feltkamp et al., 2003). The involvement of HPV20 infection in the onset 
of skin papillomas and malignant transformation was demonstrated in HPV20 E6/E7 
transgenic mice chronically exposed to UV-irradiation (Michel et al., 2006).  Interestingly, 
HPV20 has been also found in patients with head and neck and esophageal SCC (de Villiers 
et al., 1999; Lavergne and de Villiers, 1999). However, the role of HPV20 in oropharyngeal 
and esophageal cancer onset and progression has not yet been elucidated. 
 DNA repair and apoptosis are induced in skin tissue as defense mechanisms after UV 
damage. However, it has been described that primary keratinocytes expressing HPV20 E6/E7 
or E6 proteins prevent apoptosis after UV exposure (Struijk et al., 2008), promoting the viral 
infection in UV-exposed sites. Similarly to the situation in the skin, where HPV20 acts in 
cooperation with UV-irradiation, we speculated that the virus might interact with carcinogens 
(e.g. tobacco and alcohol) in the oropharyngeal and esophageal epithelia to cause malignancy.  
4-NQO is a synthetic carcinogen which induces oral SCC in rodents which undergo 
chronic 4-NQO uptake in the drinking water (Miyamoto et al., 2008; Srinivasan et al., 2008; 
Vered et al., 2005). This chemical mimics the effect of UV irradiation by formation of 
guanine adducts, inducing DNA damage (Snyderwine and Bohr, 1992). 4-NQO behaves 
similarly to tobacco, creating DNA adducts, single-strand DNA breaks, pyrimidine dimmers 
and formation of oxidized bases (Kim et al., 2006). 4-NQO has been largely used in in vitro 
models because, contrary to tobacco compounds, does not need metabolic activation.  
Studying the cellular and viral factors involved in HPV20 promoter activation is 
important to understand the infection mechanism of this cutaneous virus. Promoter activation 
assays demonstrated a 4-fold activation of HPV20 URR by wtp53 whereas mutp53R248W 
expression did not modify the promoter activity (Fig. 10). When TAp63α or ∆Np63α were 
expressed, HPV20 URR was highly up-regulated, 25-fold and 35-fold respectively (Fig. 11), 
in accordance with previous reports (Fei et al., 2006; Fei et al., 2005). Interestingly, Flag-
tagged HPV20 E6, Flag-tagged HPV20 E7 and Flag-tagged HPV20 E6/E7 expression led to 
an enhancement in HPV20 URR activity, indicating that the viral proteins themselves are able 
to induce promoter activation (Fig. 12 and 19). Flag-tagged HPV20 E6 expression did not 
influence the activation pattern of wtp53, TAp63α or ∆Np63α on HPV20 URR (Fig. 13 and 
14). When cells were treated for 24 h with the carcinogen 4-NQO, HPV20 promoter was 
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activated and the chemical enhanced the Flag-tagged HPV20 E6, Flag-tagged HPV20 E7 as 
well as Flag-tagged HPV20 E6/E7 effect on HPV20 URR activation (Fig. 19). Thus, our 
results indicated the possible cooperation of cellular factors (wtp53, TAp63α and ∆Np63α), 
viral proteins (HPV20 E6 and E7) and chemical carcinogens (4-NQO) in the pathogenesis of 
HPV-associated cutaneous lesions. Experimental approaches with the presence of the 
complete HPV genome are necessary to elucidate the exact mechanistic action of HPV20.  
Our results in HPV20 promoter activation studies prompted us to investigate the effect 
of Flag-tagged HPV20 E6 expression and/or 4-NQO treatment in organotypic cell culture 
where keratinocytes differentiate, mimicing the in vivo situation in epidermal tissue. In the 
organotypic culture model, epidermal stratification and expression of differentiation-specific 
proteins occurs, allowing the characterization of Flag-tagged HPV20 E6 constitutive 
expression and 4-NQO treatment in epidermal development and the determination of cellular 
factors that may be affected.  
NIKS cells grown on a collagen matrix underwent terminal epidermal differentiation 
and stratified. Flag-tagged HPV20 E6 expression altered the epidermal morphology, showing 
clear features of disturbed stratification and dyskeratosis (Fig. 24). The epidermal basal cell 
layer remained intact but the stratum spinosum was poorly developed and normal orientation 
of the epidermal layers was lost.  Flag-tagged HPV20 E6 rafts presented a stratum 
granulosum that differ from the typical layer with dense basophilic keratohyalin granules of a 
healthy epidermis (Gartner and Hiatt, 2007). Instead, ultrastructural examination revealed 
fewer keratin granules very heterogeneous in size and lipid droplets accumulation (Fig. 32 C). 
The parabasal layer showed basophilic nuclei as observed for Epidermodysplasia 
verruciformis HPV types (Alpsoy et al., 2002) as well as anucleated eosinophilic inclusions 
resembling dyskeratotic cells.  
Foamy-like keratinocytes were present in the upper layers of the Flag-tagged HPV20 
E6 rafts. These aberrant keratinocytes have been found in lesions infected with 
Epidermodysplasia verruciformis-HPV types (Berger et al., 1991), and also in pityriasis 
versicolor-like lesions infected with HPV20 (Weber et al., 1994). These previous reports 
combined with our results open the question whether HPV20 E6 expression is responsible for 
the formation of foamy-like keratinocytes observed in patients and how other HPV20 viral 
proteins contribute to it. It still remains to be elucidated whether this ability of HPV20 E6 to 
form foamy-like keratinocytes is a unique feature of HPV20 or it is shared by other HPV 
types. Flag-tagged HPV20 E6 rafts also showed bubble-like cavernae formations in the 
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stratum corneum that probably corresponded to failures in cell-cell adherence, alterations in 
cellular composition and lipid extrusion (Fig. 24).  
Aberrant morphology of Flag-tagged HPV20 E6 organotypic cultures suggested 
possible differences in the stage of keratinocyte differentiation, as measured by occurrence 
and distribution of specific keratins and proteins of the cornified envelope:  
• Cytokeratin 14 is present in the epidermal undifferentiated compartment that contains the 
stem cells of the skin (reviewed in Moll et al., 2008). This protein is highly up-regulated 
in oral carcinomas of snuff dippers patients (Ibrahim et al., 1998) as well as in both 
keratinizing and non-keratinizing squamous cell cervical carcinomas, where cytokeratin 
14 is not only confined to the basal cells but it also localizes in suprabasal layers (Smedts 
et al., 1992). In our organotypic system, cytokeratin 14 was up-regulated and expressed 
throughout the entire suprabasal compartment in Flag-tagged HPV20 E6-expressing 
epidermis, with a prominent staining of the eosinophilic dyskeratotic cells of the upper 
layers (Fig. 29 A and B). In contrast, it was confined to the basal layer in the pLXSN 
control raft. The up-regulation of cytokeratin 14, typical of undifferentiated cells, 
indicates that Flag-tagged HPV20 E6 organotypic cultures retain features of a simpler 
epidermis, corresponding to a less differentiated phenotype. 
• Cytokeratin 10 is normally expressed in all suprabasal layers of the skin.                      
Down-regulation of this early differentiation marker has been reported in invasive cervical 
SCC (Carrilho et al., 2004; Maddox et al., 1999).  In addition, organotypic cultures of 
primary keratinocytes expressing HPV20 E6/E7 showed a delay in cytokeratin 10 
expression (Boxman et al., 2001). Interestingly, we observed the same tendency without 
the involvement of HPV20 E7. Cytokeratin 10 protein localization was delayed to the 
second and third suprabasal layers of Flag-tagged HPV20 E6 rafts, being more obvious in 
HPV16 E6/E7 samples (Fig. 29 A and C).  
• Late differentiation markers staining revealed delayed differentiation in Flag-tagged 
HPV20 E6 as well as 16 E6/E7 organotypic cultures. Involucrin is a keratin-associated 
protein indicative of epithelial differentiation (Rossi et al., 1998). Rafts harboring Flag-
tagged HPV20 E6 manifested a delay in the onset of involucrin expression in the lower 
spinosum layer (Fig. 30 A), contrary to pLXSN control raft culture where involucrin was 
detected throughout the entire suprabasal compartment. Similarly, the late differentiation 
marker loricrin was reduced in Flag-tagged HPV20 E6 organotypic cultures, as previously 
reported in HPV20 E6/E7 and HPV27 E6/E7 transgenic mice chronically exposed to UV 
(Michel et al., 2006), while it disappeared in HPV16 E6/E7 (Fig. 30 B). 
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Epithelial cancers are characterized by immortalization and inhibition of terminal 
differentiation. When taken together, our results indicate that HPV20 E6 by itself induces 
aberrant and incomplete differentiation in raft cultures as evidenced by over-expression and 
altered expression profile of cytokeratin 14 and delayed expression of cytokeratin 10, 
involucrin and loricrin. Similar results has been previously shown for HPV16 E7, HPV16 
E1^E4, HPV18 E6/E7, HPV6, HPV11, EV-HPV5, 12, 15, 17, 20 and HPV38 E6/E7 (Boxman 
et al., 2001; Flores et al., 2000; Garner-Hamrick et al., 2004; Mullink et al., 1991; Nakahara 
et al., 2005; Woodworth et al., 1992). 
HPV protein expression alters several cellular factors of the host cell. E6 protein of 
high risk HPV types targets p53 tumor suppressor to proteosomal degradation through 
complex formation with ubiquitin ligase E6AP (Huibregtse et al., 1991). In contrast, 
cutaneous HPV E6 proteins are unable to promote p53 degradation (Pim et al., 2002). In our 
studies p53 levels were increased in Flag-tagged HPV20 E6 monolayer (Fig. 20) and rafts 
cultures, where expression was extended into the suprabasal compartment (Fig. 28 A and B). 
Over-expression of p53 may lead to G1 cell cycle arrest and apoptosis (reviewed in 
Vogelstein et al., 2000). However, p53 accumulation in Flag-tagged HPV20 E6 rafts did not 
alter proliferation rates (Fig. 31). A similar p53 expression pattern was observed in HPV20 
E6/E7-expressing transgenic mice chronically exposed to UV (Michel et al., 2006), indicating 
the influence of HPV20 E6 in p53 over-expression or stabilization. Furthermore, it has been 
reported p53 accumulation in different tissues infected by several HPV types: E7 of high risk 
genital HPV types led to increased p53 levels but the protein activity was impaired (Munger 
et al., 2001). Cutaneous HPV38 E6/E7 are able to immortalize keratinocytes and lead to 
accumulation of wtp53 (Accardi et al., 2006); in those HPV38 E6/E7- expressing 
keratinocytes, stabilized p53 has changes in the phosphorylation pattern, localizes exclusively 
in the nucleus and cells proliferate normally, without increased apoptosis. In addition, this 
impairment in p53 functionality was found to be induced by up-regulation of ∆Np73, which 
inhibits the transcriptional regulatory properties of p53 in growth arrest and apoptosis. Further 
investigation of p53 mutations, phosphorylation pattern, localization and functionality under 
the context of HPV20 E6 expression is necessary for understanding the relevance of p53 
accumulation. 
The cyclin-dependent kinase inhibitor p21CIP1 is a transcriptional target of p53 that 
induces G1 arrest after DNA damage (Waldman et al., 1995). However, it is also involved in 
terminal differentiation and senescence independently of p53 (Macleod et al., 1995; Parker et 
al., 1995). p21CIP1 was up-regulated in Flag-tagged HPV20 E6 and HPV16 E6/E7 organotypic 
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cultures (Fig. 28 A and C), probably induced by p21CIP1 protein stabilization and not by 
transcription activation (Jones et al., 1997). p21CIP1 has p53-dependent and independent 
functions in cell cycle and differentiation. The role of p21CIP1 accumulation in Flag-tagged 
HPV20 E6 and HPV16 E6/E7 organotypic cultures remains to be elucidated. However, a 
perturbed function of p21CIP1 cannot be excluded considering that its up-regulation did not 
negatively influence cell proliferation in the organotypic cell cultures (Fig. 31).  
∆Np63α  is mainly expressed in the basal cells of normal epithelium and plays a 
crucial role in epithelial morphogenesis and differentiation (reviewed in Candi et al., 2007). 
An organotypic culture model where ∆Np63α  was knocked-down by siRNA techniques 
showed that several proteins involved in skin development (cytokeratin 1 and 10, involucrin, 
loricrin and corneodesmin) have an altered expression profile in the absence of ∆Np63α  
(McKeon, 2004). This protein has the transactivation domain present in the TAp53 isoforms 
partially deleted. It can block the function of p53, TAp63 and TAp73 proteins -that may occur 
by DNA binding site competition in the promoter of target genes and by formation of hetero-
oligomers through binding to the transactivation domain of p53 family TA isoforms 
(reviewed in Yang and McKeon, 2000). ∆Np63α is up-regulated when Flag-tagged HPV20 
E6 is expressed in monolayer (Fig. 20) and organotypic cultures (Fig. 28 A and D). ∆Np63α 
accumulation has been observed in bladder, breast, cervix, head and neck, lung and prostrate 
cancer (reviewed in Westfall and Pietenpol, 2004), pointing to a possible role of this protein 
as oncogene (Hagiwara et al., 1999). A previous report from our lab described wtp53-
mediated degradation of HPV20 E6 whereas the UV-induced mutant p53R248W and 
∆Np63α exerted a protective effect on HPV20 E6 (Fei and de Villiers, 2008). In our system, 
p53 was accumulated in Flag-tagged HPV20 E6 organotypic cultures. Whether accumulated 
p53 targeted HPV20 E6 to degradation remains uncertain. However, one can speculate that 
HPV20 E6 degradation may be protected by the observed ∆Np63α up-regulation, as well as 
by a possible p53 impaired function. 
Uncontrolled cellular proliferation is characteristic of carcinogenesis (reviewed in 
Golias et al., 2004). Therefore, possible changes in proliferation rates induced by Flag-tagged 
HPV20 E6 were studied. E7 plays a key role in promoting proliferation and deregulating cell 
cycle as demonstrated in HPV16 and 18 types (Boulet et al., 2007; Munger et al., 2001) as 
well as HPV10, 32, 48, 54 and 77 (Caldeira et al., 2000) whereas E6 seems to help E7´s 
action in unscheduled proliferation. Flag-tagged HPV20 E6 expression did not alter 
proliferation in differentiated keratinocytes of the epidermal layer, showing similar BrdU 
incorporation rates when compared to pLXSN control rafts (Fig. 31 C). In agreement with our 
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observation, organotypic cultures of primary foreskin keratinocytes expressing HPV20 E6/E7 
proteins did not present alterations in BrdU incorporation or PCNA staining (Boxman et al., 
2001). It has been demonstrated that HPV16 E6 constitutive expression in rafts does not lead 
to an increase proliferation rate (Halbert et al., 1992). In contrast, BrdU incorporation and 
PCNA labeling in HPV16 E6/E7 raft cultures were extended to the suprabasal layers (Fig. 31 
B and C), as previously reported in organotypic cultures of primary keratinocytes (Blanton et 
al., 1992; Halbert et al., 1992).  
PCNA is an auxiliary factor for DNA polymerase δ and ε, important during DNA 
replication and repair. It is a cellular target of p21CIP1, which binds it inducing cell cycle arrest 
(Li et al., 1994). Western blot analysis of proteins extracted from raft cultures showed a 
down-regulation of PCNA levels in Flag-tagged HPV20 E6 samples (Fig. 31 A). PCNA 
constitutes a downstream target of p53 (Mercer et al., 1991), indicating that p53 accumulation 
increases p21CIP1 levels, that binds and blocks PCNA expression. Our results might indicate 
the decreased levels of PCNA as a consequence of p53 and p21CIP1 accumulation. 
Proliferation rates were indeed not altered, as demonstrated by BrdU incorporation. However, 
analysis of other proliferation markers such as Ki67 or cyclin D1 may corroborate these 
results. 
Flag-tagged HPV20 E6 organotypic cultures of keratinocytes showed differences in 
epidermal morphology and differentiation pattern, as well as overexpression of cellular 
factors p53, p21CIP1 and ∆Np63α, in contrast to the pLXSN control rafts. Flag-tagged HPV20 
E6 expressing rafts showed failures in the apoptosis program as observed by the formation of 
apoptotic figures in the uppermost parts of the epidermis (Fig. 32 C). In addition, stratum 
corneum was present in Flag-tagged HPV20 E6 and HPV16 E6/E7 organotypic cultures (Fig. 
24 and 25) but its appearance was thinner and less compact than in control pLXSN epidermis, 
indicating a disturbed and delayed differentiation program. A functional epidermal barrier 
needs a correct balance between differentiation, proliferation and apoptosis rates (Presland 
and Dale, 2000). Because of the alterations observed in epidermal morphology, apoptosis and 
differentiation pattern, aberrations in barrier function were suspected. Disturbance was 
studied by Lucifer yellow dye penetration (Fig. 35) and Biotin uptake (Fig. 36 A) assays. Our 
results indicated that the cornified layer of Flag-tagged HPV20 E6 rafts presented a perturbed 
barrier function both outside-in and inside-out.  
The defective barrier prompted us to analyze the desmosomal localization and 
presence of tight junctions in the stratum granulosum. Desmosomes play an important role in 
tissue integrity of epithelia by linking cytoskeletal components such as keratin filaments to 
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cellular membranes (Herve, 2008; Langbein et al., 2002; Stokes, 2007). Altered desmosomes 
has been described in high-grade squamous intraepithelial lesions of the cervix (Alazawi et 
al., 2003). In Flag-tagged HPV20 E6 expressing rafts, the desmosomal number and 
architecture was normal, comparable to the pLXSN control rafts (Fig. 32 B and 37). A recent 
report showed the degradation of the multi-PDZ protein PATJ, a critical component of tight 
junction, by HPV18 E6 and E6* proteins (Storrs and Silverstein, 2007). Adenovirus E4-ORF1 
protein also binds to several PDZ proteins that complexes to tight junctions, inhibiting the 
formation of these structures (Latorre et al., 2005). In our system, tight junctions were 
disrupted in the Flag-tagged HPV20 E6-expressing rafts as demonstrated by cingulin staining 
(Fig. 36 B), thus explaining the impaired inside-out barrier observed by Biotin uptake (Fig. 
36 A). PDZ binding motifs is a specific feature of high risk mucosal HPV E6 proteins 
(Watson et al., 2003) whereas cutaneous HPV E6 are not able to target proteosome-mediated 
PDZ proteins degradation (Elbel et al., 1997; Fei and de Villiers, 2008; Pim et al., 2002). 
Therefore, HPV20 E6 can not interfere with PDZ proteins and its molecular mechanism for 
targeting tight junction disruption requires further investigation.   
Ceramides, fatty acids and cholesterol form the extracellular lamellar membrane, a 
densely packed structure in the stratum corneum (Bouwstra and Ponec, 2006; Elias and 
Menon, 1991). Alteration in these components leads to an accumulation of fatty acids and 
impairment of the barrier function (Feingold, 2007). These modifications may occur without 
alterations in proliferation and stratified organization in the keratinocytes as demonstrated in 
transgenic mice with inactivating mutations in 12R-lipoxigenase (12R-LOX) and epidermal 
LOX-3 (Epp et al., 2007) and in patients with autosomal recessive congenital ichthyosis 
(ARCI) (Eckl et al., 2005). Topical application of oleic acid and palmitoleic acid on hairless 
mouse skin induces increased transepidermal water loss (TEWL) as well as scaly skin, 
abnormal keratinization and hyperplasia (Katsuta et al., 2005). In our system, the lipid 
composition of the organotypic raft cultures was analyzed, and several unsaturated fatty acids 
were found to be significantly up-regulated (Fig. 33). Interestingly, both oleic acid and 
palmitoleic acid were increased in Flag-tagged HPV20 E6 organotypic cultures, which may 
contribute to the observed loss of epidermal barrier function. It has recently been reported that 
the cornified envelope is not only formed by covalent bonds between glutamic acid residues 
of proteins and ceramides but also between free fatty acids and serine residues (Lopez et al., 
2007),. Alterations in fatty acid content lead to pertubance of the cornified envelope, as 
observed in Flag-tagged HPV20 E6 organotypic cultures. Aberrant lipid metabolism was also 
revealed by lipid accumulation into lipid droplets in the stratum granulosum and the basal 
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membrane, as demonstrated by electron microscopy (Fig. 32 C) and Oil Red O staining of 
organotypic culture cryosections (Fig. 34). Lipids present in the skin are particularly 
susceptible to oxidation. Unsaturated fatty acids oxidation occurs either spontaneously by 
reaction with oxygen on exposure to air or in the presence of light. Lipid peroxidation 
produces free radicals that are mutagenic and carcinogenic (reviewed in Briganti and Picardo, 
2003). Flag-tagged HPV20 E6 induced abnormal lipid synthesis and accumulation, what may 
lead to increased formation of free radical species, especially after UV radiation, facilitating 
the onset of malignancies in viral infected epithelia. In summary, Flag-tagged HPV20 E6 
expression leads to impaired barrier function, disruption of tight junctions and altered lipid 
composition. These alterations in the epidermis may be crucial during HPV infection and its 
molecular mechanisms and relevance in disease requires further investigation. 
HPV20 requires UV-irradiation for inducing skin carcinogenesis. In a similar way, 
oropharyngeal and esophageal cancer may be promoted by the interaction and cooperation of 
different risk factors. In order to investigate the possible synergistic effect of tobacco/alcohol 
use and HPV20 infection, HPV monolayer and organotypic raft cultures models were treated 
with the UV-mimetic 4-NQO. This chemical was used as carcinogen model, comparable with 
the tobacco effect in the oral and laryngeal mucosa. In our studies, the influence of short term 
4-NQO treatment in cell death, regulation of cell cycle, activation profile of HPV20 viral 
promoter and epidermal morphology and development was investigated combined with the 
expression of Flag-tagged HPV20 E6 protein. 4-NQO promotes apoptosis at high doses via 
p53-dependent mitochondrial signalling pathway (Han et al., 2007). Low dose (≤ 3 µM) 4-
NQO treatment in immortalized keratinocytes induced minimal cell death (Fig. 17) and 
facilitated entry into S-phase and G2/M (Fig. 18), as previously described (Heron-Milhavet et 
al., 2001). In accordance with Han et al. (2007), we observed G1 arrest and apoptosis when 4-
NQO was used at high concentration (Fig. 18 B). It has been reported that E6 proteins of 
HPV8 and 38 of the Genus Beta papillomavirus are able to expand keratinocyte life span 
whereas E6 of HPV20 and HPV5 do not significantly change the population doublings 
(Bedard et al., 2008). In our studies, we confirmed that Flag-tagged HPV20 E6 was not able 
to extend life span of the cells (Fig. 22).  One single report described immortalization of 
normal human fibroblasts by chronic exposure to 4-NQO (Bai et al., 1993). However, in our 
system 4-NQO short term treatment was not sufficient for immortalizing primary 
keratinocytes alone or expressing Flag-tagged HPV20 E6, suggesting that the chemical action 
varies upon different cell types and/or there is a need to perform the studies with longer 4-
NQO exposure time in order to achieve immortalization. 4-NQO induces p21CIP1 over-
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expression allowing DNA repair and p53-dependent apoptosis through mitochondrial 
signaling pathway when damage can not be repaired (Han et al., 2007). Interestingly, p53 was 
up-regulated in keratinocytes cells transiently transfected with Flag-tagged HPV20 E6 and 
treated with 4-NQO in comparison to control and Flag-tagged HPV20 E6-transfected cells not 
incubated with the chemical (Fig. 20). However, in organotypic cultures, 4-NQO did not alter 
the p53 and p21CIP1 expression and localization pattern in the epidermis. Expression levels of 
Flag-tagged HPV20 E6 were slightly increased after 4-NQO treatment (Fig. 20 and 27 B), 
suggesting that chemical exposure stabilizes the viral protein, which might have a positive 
effect in the pathogenesis of the virus.  
Li and coworkers demonstrated an increase in mRNA of PCNA after short exposure to 
4-NQO in human hepatoblastoma cell line Hep G2 and the human cervical epithelial cell line 
HeLa (Li et al., 2005). In our monolayer and organotypic raft culture system, no difference in 
PCNA expression was found after 4-NQO treatment (Fig. 20 and 31 A, B). This difference 
could be attributed to a short 4-NQO treatment as well as differences in cellular type and 
protein levels of PCNA upstream targets like p53. 
Taken together, the delay in cytokeratin 10 and involucrin expression (Fig. 29 C and 
30 A) and absence of loricrin staining (Fig. 30 B) when 4-NQO was applied to the Flag-
tagged HPV20 E6 organotypic culture medium points the possible synergistic effect of virus 
infection and chemical treatment in malignant conversion by formation of a less differentiated 
epidermis. Moreover, HPV20 URR up-regulation in monolayer keratinocytes (Fig. 19) 
together with increased Flag-tagged HPV20 E6 levels (Fig. 20 and 27 B) indicate that the 
chemical has a positive influence on the viral protein expression and therefore cooperates with 
HPV20 during infection and tumor progression. Longer chemical treatments are necessary to 
test the viral influence in cells chronically exposed to 4-NQO, mimicing the natural situation 
that occurs in oropharyngeal and esophageal cancer patients with alcohol/tobacco use and 
who are positive for HPV20 viral infection. 
Organotypic raft culture studies show that keratinocytes expressing Flag-tagged 
HPV20 E6 are able to stratify but fail to form a normal epidermis and present aberrant 
differentiation. The normal keratin pattern is disturbed, resembling simpler epithelia and this 
phenotype is enhanced after 4-NQO treatment. Cellular protein p53 accumulates whereas 
p21CIP1 and ∆Np63α modify their expression pattern in the epithelia. Organotypic raft cultures 
expressing Flag-tagged HPV20 E6 present foamy-like keratinocytes resembling the typical 
structures found in Epidermodysplasia verruciformis patients and pityriasis versicolor-like 
lesions infected with HPV20, indicating a probably involvement of HPV20 E6 in the 
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formation of such aberrant keratinocytes. In addition, Flag-tagged HPV20 E6 expression is 
capable of altering the functionality of the skin barrier function. That is probably done by 
abrogation of tight junction formation in the stratum granulosum and changes in the lipid 
metabolism of the skin leading to its accumulation and deregulated composition. Disruption 
of the skin barrier is related to a number of cutaneous diseases, all connected with underlying 
genetic and immune disorders. These include different forms of ichthyosis, atopic dermatitis 
and other eczemas (Elias et al., 2008; Hanifin, 2008; Hoffjan and Stemmler, 2007). 
Correlation between these diseases and cutaneous HPV requires further investigation. Future 
studies with other cutaneous HPV and different E6 proteins will provide insight into HPV 
type specificity in the observed features and relevance in the pathogenesis of disease.  
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